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Abstract 
 
 
Neuropathic pain is a complex clinical syndrome characterized by increased 
sensitivity to thermal and/or mechanical stimuli that may or may not be accompanied by 
the phenomenon of spontaneous or aberrant pain sensations.   
Over the past decade, the mechanisms underlying the behavioral manifestations 
of inflammatory neuropathic pain have become more clearly elucidated. These include 
the involvement of: 1) transient receptor potential vanilloid receptor 1 (TRPV1) in the 
generation of thermal hyperalgesia; 2) acid sensing ion channel 3 (ASIC3) in some 
aspects of the development/maintenance of mechanical hypersensitivity; 3) the 
tetrodotoxin resistant sodium channels Nav1.8 and Nav1.9 in both hyperalgesia and 
spontaneous pain; and 4) activation of the MAP Kinases p38 and ERK1/2 in the 
regulation of expression of the aforementioned molecules. 
Interestingly, it is the pro-inflammatory neurotrophin nerve growth factor (NGF) 
that is the common link between all of these mediators of neuropathic pain.  Increased 
availability of NGF under conditions of inflammation has been shown to drive increased 
expression/upregulation of TRPV1, ASIC3, Nav1.8 and Nav1.9, as well as phospho-p38 
and phospho-ERK1/2. 
Evidence presented here continues to support a role for neurotrophin-3 (NT-3) in 
antagonizing the effects of increased NGF on trkA signaling, neuropathic pain behaviors 
and some of the molecules associated with the generation of such behaviors. 
More specifically, the work culminating in this thesis demonstrates a novel role 
for NT-3 in negative modulation of TRPV1, ASIC3, Nav1.8 and Nav1.9, as well as 
phospho-p38 expression in response to the chronic constriction injury model of 
neuropathic pain.  Finally, initial insights into how this negative regulation of these 
nociceptive markers might occur is elucidated in studies demonstrating that NT-3 
differentially affects levels of the key signaling molecule phospho-ERK in trkA-positive 
versus trkC-positive neurons in naïve dorsal root ganglia (DRG).  
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1 Introduction 
 
 Neuropathic pain is a chronic pain syndrome resulting from injury to a peripheral 
nerve that is characterized by both an increased sensitivity to thermal stimuli (thermal 
hyperalgesia), mechanical stimuli (mechanical allodynia) and aberrant pain sensations 
(spontaneous pain). The chronic condition of this pain state can be both physically and 
mentally debilitating to those who are afflicted and to date no successful treatment 
regimens are available.  The symptoms and syndromes associated with neuropathic pain 
are well known, but until the underlying mechanisms that drive the development of these 
syndromes are identified and understood, effective global treatments are not likely to be 
available.  It is for this reason that the investigation of both behavioral and biochemical 
aspects of neuropathic pain remain a priority. 
 The chronic constriction injury (CCI) of the sciatic nerve is a widely used model 
of neuropathic pain.  This model produces neuropathic pain sensations similar to those 
observed in humans and evokes a series of molecular, biochemical and cytoarchitectural 
changes in primary sensory neurons  believed to contribute to the ensuing pain state 
(Bennett and Xie, 1988; Kajander and Bennett, 1992; Nahin et al., 1994; Miki et al., 
1998).  In addition, some key molecules involved in the generation and maintenance of 
neuropathic pain states have been identified.  Of these, the neurotrophin nerve growth 
factor (NGF), which has been demonstrated to influence the phenotype of these primary 
sensory neurons and be a major regulator of inflammatory and homeostatic pain states 
(Lewin and Mendell, 1993; Woolf et al., 1994; Verge et al., 1995; Woolf, 1996; 
Herzberg et al., 1997; Ramer et al., 1998; Theodosiou et al., 1999), is the most 
commonly known.  More recently, a novel potential role for another member of the NGF 
family of neurotrophins  neurotrophin-3 (NT-3)  in acting to antagonize the pro-
inflammatory NGF pathway and algesia-associated phenotype has been revealed (Gratto 
and Verge, 2003; Wilson-Gerwing and Verge, 2006).  My thesis will examine this novel 
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role by elucidating the behavioral and biochemical implications of NT-3s capacity to 
alter nociceptive pathways using the CCI model of neuropathic pain. 
 
 
1.1 An overview of primary sensory neurons associated with pain transmission 
 
Biochemical changes that are associated with neuropathic pain can be examined 
at various levels of the nervous system.  These include, but are not limited to, changes at 
the level of the brain, the level of the spinal cord and at the level of the primary sensory 
neurons - the first relay point.  For the purpose of this thesis, I have chosen to focus in 
on those changes that occur at the level of the primary sensory neuron. 
Primary sensory neurons are pseudo-unipolar (reviewed in Hokfelt et al., 1997; 
Nolte, 1999), with their cell bodies residing within the dorsal root ganglion (DRG). The 
axonal processes exit the cell body at a single site with one process projecting to 
peripheral tissues, and a second process projecting centrally and terminating in either the 
dorsal horn of the spinal cord or sending a collateral via the dorsal columns to terminate 
in brainstem nuclei (reviewed in Hokfelt et al., 1997).  These neurons are responsible for 
the gathering of sensory information from the external environment and transmitting it 
to the central nervous system so that the incoming sensory information can be dealt with 
accordingly (Woolf, 1996). 
Primary sensory neurons that convey nociceptive information can be classified 
according to their morphology and physiology.  With this type of classification, three 
basic categories are evident for those sensory neurons believed involved in the 
neuropathic pain response.  The first is comprised of large, myelinated axons that 
respond primarily to innocuous mechanical stimuli (Aβ fibers) (Willis and Coggeshall, 
1991; reviewed in Millan, 1999).  Aβ fibers have very rapid conduction velocities due to 
the extensive myelin surrounding the axons (30-100 m/s) (reviewed in Millan, 1999; 
Nolte, 1999).  The second group, Aδ fibers, are of medium size and have thinly 
myelinated axons (Furst, 1999; reviewed in Millan, 1999; Nolte, 1999).  The Aδ fibers 
rapidly transduce action potentials (reviewed in Stucky et al., 2001) at a rate of 5-30 m/s 
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(reviewed in Millan, 1999; Nolte, 1999) and are nociceptors that are responsible for the 
experience of fast, prickling, sharp pain (Furst, 1999; Nolte, 1999; reviewed in Stucky et 
al., 2001).  The final category consists of small neurons whose axons are not myelinated 
(C fibers) (Willis and Coggeshall, 1991; Nolte, 1999; reviewed in Stucky et al., 2001) 
and have slow conduction velocities (0.5-2 m/s) (reviewed in Millan, 1999; Nolte, 1999; 
reviewed in Stucky et al., 2001).  C fibers are also known as polymodal nociceptors 
(Willis and Coggeshall, 1991; reviewed in Millan, 1999) and mediate the experience of 
slow, dull, aching pain and chemosensation (Furst, 1999; reviewed in Millan, 1999; 
Nolte, 1999; reviewed in Stucky et al., 2001). 
Just as important as the physiological distinctions between these three classes of 
nociceptive sensory neurons are their specific sites of termination within the spinal cord. 
The dorsal horn of the spinal cord receives sensory input from the periphery.  Under 
normal physiological conditions, large Aβ fibers project deep into the dorsal horn to 
terminate in laminas III and V (Shortland et al., 1989; Furst, 1999; reviewed in Millan, 
1999; Nolte, 1999).  Intermediate Aδ fibers, and small C fibers, terminate primarily in 
lamina I (marginal zone) and lamina IIouter (substantia gelatinosa) (Light and Perl, 1979; 
Furst, 1999; reviewed in Millan, 1999; Nolte, 1999). 
Sensory neurons can also be classified on a histochemical basis into three broad 
categories. While these categories are largely histochemically distinct, it is important to 
realize that there is some degree of overlap among them.  The first group of DRG cells 
can be identified by the presence of phosphorylated heavy-chain neurofilament (Lawson 
et al., 1984) that can be identified using the antibody RT97 (McMahon, 1996).  This is 
the cell group that was initially identified as the Large Light neurons (reviewed in 
Lawson, 1992).  Morphologically, the Large Light neurons have myelinated axons and 
it is believed that they transmit information from peripheral mechanoreceptors (Lawson 
et al., 1984; reviewed in McMahon et al., 1997).  The second grouping of DRG cells is 
made up of populations of cells that express neuropeptides and receptor tyrosine kinases 
(trks) (reviewed in McMahon, 1996; McMahon et al., 1997).  The best single 
histochemical marker for this population is calcitonin gene-related peptide (CGRP) 
(McMahon, 1996; reviewed in McMahon et al., 1997; Stucky et al., 2001).  
Morphologically, this group of cells are primarily small to medium in size and their 
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axons are unmyelinated (reviewed in McMahon, 1996; McMahon et al., 1997).  This is 
the cell group that corresponds to those cells initially identified as the Small Dark 
neurons (reviewed in Lawson, 1992).  These Small Dark neurons are believed to 
transmit information from nociceptors and thermoreceptors (reviewed in Lawson, 1992; 
reviewed in McMahon, 1996).  The final histochemical category of DRG sensory 
neurons are those that bind the plant lectin Griffonia Simplifolia IB4 and are generally 
non-peptidergic and lack trk receptors (Silverman and Kruger, 1990; Alvarez et al., 
1991; reviewed in Stucky et al., 2001).  Morphologically, these neurons, like the 
peptidergic population described above, are small, their axons are not myelinated, and 
receive sensory information primarily from nociceptors and thermoreceptors (Willis and 
Coggeshall, 1991). 
Of particular interest to this thesis are those sensory neurons that respond to 
noxious stimuli  the nociceptors.  Nociceptors are very diverse in their ability to 
respond to various types of stimulation.  Specifically, they can be activated by thermal, 
chemical and/or mechanical stimuli (Snider and McMahon, 1998; Furst, 1999; reviewed 
in Stucky, 2001).  The predominant type of nociceptor is capable of responding to all 
three of these stimuli and is referred to as a polymodal nociceptor (reviewed in Snider 
and McMahon, 1998; reviewed in Koltzenburg, 1999).  A second specific type of 
nociceptor is the silent or sleeping nociceptor that becomes activated as a result of 
inflammation or tissue injury (Snider and McMahon, 1998; reviewed in Millan, 1999). 
Further properties of these specialized sensory neurons will be discussed in subsequent 
sections. 
 Characteristically, the phenotypic profiles and functional properties of all 
primary sensory neurons vary depending on the physiological state of the neuron (for 
example, homeostasis or neuropathic pain).  The signals regulating these states are 
trophic molecules and cytokines secreted by target, glial, or immune cell sources.  One 
of the most profound regulators of the differentiated state of sensory neurons is the NGF 
family of neurotrophic molecules. The elevation of NGF expression in inflammatory 
states contributes to the associated increase in thermal hypersensitivity.  It is the 
understanding of these changes and their regulation that becomes the basis for 
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understanding the transition from normal to neuropathic pain states following nerve 
injury. 
 
1.2 An introduction to neurotrophins and their receptors in sensory neurons 
 
Neurotrophins are secreted proteins (McMahon et al., 1997) having molecular 
weights of 13-15 kDa (Ross and Riopelle, 2001).  The neurotrophin family members are 
structurally homologous (McMahon et al., 1997) and exist as non-covalently linked 
homodimers (Ross and Riopelle, 2001).  Neurotrophins play important roles with 
regards to the survival, proliferation, differentiation and phenotypic regulation of 
developing sensory neurons (Levi-Montalcini, 1987; Barde, 1989; Otten et al., 1994; 
McMahon and Priestly, 1995; reviewed in McMahon et al., 1997; Ross and Riopelle, 
2001; Stucky, 2001).  In mature sensory neurons, neurotrophins have been demonstrated 
to influence the phenotypic maintenance of overlapping subpopulations of these cells 
(reviewed in Woolf and Mannion, 1999).  
Under normal physiological conditions, DRG sensory neurons derive their 
primary source of neurotrophins from the peripheral target tissues that these neurons 
innervate (Korsching and Thoenen, 1983a; Heumann et al., 1984; Korsching and 
Thoenen, 1985; Goedert et al., 1986; Ernfors et al., 1990; Wetmore and Olson, 1995).  
The neurotrophins bind to receptors on the neurons and are transported retrogradely as 
signaling endosomes (reviewed in Ginty and Segal, 2002) to the cell body (Korsching 
and Thoenen, 1983b; DiStefano et al., 1992; reviewed in Stucky, 2001; Miller and 
Kaplan, 2002). 
The first neurotrophic factor to be described was nerve growth factor (NGF) 
(Levi-Montalcini and Hamburger, 1951).  Subsequently, brain derived neurotrophic 
factor (BDNF) (Barde et al., 1982), neurotrophin-3 (NT-3) (Ernfors et al., 1990; Hohn et 
al., 1990; Jones and Reichardt, 1990: Maisonpierre et al., 1990; Rosenthal et al., 1990) 
and neurotrophin-4/5 (NT-4/5) (Berkemeier et al., 1991; Hallbook et al., 1991) - all 
members of the NGF family of neurotrophins - were also isolated.  
The actions of neurotrophins are mediated via select high-affinity interactions 
with the trk family of receptor tyrosine kinases (Chao, 1992; Barbacid, 1994; Bothwell, 
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1995), although all of the neurotrophins interact with similar affinity with the common 
neurotrophin receptor  p75 (Johnson et al., 1986; Radeke et al., 1987; Bothwell, 1996; 
McMahon et al., 1997).  To date NGF, BDNF and NT-3 have been shown to have the 
most profound actions on mature sensory neurons, details of which will be elucidated 
below. 
 
 
1.2.1 Nerve growth factor (NGF) 
 
 As described above, NGF was the first target-derived neurotrophic factor to be 
isolated and described (Levi-Montalcini and Hamburger, 1951; reviewed in Lewin and 
Barde, 1996).  As a trophic factor, NGF has been demonstrated to promote survival, 
growth and differentiation of neural crest-derived sensory neurons and peripheral 
sensory neurons (Scully and Otten, 1995; Ramer et al., 1998).  In support of a role in 
survival, it has been shown that many sensory neurons do not survive early embryonic 
life in the absence of NGF (Johnson et al., 1986; Ruit et al., 1992; reviewed in Acheson 
and Lindsay, 1996).  Additionally, removal of the target and consequent removal of 
target-derived NGF also results in neuronal death (reviewed in Acheson and Lindsay, 
1996).  Conversely, if the target size is increased  thereby increasing the amount of 
NGF available - there is a subsequent increase in neuronal survival (reviewed in 
Acheson and Lindsay, 1996).  Further evidence for NGFs role in neuronal survival 
comes from experiments that use anti-sera to sequester NGF during embryonic 
development, resulting in dramatic neuronal loss (Cohen, 1960; Levi-Montalcini and 
Angeletti, 1966). 
 NGF is also a potent mediator of neuronal phenotype in adult sensory neurons.  
The model that has dominated this research is that of sciatic nerve injury which ranges 
from partial nerve injury to complete transection of the nerve.  Injury of the sciatic nerve 
interrupts the normal retrograde flow of NGF from the target tissue (Korsching and 
Thoenen, 1983b; Raivich et al., 1991) leading to phenotypic changes in DRG neurons 
(Villar et al., 1989; Gold et al., 1991; reviewed in Verge et al., 2002).  The NGF 
responsive subpopulation of sensory neurons express the neuropeptides substance P (SP) 
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and calcitonin gene related peptide (CGRP)  both key molecules in the regulation of 
pain states (Verge et al., 1989a).  Administration of exogenous, intrathecal NGF has 
been shown to both prevent (when given at the time of peripheral nerve injury) and 
reverse (when given after phenotypic changes due to peripheral nerve injury have been 
allowed to occur) many phenotypic changes in DRG neurons following peripheral nerve 
injury including alterations in the neuropeptides SP and CGRP (Yip et al., 1984; 
Fitzgerald et al., 1985; Rich et al., 1987; Verge et al., 1989b; Verge et al., 1990; Gold et 
al., 1991; Verge et al., 1995). 
 More recently, a role for NGF in both neuropathic pain and inflammation has 
come to light (for reviews see Otten et al., 1994; McMahon, 1996).  These aspects of 
NGF will be discussed in detail in a subsequent section entitled Neurotrophins and 
Pain. 
 
 
1.2.2 Brain derived neurotrophic factor (BDNF) 
 
 The second member of the NGF family of neurotrophins to be described was 
BDNF purified from pig brain (Barde et al., 1982; Hofer and Barde, 1988).  Hofer and 
Barde (1988) and Lindsay et al. (1985) both demonstrated that BDNF is capable of 
promoting the survival of a population of peripheral sensory neurons that do not require 
NGF for survival.  In vitro studies reveal that placode-derived sensory neurons, neural 
crest-derived sensory neurons and motor neurons are responsive to BDNF (Lindsay et 
al., 1985; Davies et al., 1986; Hohn et al., 1990; Wong et al., 1993; reviewed in Cho et 
al., 1999).  With regard to primary sensory neurons, BDNF is a trophic factor for Aβ 
fibers (reviewed in Millan, 1999) and is essential for proper mechanosensitivity of 
Merkel cells (reviewed in Koltzenburg, 1999). A significant loss of sensory neurons is 
observed in BDNF knock-out animals, although it is not as severe as observed in NGF 
knock-out mice (about 30% of total DRG neurons as opposed to about 80% in NGF 
knock-out animals) (Klein, 1994; reviewed in Acheson and Lindsay, 1996; McMahon et 
al., 1997; Mogil and Grisel, 1998). 
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 Although BDNF shares many commonalties with NGF, there are two major 
differences with respect to sensory neuron biology.  First, BDNF mRNA is detectable in 
normal DRG neurons (Ernfors et al., 1990; Wetmore and Olson, 1995; Tonra, 1999) 
whereas NGF mRNA is not (Davies et al., 1987; Ernfors et al., 1990; Wetmore and 
Olson, 1995).  Specifically, under normal physiological conditions, it is the nociceptive, 
NGF responsive, trkA-positive sensory neurons (C fibers) that express BDNF (Michael 
et al., 1997; Mannion et al., 1999; Zhou et al., 1999).  Interestingly, after peripheral 
nerve injury, these small neurons decrease their synthesis of BDNF and large neurons 
expressing the cognate receptors for BDNF and NT-3, trkB and trkC respectively, now 
express BDNF (Zhou et al., 1999).  The second dissimilarity is that neuronally 
synthesized BDNF is transported anterogradely to the spinal cord in secretory vesicles 
(Zhou and Rush, 1996; Mannion et al., 1999; Tonra, 1999) in addition to the traditional 
target derived BDNF that is retrogradely transported to the cell body (Tonra, 1999).  
This supports possible roles for BDNF as both an autocrine and/or paracrine regulator of 
sensory neurons (Acheson et al., 1995; Acheson and Lindsay, 1996; Tonra, 1999). 
 
 
1.2.3 Neurotrophin-3 (NT-3) 
 
 The third member of the NGF family of neurotrophins to be described was NT-3.  
As an NGF homologue, it is not surprising that NT-3s trophic effects include neuronal 
survival, growth and phenotypic modulation of neurons. 
 Developmentally, NT-3 plays an important role in survival of slowly adapting 
mechanoreceptors that innervate Merkel cells (Airaksinen et al., 1996; reviewed in 
Koltzenburg, 1999), muscle sensory afferents (innervating muscle spindle afferents and 
Golgi tendon organs) (Helgren et al., 1997; reviewed in Koltzenburg, 1999) and 
sympathetic neurons (Zhou et al., 1999).  Additional support for NT-3s role as a 
survival factor stems from NT-3 knock-out animals that completely lack proprioceptive 
neurons (lack of muscle spindles) (Ernfors et al., 1994; Farinas et al., 1994; Klein, 1994; 
Klein et al., 1994; Tessarollo et al., 1994). 
 9
 Phenotypic modulation of DRG neurons has also been demonstrated for NT-3.  
Nerve injury-induced phenotypic changes in large DRG neurons can be reversed by 
providing exogenous NT-3.  These changes include gene expression for neurotrophin 
receptors trkC and p75 (Gratto, 2002), cytoskeletal components, immediate early genes 
(Verge et al., 1996), neuropeptides (Jongsma Wallin et al., 2001) and the neurotrophin 
BDNF (Karchewski et al., 2002).  In addition to our group, Sterne et al. (1998) report 
that administration of exogenous NT-3 following peripheral nerve transection was 
capable of influencing neuropeptide tyrosine (NPY) expression in DRG neurons. 
 Similar to NGF, NT-3 is produced in peripheral targets (skin, muscle, and 
viscera) and is retrogradely transported to the cell body (Helgren et al., 1997; Zhou et 
al., 1999).  Like BDNF, NT-3 also undergoes anterograde transport to neurons and target 
cells potentially functioning as a neuromodulator and trophic factor (Altar and 
DiStefano, 1998). 
 
 
1.2.4 The trk family of receptors 
 
 The receptor tyrosine kinase family of neurotrophin receptors, characterized by a 
cytoplasmic tyrosine kinase domain and extracellularly, two cysteine clusters, leucine 
rich domains, and two cysteine rich domains (Chao and Hempstead, 1995) is composed 
of three members  tropomyosin-related kinase (trk)A, trkB and trkC  that selectively 
bind neurotrophins with similar high affinity (reviewed in McMahon et al., 1997). NGF 
binds to trkA (Kaplan et al., 1991; Klein et al., 1991), BDNF and NT-4/5 both bind to 
trkB (Klein et al., 1990; Soppet et al., 1991; Squinto et al., 1991) and NT-3 binds 
primarily to trkC, but can also interact with trkB and an isoform of trkA that contains a 6 
amino acid insert in the extracellular binding domain (Lambelle et al., 1991; Ip et al., 
1993). Activation of the trks is dependent on ligand-mediated dimerization of the 
receptor (Hantzopoulous et al., 1994) and results in activation of several signaling 
pathways (i.e. MAPK, Akt, IP3) that in turn promote changes in survival, gene 
expression and neurite outgrowth (reviewed in Miller and Kaplan, 2002). 
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 Extensive work has been undertaken to characterize the prevalence of the trk 
receptors in adult lumbar sensory neurons.  It has been described that approximately 40-
45% of DRG sensory neurons express trkA, about 30% express trkB and there are 
approximately 40% that express trkC (Karchewski et al., 1999).  It is easy to see that 
together these numbers encompass greater than 100% of the sensory neuron population.  
This is due to the overlap of trk receptors that was previously mentioned.  Karchewski et 
al. (1999) went on to further characterize these DRG neurons and found that about 10% 
of DRG neurons expressed both trkA and trkB, about 20% expressed both trkA and 
trkC, about 15% expressed both trkB and trkC and finally, there are about 3% of DRG 
neurons that express all three trk receptors.  There is also a subpopulation of sensory 
neurons (approximately 20%) that do not express any neurotrophin receptors, bind the 
lectin IB-4 and are responsive to the growth factor glial derived neurotrophic factor 
(GDNF) (McMahon et al., 1994; Bennett et al., 1998; Karchewski et al., 1999). 
 Transgenic studies using knock-out mice have been used to assess the key 
developmental roles of these trk receptors.  Deletion of the trkA receptor (as in deletion 
of NGF) results in the loss of approximately 70-80% of small diameter sensory neurons 
(reviewed in McMahon et al., 1997; Mogil and Grisel, 1998).  Additionally, these 
knock-out mice were insensitive to both thermal and mechanical stimulation (Mogil and 
Grisel, 1998).  The selective deletion of the trkB receptor (as seen with deletion of 
BDNF) displays a loss of sensory neurons (not as profound as with the trkA knock-outs), 
a subsequent loss of sensitivity to tactile stimulation, and also a loss of motor neurons 
(Klein, 1994; reviewed in McMahon et al., 1997).  Mice deficient in the trkC receptor 
(as seen with NT-3 knock-out animals) have a loss of sensory neurons responsible for 
proprioception, the result being abnormal movements (Klein, 1994; Klein et al., 1994). 
 
 
1.2.5 p75 
 
 The p75 neurotrophin receptor is capable of binding all members of the NGF 
family of neurotrophins with approximately equal specificity, but a lower affinity than 
the trk receptors and (reviewed in Bothwell, 1996 and McMahon et al., 1997).  In the 
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presence of trk, p75s primary role appears to be modulatory (Bothwell, 1996) creating a 
higher affinity state for NGF binding (Chao and Hemstead, 1995; Ross et al., 1998; 
Shamovsky et al., 1999), although in the absence of trk expression, it can actively 
participate in cell death programs (Rabizadeh et al., 1993; Bothwell, 1996; Frade et al., 
1996).  Approximately 80% of all DRG neurons express p75 (this equates to virtually 
every neuron that expresses a trk receptor) (Karchewski et al., 1999).  p75 knock-out 
mice develop a dramatic insensitivity to thermal stimuli compared to wild-type mice 
(Mogil and Grisel, 1998); however, it is interesting to note that thermal hyperalgesia can 
be induced by NGF even in the absence of p75 (Bergmann et al., 1998).  The function of 
p75, then, is still not well understood. 
 
 
1.3 An introduction to neuropathic pain 
 
In order to begin a discussion about neuropathic pain, it is important to 
understand what is meant by the term nociception.  Nociception refers to the process 
whereby specialized sensory neurons  primarily Aδ and C fibers (nociceptors) - detect 
the presence of noxious stimuli (Caterina et al., 1997; Furst, 1999; Loeser and Melzak, 
1999).  Pain, as defined by IASP Task Force on Toxonomy (1994), is an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage. 
 
 
1.3.1 Normal pain transmission 
 
Under normal, physiological conditions, the transmission of nociceptive 
information from the periphery to the central nervous system (CNS) takes place via a 
specific pathway.  First, nociceptive afferent fibers (Aδ and C fibers) are activated by 
noxious stimuli that is thermal, mechanical, or chemical in nature (Caterina et al., 1997; 
Furst, 1999; Loeser and Melzack, 1999).  These nociceptive fibers transmit this 
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information to the substantia gelatinosa of the spinal cord where second order neurons 
project this information to the thalamus (Furst, 1999; Nolte, 1999).  Finally, the cerebral 
cortex receives the nociceptive information from the thalamus (Furst, 1999; Nolte, 
1999).  This system is highly organized and precise.  However, under pathological 
conditions, such as neuropathic pain, the mechanisms of pain transduction become 
highly variable and convoluted. 
 
1.3.2 Neuropathic pain 
 
In its essence, neuropathic pain is the type of pain that occurs as a result of injury 
to a nerve and becomes a pathological condition.  Neuropathic pain is observed in such 
conditions as causalgia, reflex sympathetic dystrophy and diabetic neuropathy.  For the 
purpose of this thesis, the pathological condition resulting in neuropathic pain will be 
limited to pain resulting from injury to a peripheral nerve  namely the sciatic nerve. 
The study of neuropathic pain is both essential and intriguing.  Essential in the 
respect that the mechanisms of neuropathic pain are not well understood and current 
treatments for neuropathic pain are not very effective (Woolf and Mannion, 1999).  
Intriguing in the respect that the etiology of neuropathic pain is diverse and it is not 
likely that there exists one solitary solution to its treatment. 
There are three important differences between neuropathic pain and normal, non-
pathological pain.  First, neuropathic pain is persistent (as opposed to transient) and 
appears to serve no biological function (reviewed in Millan, 1999; Schwartzman and 
Maleki, 1999; Vaillancourt and Langevin, 1999).  The principal role of physiological 
pain is to protect the organism (for example, to remove the foot from a sharp rock or to 
take the hand away from a hot stove).  Second, neuropathic pain results in an increased 
sensitivity to stimuli (Woolf and Costigan, 1999; Woolf and Mannion, 1999).  
Specifically, this stimulus-evoked pain can be characterized as either hyperalgesia or 
allodynia (see below) (Woolf and Mannion, 1999).  These two hallmarks of neuropathic 
pain are believed to result from the sensitization of peripheral nociceptors (Mannion et 
al., 1999; Urban and Gebhart, 1999) and/or the sprouting of Aβ fibers from lamina V 
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into lamina II of the spinal cord (where nociceptive afferents terminate) (Woolf and 
Decosterd, 1999).  Finally, it is the phenomenon of stimulus-independent, or 
spontaneous pain that distinguishes neuropathic pain from physiological pain (Woolf 
and Mannion, 1999).  Spontaneous pain, as its name suggests, takes place in the 
apparent absence of any stimuli.  Possible reasons for the production of stimulus-
independent pain are spontaneous activity of the A and C fibers (Mannion et al., 1999; 
Woolf and Decosterd, 1999; Woolf and Mannion, 1999) and/or the formation of 
sympathetic baskets around the large sized neurons in the DRG (Ramer et al., 1999; 
Woolf and Decosterd, 1999; Woolf and Mannion, 1999). 
 
 
1.3.3 The chronic constriction injury (CCI) model of neuropathic pain 
 
 The chronic constriction injury (CCI) model of neuropathic pain involves a 
partial lesion of the sciatic nerve induced by tying loosely constrictive chromic gut 
sutures around the sciatic nerve (Bennett and Xie, 1988).  This results in the slow, 
edematous axotomy of predominantly large diameter myelinated axons (90% of Aβ and 
Aδ fibers and 30% of C fibers) by three days post-ligation (Kajander and Bennett, 1992) 
while the uninjured, smaller axons remain intact, but exposed to the Wallerian 
degenerating nerve in which many pro-inflammatory molecules are produced  a state 
akin to that observed in man (Bennett and Xie, 1988). The CCI model, similar to pain 
sensations seen in man, generates a reproducible thermal hyperalgesia and mechanical 
allodynia (Bennett and Xie, 1988).  
 
 
1.3.4 Inflammation and pain 
 
 As previously described, the CCI model exposes the uninjured axons to an 
inflamed environment resulting, in part, from the presence of inflammatory and immune 
cells (such as mast cells and macrophages) that are recruited to aid in the Wallerian 
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degeneration of the injured nerve and to facilitate its regeneration (Perkins and Tracey, 
2000).  These inflammatory and immune cells release a variety of neuroactive agents 
including cytokines (interleukin-6 (IL-6), for example) and growth factors (NGF, for 
example) (Woolf and Costigan, 1999).  Given the ability of NGF to directly regulate 
pain responses and the elevation of endogenous NGF levels in a variety of inflammatory 
states (reviewed in McMahon, 1996) it is not surprising that NGF appears to play an 
important role in the development of abnormal sensations in several models of persistent 
inflammatory/ neuropathic pain. 
 
 
1.3.5 Thermal hyperalgesia 
 
 Hyperalgesia following nerve injury is identified as an increased sensitivity to a 
normally noxious stimulus (a decreased threshold) and/or suprathreshold stimulation 
producing an abnormally exaggerated response (reviewed in Millan, 1999; Woolf and 
Mannion, 1999).  Thermal hyperalgesia then, refers to an increased sensitivity to heat 
stimuli.  It is believed that the unmyelinated C fibers (in hairy skin) and the Aδ fibers (in 
non-hairy skin) contribute to this hyperalgesic state (Millan, 1999). 
 The development of thermal hyperalgesia has been demonstrated to result from a 
vast array of biological molecules.  These molecules include: pro-inflammatory 
cytokines (specifically, tumor necrosis factor alpha  TNF-α) (Sommer et al., 1998); 
growth factors (such as NGF) (Theodosiou et al., 1999); free radicals interacting with 
nitric oxide (Khalil et al., 1999); inflammatory mediators (such as prostaglandins) 
(Syriatowicz et al., 1999); and inflammatory cells (such as neutrophils) (Perkins and 
Tracey, 2000).  More recently, the capsaicin receptor - transient receptor potential 
vanilloid receptor-1 (TRPV1) - which transduces noxious thermal stimuli (Caterina et 
al., 1997), has become a candidate mechanism responsible for the experience of thermal 
hyperalgesia (Caterina et al., 2000; Caterina and Julius, 2001). 
 It is also believed that thermal hyperalgesia is a phenomenon that is mediated 
entirely by peripheral mechanisms.  These mechanisms are reviewed in Millan (1999) 
 15
and include the excitation of nociceptive fibers, the subsequent sensitization of these 
nociceptive fibers, phenotypic alterations in sensory neurons, as well as indirect 
modulation of sensory neurons resulting from interactions with components of the 
immune system and the sympathetic nervous system. 
 
 
1.3.6 Mechanical allodynia 
 
 Following nerve injury, painful sensations can also be elicited by a normally 
non-noxious stimulus  commonly referred to as allodynia (Woolf and Mannion, 1999).  
Although the term allodynia has been accepted by many, there exists a controversy in 
the field regarding whether or not the behavior elicited by mechanical stimuli is in fact 
painful, or simply reflects a heightened awareness of the stimuli.  For this reason, 
throughout the remainder of this thesis, the terms mechanical allodynia and mechanical 
hypersensitivity will be used interchangeably.  It has been proposed that two different 
pathways can result in allodynic experiences (Millan, 1999; Woolf and Mannion, 1999). 
First, myelinated mechanosensitive Aβ fibers (that do not normally convey painful 
information) become responsive to sympathetic stimulation (basket formation around 
these fibers) (Deng et al., 2000; Sun et al., 2001) and unrelatedly, Aβ fibers are also 
believed to sprout into lamina II of the dorsal horn (see above) (Woolf and Decosterd, 
1999). Further evidence of this comes from Field et al. (1999) who demonstrated that Aδ 
and Aβ/capsaicin insensitive primary sensory neurons were responsible for the signaling 
of allodynia in the rat. Second, reduced thresholds or peripheral nociceptors may be able 
to elicit a painful response from a non-noxious stimulus (reviewed in Millan, 1999; 
Woolf and Mannion, 1999). 
 Unlike hyperalgesia, allodynia (mechanical hypersensitivity) is believed to be 
under the control of central (rather than peripheral) mechanisms.  Millan (1999) reviews 
three central mechanisms: increased excitability and/or sensitization of dorsal horn 
neurons; alterations in ascending and descending mechanisms of nociception; and 
adaptive changes in higher centers (thalamus, cortex, etc).  Pursuant to this, it has 
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recently been demonstrated that tactile allodynia requires ascending input to supraspinal 
sites (Sun et al., 2001). 
 It is apparent that the mechanisms that underlie allodynia are not yet clearly 
understood, and only minimal information regarding its development is readily 
available. 
 
 
1.4 Neurotrophins and pain 
 
 The mediation of nociception by neurotrophins has been best characterized for 
NGF with its ability to influence peptides, cytokines, ion channels, and signaling 
pathways involved in the transfer of nociceptive information.  In the intact state, these 
peptides are markers of the trkA population of sensory neurons and include substance P 
(SP), calcitonin gene related peptide (CGRP) and more recently pituitary adenylate 
cyclase activating peptide (PACAP) (Verge et al., 1989a, 1989b, 1992, 1995; Jongsma 
Wallin et al., 2001).  Expression of these peptides is elevated in the presence of excess 
levels of NGF, such as observed with exogenous application of NGF (Verge et al., 1995; 
Amann et al., 1996; Fernyhough et al., 1998; Schuligoi and Amann, 1998) or with 
exposure to inflamed tissue that also has elevated levels of NGF (Verge et al., 1995; 
Zhang et al., 1995; Dickinson et al., 1999; Jongsma Wallin et al., 2001). 
 The role of NGF in nociception extends beyond the phenotypic regulation of the 
trkA-positive population of DRG neurons.  Both local and systemic administration of 
NGF induce pain as reflected by the presence of hyperalgesia (Lewin et al., 1993; Woolf 
et al., 1994; Amann et al., 1996; Malcangio et al., 1997; Schuligoi and Amann, 1998), 
whereas sequestration of NGF using antibodies to NGF mitigates the development of 
hyperalgesia following nerve injury (Herzberg et al., 1997; Ro et al., 1999; Theodosiou 
et al., 1999). Spontaneous pain, another aspect of neuropathic pain, is potentially 
influenced by sympathetic basket formation around the larger sized neurons in the DRG 
as previously described.  This sympathetic sprouting is encouraged by intrathecal NGF 
(Jones et al., 1999) and in a separate set of experiments, anti-NGF administration 
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differentially impeded this sprouting depending on the nerve injury model employed (Ro 
et al., 1996; Ramer and Bisby, 1999; Deng et al., 2000). 
 Although there is a plethora of evidence for the involvement of NGF in the 
development of nociception, Ren et al. (1995) report that NGF infused onto the ligated 
nerve immediately after ligation served to prevent the development of both thermal and 
mechanical hypersensitivity. In addition, the sprouting of Aβ fibers from lamina V into 
lamina II (a possible mechanism for the establishment of hyperalgesia and/or allodynia) 
is effectively prevented by intrathecal administration of NGF (Bennett et al., 1996). This 
evidence strengthens many peoples hypothesis that NGF plays a key role in 
nociception, whereas its absence following injury may also influence plasticity events 
and neuropathic pain associated with this state. 
 A role for BDNF in neuropathic pain has also been well characterized, and 
although it is not the direct focus of this thesis, bears mentioning.  Under inflammatory 
conditions, BDNF expression is elevated in an NGF dependent fashion (Cho et al., 
1997a, 1997b) and appears to be an important mediator of central sensitization derived 
inflammatory pain (Kerr et al., 1999; Mannion et al., 1999; reviewed in Obata and 
Noguchi, 2006).   In the uninjured state, BDNF is localized primarily to the NGF  
responsive (trkA-positive) population of DRG sensory neurons (Apfel et al., 1996; 
Kashiba et al., 1997; Michael et al., 1997, 1999; Karchewski et al., 1999), but undergoes 
a phenotypic switch in response to nerve injury whereby BDNF expression in trkA-
positive neurons is decreased and expression in trkB- and trkC-positive neurons is 
increased (Michael et al., 1999; Zhou et al., 1999; Karchewski et al., 2002).  However, 
under conditions of inflammation or NGF administration, BDNF is upregulated in the 
small and medium sized (trkA-positive) DRG neurons (Apfel et al., 1996; Verge et al., 
1996; Michael et al., 1997).  A direct role for BDNF in the generation of neuropathic 
pain behaviors has also been demonstrated whereby exogenous BDNF was able to 
induce both thermal hyperalgesia and mechanical allodynia (Shu et al., 1999; Miki et al., 
2000; Zhou et al., 2000).  Subsequently, hyperalgesia elicited by BDNF sensitization of 
nociceptive afferents has been shown to be blocked by inhibitors of BDNF (Kerr et al., 
1999; Thompson et al., 1999; Pezet et al., 2002).  There is also compelling evidence that 
the process of inflammatory pain involves endogenous BDNF (Kerr et al., 1999; 
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Mannion et al., 1999; Thompson et al., 1999; Groth and Aanonsen, 2002; Matayoshi et 
al., 2005).  It appears that BDNF signals through the DRG to the dorsal horn of the 
spinal cord promoting the development of chronic (central) pain (Obata et al., 2006; 
reviewed in Obata and Noguchi, 2006). 
 In contrast to NGF and BDNF, the role for NT-3 in nociceptive modulation is not 
yet clearly understood.  NT-3 is able to effect changes in peptide content in both small 
and large fiber sensory neurons following complete or partial injuries that are believed to 
contribute to the ensuing pain state.  Following injury, large fiber populations that 
express trkB and trkC begin to express many of the peptides and molecules that, in the 
intact state, are associated with nociceptive function in the trkA subpopulation (i.e. SP, 
CGRP, PACAP, BDNF) (Zhou et al., 1999; Jongsma et al., 2000; Malcangio et al., 
2000; Jongsma Wallin et al., 2001; Karchewski et al., 2002). 
 A role for NT-3 in counteracting some of the changes in neuropeptide content in 
this diverse size range of neurons is strongly supported by its ability to mitigate injury-
associated increases in Galanin, NPY, PACAP, BDNF (Gratto et al., 1994, 1995; Sterne 
et al., 1998; Karchewski et al., 2002; Wilson-Gerwing and Verge, 2006), SP (Gratto et 
al., 1994, 1995; Gratto 2002) and the pro-inflammatory, pro-nociceptive cytokine IL-6 
(Verge and Johnston, 2000) that is also elevated in this population of chronically 
transected neurons (Murphy et al., 1995; Murphy et al., 1999). 
 Concerning the impact of NT-3 on the development of thermal and/or 
mechanical hypersensitivity, reports are not consistent.  While I have previously 
reported that intrathecal infusion of NT-3 at the time of CCI can effectively prevent the 
development of thermal hyperalgesia and not impact mechanical hypersensitivity 
(Wilson-Gerwing et al., 2005), Gandhi et al. (2004) have reported that NT-3 can 
effectively treat mechanical hypersensitivity resulting from intramuscular acid 
injections.  Malcangio et al. (1997) found that exogenous NT-3 induced hypoalgesia to 
mechanical, but not to thermal stimuli, while White (1998) found that NT-3 significantly 
reduced mechanical nociceptive thresholds as compared to saline controls.  Finally, Shu 
et al. (1999) reports that NT-3 does not elicit sensitization to thermal stimuli.  Clearly, 
more research must be undertaken to sort out NT-3s role in affecting changes to 
nociceptive threshold. 
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1.5 Recent molecules of interest to pain research 
 
 Over the past decade, the focus of investigations into the mechanisms and 
modulators of neuropathic pain has shifted from the examination of peptides and their 
related receptors to that of a variety of ion channels.  Of primary interest to the 
development and maintenance of thermal hyperalgesia has been the capsaicin receptor 
transient receptor potential vanilloid receptor-1 (TRPV1) (Caterina et al., 1997, 2000; 
Davis et al., 2000; Garcia-Martinez et al., 2002).  Another channel that has garnered 
much attention and controversy regarding its function is the acid sensing ion channel 3 
(ASIC3) that is known to respond to tissue acidosis as occurs under inflammatory 
conditions (Steen et al., 1992; Rang et al., 1991; Reeh and Steen, 1996; Helminger et al., 
1997; Jacobus et al., 1977).  It has been proposed that ASIC3 plays a functional role in 
both nociception (Krishtal and Pidoplichko, 1981; Benson et al., 1999) and 
mechanosensation (Garcia-Anoveras et al., 2001; Price et al., 2001; Sluka et al., 2003; 
Mogil et al., 2005). Lastly, much attention has been paid to the tetrodotoxin resistant 
(TTX-R) sodium channels Nav1.8 and Nav1.9.  One of the hallmarks of neuropathic pain 
is a change in the sensitivity of nociceptors (reviewed in Devor, 2006).  It has long been 
known that the key modulators of cellular excitability are sodium channels (Hodgkin 
and Huxley, 1952).  More recently, the involvement of sodium channels in the 
conveyance of increased neuronal sensitivity following nerve injury and inflammation 
have been the subject of vast amounts of research (for reviews see Lee et al., 2005; Amir 
et al., 2006; Rogers et al., 2006).  
These channels (TRPV1, ASIC3, Nav1.8 and Nav1.9) are of particular interest to 
this thesis work as they have each been demonstrated to be positively regulated by NGF 
(Dib-Hajj et al., 1998; Fjell et al., 1999; Ji et al., 2002b; Mamet et al., 2002; Mamet et 
al., 2003; Fang et al., 2005).  For each of TRPV1, ASIC3, and Nav1.8, this NGF-related 
regulation occurs as a result of activation of various trkA/mitogen activated protein 
kinase (MAPK) pathways (Ji et al., 2002b; Mamet et al., 2003; Fang et al., 2005).  In 
light of these reports, an examination of the MAPKs phospho-p38 and phospho- 
extracellular signal related kinase (pERK) were also examined as they have been shown 
to be activated by inflammatory mediators and are proposed to participate in the 
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generation and perhaps maintenance of pain syndromes following nerve injury (Ji et al., 
2002a; Obata et al., 2004; reviewed in Ma and Quirion, 2005). 
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2 Hypothesis and Specific Aims 
 
Neuropathic pain is a complex clinical problem occurring in response to 
peripheral nerve damage and characterized by hyperalgesia, allodynia, and spontaneous 
pain.  The signals regulating these responses have become better elucidated in the past 
decade, and include the promotion of thermal hyperalgesia, nociceptor phenotype and 
pain-related ion channels by the neurotrophin nerve growth factor (NGF).  Recent 
evidence in our lab suggests that another member of this family of molecules, 
neurotrophin-3 (NT-3), acts in an antagonistic fashion to NGF in regulation of 
nociceptor phenotype.   
 The chronic constriction injury (CCI) model of neuropathic pain involves a 
partial lesion of the sciatic nerve induced by loosely tying the sciatic nerve with chromic 
gut sutures.  This injury results in the slow, edematous axotomy of predominantly large 
diameter axons while leaving the intact smaller diameter axons exposed to a pro-
inflammatory environment.   The behavioral components of this injury include an 
increase in sensitivity to both thermal and mechanical stimuli, and the development of 
spontaneous pain.  Thus, employing the CCI in rats, with or without intrathecal infusion 
of NT-3 via a mini osmotic pump, I have previously demonstrated that NT-3 can prevent 
some of the changes of sensory neurons that occur in response to CCI injury and are 
believed to contribute to neuropathic pain states.  These findings demonstrated that NT-3 
can antagonize the development of thermal hyperalgesia and molecules complicit in this 
behavior.  This was the first direct demonstration of a role for NT-3 in antagonizing 
aspects of the NGF/trkA interaction associated neuropathic pain state.  However, the 
true extent of NT-3s ability to antagonize nociceptive phenotype in sensory neurons, 
especially the trkA subpopulation, remained to be elucidated and is the major focus of 
my PhD thesis.   
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To achieve this I continued to investigate my original hypothesis that NT-3 
mitigates neuropathic pain and cellular signaling associated with inflamed states by 
attenuating signaling associating with NGF mediated trkA activation and thus 
presumably mitigating the normal upregulation of key molecules believed to contribute 
to this pain state.   
 
Specific Aims 
 
To test this hypothesis and to reveal the behavioral and biochemical 
consequences of NT-3 affects on CCI-associated neuropathic changes, I addressed the 
following aims: 
 
1) To assess the ability of exogenous NT-3 to reverse neuropathic pain 
behaviors if administered after their establishment.   
 
2)  To assess the ability of NT-3 to modulate the transient receptor potential 
vanilloid receptor-1 (TRPV1) pathway involved in thermal hyperalgesia 
 
3)  To assess the ability of exogenous NT-3 to mitigate elevated acid sensing 
ion channel 3 (ASIC3), phospho-p38 mitogen activated kinase (MAPK), and 
activated (phosphorylated)-extracellular regulated kinase (phospho-ERK) signaling 
associated with inflammation. 
 
4) To assess the ability of exogenous NT-3 to mitigate sodium channel 
expression implicated in neuropathic pain. 
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3 Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic 
pain and attenuates transient receptor potential vanilloid receptor-1 expression in 
adult sensory neurons 
 
 
3.1 Abstract 
 
Neurotrophin-3 (NT-3) negatively modulates nerve growth factor (NGF) receptor 
expression and associated nociceptive phenotype in intact neurons, suggesting a 
beneficial role in treating aspects of neuropathic pain mediated by NGF.  I report that 
NT-3 is effective at suppressing thermal hyperalgesia associated with chronic 
constriction injury (CCI); however, NT-3 does not alter the mechanical hypersensitivity 
that also develops with CCI.  Thermal hyperalgesia is critically linked to expression and 
activation of the capsaicin receptor, transient receptor potential vanilloid receptor-1 
(TRPV1).  Thus, its modulation by NT-3 after CCI was examined.  CCI results in 
elevated TRPV1 expression at both the mRNA and protein levels in predominantly 
small-to-medium neurons, with the percentage of neurons expressing TRPV1 remaining 
unchanged at ~56%.  Attenuation of thermal hyperalgesia mediated by NT-3 correlates 
with decreased TRPV1 expression such that only ~26% of neurons ipsilateral to CCI 
expressed detectable TRPV1 mRNA.  NT-3 effected a decrease in expression of the 
activated component of the signaling pathway linked to regulation of TRPV1 
expression, phospho-p38 MAPK (Ji et al., 2002b), in neurons ipsilateral to CCI.  
Exogenous NT-3 could both prevent the onset of thermal hyperalgesia and reverse 
established thermal hyperalgesia and elevated TRPV1 expression 1 week after CCI.  
Continuous infusion is required for the suppression of both thermal hyperalgesia and 
TRPV1 expression, because removal of NT-3 resulted in a prompt reestablishment of the
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hyperalgesic state and corresponding CCI-associated TRPV1 phenotype.  In conclusion, 
although NGF drives inflammation-associated thermal hyperalgesia via its regulation of 
TRPV1 expression, NT-3 is now identified as a potent negative modulator of this state. 
 
 
3.2 Introduction 
 
Neuropathic pain is a complex clinical problem that occurs in response to peripheral 
nerve damage and is characterized, in part, by hypersensitivity to thermal and/or 
mechanical stimuli.  The signals regulating these responses are complex and include the 
promotion of thermal hyperalgesia and nociceptor phenotype by the neurotrophin nerve 
growth factor (NGF) through activation of its receptor, tropomyosin-related kinase A 
(trkA) (Verge et al., 1989b, 1995; Lewin and Mendell, 1993; Jongsma Wallin et al., 
2001, 2003).  Recently, it has been shown that the upregulation of NGF after peripheral 
inflammation leads to the activation of the mitogen-activated protein kinase (MAPK) 
p38 (Ji et al., 2002b).  Widmann et al. (1999) and Ji and Woolf (2001) characterized p38 
MAPK as a protein kinase that is stress-activated and plays a role in both injury 
responses and cell death.  Secondary to p38 MAPK activation by NGF is the 
upregulation of the transient receptor potential vanilloid receptor-1 (TRPV1) (Ji et al., 
2002b).  TRPV1, in turn, plays a critical role in inflammation and injury-induced 
thermal hyperalgesia (Caterina et al., 1997, 2000; Davis et al., 2000; Garcia-Martinez et 
al., 2002).  Thus, NGF is linked to TRPV1-mediated thermal hyperalgesia, having a role 
in both sensitization and positive regulation of TRPV1 expression (Chuang et al., 2001; 
Winston et al., 2001; Ji et al., 2002b). 
 Evidence emerging from our lab indicates that another neurotrophin, 
neurotrophin-3 (NT-3), acts in a manner that is antagonistic to NGF.  Although trkA is 
the cognate receptor for NGF, NT-3 is also capable of activating trkA and trkB in 
addition to its own cognate receptor (trkC) (for review, see Lindsay, 1996).  Our 
findings reveal that in intact neurons, NT-3 effects a notable reduction in trkA, high-
affinity NGF binding sites, brain-derived neurotrophic factor (BDNF), substance P, 
calcitonin gene-related peptide, and pituitary cAMP-activated peptide levels (Verge et 
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al., 1989a,b, 1992, 1995; Jongsma Wallin et al., 2001; Karchewski et al., 2002; Gratto 
and Verge, 2003).  This ability of NT-3 to antagonize nociceptive phenotype in sensory 
neurons led me to speculate that exogenous NT-3 may prove beneficial in the treatment 
of neuropathic pain.  Thus, in this study, I examined whether NT-3 could functionally 
antagonize neuropathic pain associated with chronic constriction injury (CCI), an injury 
that elicits a series of changes in primary sensory neurons believed to contribute to the 
ensuing neuropathic pain state (Bennett and Xie, 1988; Kajander and Bennett, 1992; 
Nahin et al., 1994; Miki et al., 1998).  The evaluation focuses on the ability of NT-3 to 
alter activation of p38 MAPK and subsequent elevation of TRPV1, as well as the 
resultant thermal hyperalgesia associated with CCI. 
 
 
3.3 Material and methods 
 
3.3.1 Animal surgery 
 
All animal procedures were conducted in accordance with the National Institutes 
of Health policy on the use of animals in research and the University of Saskatchewan 
animal care committee guidelines (protocol 19920164).  A total of 45 young adult male 
Wistar rats (Charles River Laboratories, Wilmington, MA) weighing 250-300 g were 
used.  Animals were anesthetised for surgery with sodium pentobarbital (Somnitol, 65 
mg/kg; MTC Pharm, Cambridge, Ontario, Canada).  Preoperative and postoperative (for 
24 h) subcutaneous injections of buprenorphine (Temgesic, 0.1-0.2 mg/kg) were given 
to alleviate any postoperative discomfort.  To examine the influence of NT-3 on 
development of neuropathic pain responses, 10 rats were used: 5 underwent 7 d 
unilateral CCI of the right sciatic nerve as described by Bennett and Xie (1988) during 
which the sciatic nerve was exposed and loosely ligated with four chromic gut sutures 
(intact; CCI); and 5 rats received 7 d unilateral CCI with intrathecal infusion of NT-3 for 
the duration of the injury (intact + NT-3, CCI + NT-3).  To examine the ability of NT-3 
to reverse neuropathic pain responses and whether continuous infusion is required for 
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the effect, 21 rats were used: 7 underwent 14 d unilateral CCI; 7 received intrathecal 
infusion of NT-3 on day 7 after CCI [intact + NT-3 (delayed), CCI + NT-3 (delayed)]; 
and 7 rats received intrathecal infusion of NT-3 at the time of CCI with pump removal at 
7 d after CCI [intact + NT-3 (immediately); CCI + NT-3 (immediately)].  To examine 
the effect of NT-3 on total protein levels using Western blot analysis, 12 rats were used: 
6 rats underwent 7 d unilateral CCI and 6 rats received 7 d unilateral CCI with 
intrathecal infusion of NT-3 for the duration of the injury (intact + NT-3; CCI + NT-3). 
NT-3 was delivered intrathecally for 7 d via mini-osmotic pumps (model 2001; 
Alza, Cupertino, CA) inserted at the lumbar sacral junction as per Verge et al., (1989a) 
at a concentration and rate of 600 ng/µl/hr (Karchewski et al., 2002) in a solution of PBS 
containing rat serum albumin (1 mg/ml), streptomycin (100 U/ml), and penicillin (100 
U/ml).  This dose of NT-3 was the minimum dose found to selectively reverse injury-
associated gene expression in injured trkC-expressing neurons (Verge et al., 1996; 
Jongsma Wallin et al., 2001; Karchewski et al., 2002).  At the conclusion of the 
experiments, rats were killed, and tissue was dissected and processed for in situ 
hybridization and/or immunohistochemistry as described below. 
 
 
3.3.2 In situ hybridization 
 
Deeply anesthetised animals were perfused via the aorta with 0.1 M PBS, pH 7.4, 
followed by rapid dissection and freezing of right and left L4 and L5 dorsal root ganglia 
(DRG) in OCT compound (Tissue Tek; Miles Laboratories, Elkhart, IN) in a cryomold 
(Tissue Tek; Miles Laboratories, Elkhart, IN).  Before sectioning, block containing pairs 
of experimental and control DRG were fused to ensure processing under identical 
conditions.  Sections were cut at 6 µm on a Micron cryostat (Zeiss, Edmonton, Alberta, 
Canada), thaw mounted onto Probe-On+ slides (Fisher Scientific, Edmonton, Alberta, 
Canada), and stored with desiccant at -20 oC until hybridization. 
Oligonucleotide probes complementary to and selective for TRPV1 mRNA 
[complementary to bases 509-542 and bases 2601-2634 (Caterina et al., 1997; Michael 
and Priestly, 1999)] were synthesized (University of Calgary DNA services, Calgary, 
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Alberta, Canada).  All probes were checked against the GenBank database (National 
Institutes of Health, Bethesda, MD) to ensure that no more than 60% homology was 
found to sequences other than the cognate transcript.  The probes were labelled at the 3-
end with α-[35S]dATP |(New England Nuclear, Boston MA) using terminal 
deoxynucleotidyl-transferase (Amersham Biosciences, Piscataway, NJ) in a buffer 
containing 10 mM CoCl2, 1 mM dithiothreitol (DTT), 300 mM Tris base, and 1.4 M 
potassium cacodylate, pH 7.2, and purified through Bio-Spin Disposable Chromatograph 
Columns (BioRad Laboratories, Hercules, CA) containing 200 mg of NENSORB PREP 
Nucleic Acid Purification Resin (DuPont NEN, Boston, MA).  Dithiothreitol was added 
to a final concentration of 10 nM.  Specific activities ranged from 4.5 to 5.0 X 106 
cpm/ng oligonucleotide. 
Hybridization was performed according to published procedures (Dagerlind et 
al., 1992).  Briefly, the sections were hybridized at 43 oC for 14-18 h in a buffer 
containing 50% formamide (Sigma Aldrich, Oakville, Ontario, Canada), 4 X SSC (1 X 
SSC = 0.15 M NaCl, 0.015 M sodium citrate), 1 X Denhardts solution (0.02% bovine 
serum albumin and 0.02% Ficoll), 1% sarcosyl (N-laurylsarcosine), 0.02 M phosphate 
buffer, pH 7.0, 10% dextran sulphate, 500 µg/ml heat-denatured sheared salmon sperm 
DNA, 200 mM dithiothreitol, and 107 cpm/ml of probe.  After hybridization, the slides 
were washed four times for 15 min in 1 X SSC at 55 oC, dehydrated in ascending 
alcohols, processed for radioautography as per Karchewski et al., (2002) and exposed for 
7-10 d before developing in D-19 (Kodak, Rochester, NY). 
The specificity of hybridization signal for the TRPV1 probes used in the study 
was confirmed using serial sections hybridized with labelled probe, labelled probe with a 
1000-fold excess of cold probe (which effectively competed all specific binding of 
labelled probe), or labelled probe with a 1000-fold excess of another, dissimilar cold 
probe of the same length and similar G-C content (which did not alter the 
hybridization signal pattern). 
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3.3.3 Quantification and analysis 
 
All slides were analyzed qualitatively, and relative changes in hybridization 
signal from one experimental group to another were noted for sections mounted on the 
same slide to avoid bias attributable to the variance in signal observed from slide to 
slide.  Slides selected for quantitative analysis had similar numbers of neurons in all 
DRG sections.  Relative changes in hybridization signal over individual neurons with a 
visible nucleus were determined in DRG from different experimental treatments 
mounted on the same slide using computer-assisted image analysis as described 
previously (Karchewski et al., 1999).  Analysis was performed as follows: for TRPV1 
mRNA (7 d injury) on 12 DRG sections or 2823 neuronal profiles (intact: n=3 animals; 
CCI: n=3 animals; intact + NT-3: n=3 animals; CCI + NT-3: n=3 animals); for TRPV1 
mRNA (14 d injury) on 12 DRG sections or 1992 neuronal profiles [intact: n=2 animals; 
CCI: n=2 animals; intact + NT-3(immediately): n=2 animals; CCI + NT-3(immediately): 
n=2 animals; intact + NT-3(delayed): n=2 animals; CCI + NT-3(delayed): n=2 animals]. 
Cells were considered labelled if they had more than five times background 
levels of silver grains, as determined by averaging grain densities over defined areas of 
the neuropil devoid of positively labelled cell bodies.  This criterion of determining 
labelled neuronal profiles correlates well with the identification of labelled versus 
unlabeled neurons as determined manually using a 63X oil immersion objective. 
 
 
3.3.4 Immunohistochemistry 
 
Deeply anesthetised animals were perfused via the aorta with 0.1M PBS 
followed by 4% paraformaldehyde.  Right and left L4 and L5 DRG were dissected, 
postfixed for 1-1.5 h, and cryoprotected in 20% sucrose overnight at 4 oC.  Paired 
experimental and control tissues were frozen in the same cryomold to ensure processing 
under identical conditions.  Transverse 10 µm sections were cut on the cryostat (Zeiss, 
Edmonton, Alberta, Canada) thaw-mounted onto Probe-On+ slides (Fisher Scientific, 
Edmonton, Alberta, Canada), and processed for immunohistochemistry. 
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For TRPV1, sections were washed three times for 10 min in 0.1 M PBS, blocked 
in 1.5% BSA, 4% horse serum, and 0.1% Triton X-100 in 0.1M PBS for 1 h at 4 oC, 
incubated overnight with rabbit anti-VR-1 (TRPV1) (10 µg/ml; Alpha Diagnostic 
International, San Antonio, TX), diluted in 0.5% BSA, 2% horse serum, and 0.1% Triton 
X-100 in PBS (0.1 M) at 4 oC, and visualized with Alexa Fluor 488 goat anti-rabbit IgG 
(1:200, Molecular Probes, Eugene, OR) in PBS (0.1 M) with 0.5% BSA and 2% horse 
serum for 50 min at room temperature.  Slides were washed and coverslipped with 50% 
glycerol/50% PBS.  For phosphorylated p38 MAPK (phospho-p38), sections were 
washed in 0.1 M PBS, blocked with 10% horse serum and 0.1% Triton X-100 in 0.1M 
PBS for 1 h at room temperature, incubated overnight with rabbit anti-phospho-p38 
MAPK (Cell Signaling Technology, Beverly, MA), diluted 1:50 in 1% BSA and 0.1% 
Triton X-100 in PBS (0.1 M) at 4 oC, and visualized using donkey anti-rabbit F(ab)2 
Cy3 conjugate (1:400, Jackson ImmunoResearch Laboratories, West Grove, PA) in 0.1 
M PBS for 1 h at room temperature.  The slides were washed and coverslipped with 
Citifluor (Marivac, Halifax, Nova Scotia, Canada).  Control sections were processed in 
the same manner, but without the primary antibody.  Results were viewed using a Zeiss 
Axioscope 50 microscope equipped with incident-light fluorescence optics and a CCD 
camera. 
 
 
3.3.5 Western blots 
 
The L4 and L5 DRG were dissected out and immediately placed in ice-chilled 
RIPA buffer (50 µl per three DRG) containing an anti-protease mixture (Sigma Aldrich, 
Oakville, Ontario, Canada) and 1 M DTT with 10 mM Na acetate, pH 5.3.  The DRG 
were flash frozen/thawed three times and homogenized (Tissue Tearor; Biospec 
Products, Bartlesville, OK), and protein was extracted using pulse sonication for 3 s.  
The samples were ultracentrifuged at 14.5 K rpm at 4 oC for 30 min.  A Bradford assay 
was conducted on the lysates so an equivalent quantity of protein could be loaded onto 
each gel.  Equivalent loading was verified by Coomassie staining after transfer of the 
SDS-PAGE. 
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Protein samples were separated by SDS-PAGE and transferred onto a 
nitrocellulose paper.  The blots were blocked with 7.5% milk powder and 0.5% Tween 
20 overnight at 4 oC.  The blots were then incubated with the phospho-p38 MAPK 
(Thr180/Tyr182) (1:1000; Cell Signaling Technology, Beverly, MA) or VR-1 (TRPV1) 
(1:1000; Alpha Diagnostic International, San Antonio, TX) primary antibody in PBS 
containing 5% milk powder and 0.5% Tween 20 overnight at 4 oC, followed by 
incubation in the HRP-linked secondary antibody (anti-rabbit IgG, 1:2000; Cell 
Signaling Technology, Beverly, MA) for 45 min at room temperature.  All washes were 
done using PBS containing 0.1% Tween 20.  A Western Lightening Chemiluminescence 
kit was used to visualize the bound HRP-conjugated secondary (PerkinElmer Life 
Sciences, Boston, MA).  The membrane was exposed to Kodak X-Omat AR film and 
developed. 
 
 
3.3.6 Assessment of behavioral responses 
 
Male Wistar rats (250g) (Charles River Laboratories, Wilmington, MA) were 
acclimatized to the facility before the start of testing.  Animals were housed individually 
in clear plastic cages and maintained in a 12 h light/dark cycle.  Food and water were 
available ad libitum.  All behavioral testing was performed at the same time of day to 
avoid hormonal cycling of the male rats. 
Thermal hyperalgesia was assessed using the Hargreaves Plantar Test 
(Hargreaves et al., 1988) (Ugo Basile, Comerio, Italy).  The animal was placed in a clear 
Plexiglas chamber atop a clear glass surface that housed a radiant heat source and 
acclimatized (~5 min).  The heat source was placed directly under the plantar surface of 
the hindpaw and activated, starting a digital timer.  The timer stopped when the paw was 
withdrawn from the heat source, indicating the paw withdrawal latency.  A maximum 
time of 30 s was in place to prevent tissue damage.  Five readings for each paw were 
taken (allowing 5 min intervals between paws to prevent sensitization).  Baseline levels 
were established for 5 d before CCI and/or pump implantation.  Behavioral testing 
resumed 2 d after surgery and continued on days 2, 4, 6, 9, 11, and 13 after surgery. 
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Because the thermal sensitivity of the uninjured paw contralateral to CCI (intact) 
was not altered throughout the experiments (Figure 3-1), the withdrawal latency of the 
CCI paw was divided by the withdrawal latency of the uninjured contralateral paw for 
each day of testing.  The highest and lowest ratios were excluded.  The remaining ratios 
were transferred into Prism graphing software (GraphPad, Version 4.0; GraphPad 
Software, San Diego, CA), and graphs were generated using the mean value for each day 
of testing +/- standard error of the mean (s.e.m.).  ANOVA was used to determine 
significant differences between experimental (NT-3 infused) and control groups (CCI 
alone) (significance p<0.05). 
Sensitivity of the hindpaw to mechanical stimulation was measured using 
calibrated von Frey filaments (Stoelting, Kiel, WI).  Animals were placed in a clear 
Plexiglas chamber atop a modified semi-opaque Plexiglas platform [built according to 
the specifications of Pitcher et al. (1999) with slight modifications] and acclimatized (~5 
min).  Briefly, a 3 mm-thick piece of semi-opaque Plexiglas was cut to 30 X 30 cm.  
Small holes (1.5 mm diameter) were drilled in a grid pattern 5 mm apart to cover the 
entire surface.  This testing surface was then placed on top of a metal frame.  Each van 
Frey filament was applied perpendicular to the plantar surface of the hindpaw five times, 
and the number of times that the paw was withdrawn from the hair was recorded.  
Increasing sizes of hairs were applied until the hindpaw was withdrawn four times out of 
five applications.  This was defined as the threshold for withdrawal.  The interval 
between application of increasing size filaments and between paws was 5 min (to 
prevent sensitization).  Baseline levels were established for 5 d before CCI and/or pump 
implantation.  Behavioral testing resumed on days 2, 4, 6, 9, 11, and 13 after surgery. 
The data obtained from the assessment of mechanical sensitivity, with 
withdrawal threshold (in grams), for the CCI paw for each day of testing were 
normalized such that the mean withdrawal thresholds for baseline were given a value of 
1.  All data collected were graphed in Prism (GraphPad, Version 4.0; GraphPad 
Software, San Diego, CA).  Graphs were generated using the mean values of all 
normalized withdrawal thresholds for each day of testing +/- s.e.m.  Significant  
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Figure 3- 1:  NT-3 infusion does not alter withdrawal latency to thermal 
stimulation of contralateral intact hindpaw. 
 
Hyperalgesia index plots represent changes in paw withdrawal latency (seconds) to 
thermal stimulation of the contralateral intact hind paw in response to 14 day CCI (A), 
14 day CCI with immediate infusion of NT-3 [followed by removal for the last 7d (B)], 
and 14 day CCI with delayed infusion of NT-3 [7d post CCI (D)].  A, Paw withdrawal 
latency on the contralateral intact hind paw is not significantly altered by CCI (n=7).  B, 
Immediate infusion of NT-3 does not significantly alter paw withdrawal latency on the 
contralateral intact hind paw (n=7).  C, Delayed infusion of NT-3 does not significantly 
alter paw withdrawal latency on the contralateral intact hind paw (n=7).  Gray line 
indicates the time of CCI; black arrow indicates the start of NT-3 infusion; gray arrow 
indicates the time of pump removal.    
 
 
differences between experimental and control groups were determined using ANOVA 
(p<0.05). 
 
 
3.4 Results 
 
3.4.1 The effect of NT-3 on neuropathic pain indices associated with CCI:  NT-3 
significantly attenuates thermal hyperalgesia 
 
The chronic constriction injury model was used to examine whether NT-3 (in its 
ability to downregulate trkA and associated phenotypes) alters behavioral indices of 
neuropathic pain.  To determine whether NT-3 might be effective at reversing thermal 
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hyperalgesia once established and if continuous infusion of NT-3 is required for this 
effect, animals underwent a 14 d unilateral CCI of the sciatic nerve.  These animals 
developed a significant increase in sensitivity to thermal stimulation in the injured 
hindpaw (p<0.0001) when compared to baseline levels (Figure 3-2A).  Delayed infusion 
of NT-3 (days 7-14 after CCI) resulted in a significant reversal of the thermal 
hyperalgesia compared to those animals having undergone CCI alone (p<0.0001) 
(Figure 3-2C).  In contrast, although immediate infusion of NT-3 significantly attenuated 
the development of thermal hyperalgesia (p<0.0001), removal of the NT-3 pumps at 7 d 
after CCI resulted in a quick reestablishment of the thermal hyperalgesic state (Figure 3-
2B).  Thus, the NT-3 mediated attenuation of thermal hyperalgesia associated with CCI 
requires continuous infusion of NT-3. 
 
 
3.4.2 NT-3 has no significant influence on mechanical hypersensitivity associated 
with CCI 
 
To determine whether delayed infusion of NT-3 or removal of exogenous NT-3 
might alter mechanical responses, the 14 d unilateral CCI model was used.  Animals 
having undergone unilateral CCI of the sciatic nerve for 14 d developed a significant 
increase in mechanical sensitivity (p<0.0001) (Figure 3-2D).  Delayed infusion of NT-3 
after CCI did not result in any perceptible changes in mechanical sensitivity compared 
with those having undergone CCI alone (Figure 3-2F).  Furthermore, removal of NT-3 
pumps at 7 d after injury did not impact the mechanical hypersensitivity (Figure 3-2E). 
 
 
3.4.3 NT-3 prevents and counteracts CCI-associated increases in TRPV1 expression 
 
Because of the dramatic influence of NT-3 on neuropathic thermal sensation, the 
regulation of TRPV1 expression was examined in the DRG of animals used for the 
behavioral studies.  Analysis of sections processed for in situ hybridization to detect  
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Figure 3- 2: Delayed infusion of NT-3 can reverse established thermal hyperalgesia 
but not mechanical sensitivity after CCI. 
 
Hyperalgesic index plots represent alterations in thermal (A-C) and mechanical (D-F) 
sensitivities in 14d CCI animals in response to immediate NT-3 [followed by removal 
for the last 7d (B, E)] or delayed NT-3 [7d post CCI (C, F)].  Gray line indicates the time 
of CCI; black arrow indicates the start of NT-3 infusion; gray arrow indicates the time of 
pump removal.  Asterisks indicate significant difference from CCI alone.  A, Thermal 
hyperalgesia is significantly increased compared with baseline levels after unilateral CCI 
and is maintained for the duration of the experiment (n=7).  B, Infusion of NT-3 is 
required for continuous prevention of thermal hyperalgesia after CCI.  Infusion of NT-3 
significantly attenuates the development of thermal hyperalgesia after unilateral CCI and 
is maintained for the duration of the 7d infusion (***p<0.0001).  After removal of the 
NT-3 pump, thermal hyperalgesia was reestablished and did not significantly differ from 
CCI alone (n=7).  C, Delayed infusion of NT-3 significantly reverses thermal 
hyperalgesia compared with CCI alone (***p<0.0001) and is maintained for the duration 
of the infusion (7d) (n=7).  D, Mechanical sensitivity is significantly increased compared 
with baseline levels after unilateral CCI and is maintained for the duration of the 
experiment (n=7).  E, Immediate NT-3 infusion does not alter mechanical sensitivity 
compared with CCI alone.  Stopping NT-3 infusion does not alter mechanical sensitivity 
compared with CCI alone (n=7).  F, Delayed infusion of NT-3 does not alter mechanical 
sensitivity compared with CCI alone. 
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neuronal expression of TRPV1 mRNA revealed that in the DRG contralateral to CCI 
(intact), detectable hybridization signal was localized over small and medium neurons 
(<40 µm) representing 56.13 +/- 0.99% (s.e.m.) of all neurons measured (Figure 3-3).  
Neurons expressing moderate to high levels of hybridization signal (>20 X background) 
accounted for 24.77 +/- 1.88% (s.e.m.) of all neurons measured.  Seven days after CCI, 
relative levels of hybridization signal over small and medium neurons were elevated and 
detectable over a few large neurons, albeit at relatively low levels (Figure 3-3).  Despite 
these alterations in expression, the overall percentage of neurons expressing TRPV1 
mRNA remained similar to that seem in the DRG contralateral to CCI [55.90 +/- 2.95% 
(s.e.m.)] with no significant change in the percentage of neurons with moderate to high 
levels of hybridization signal [25.57 +/- 5.19% (s.e.m.)]. 
NT-3 infusion effected a reduction in the levels of neuronal TRPV1 mRNA 
expression both ipsilateral (CCI + NT-3) and contralateral (intact + NT-3) to CCI 
(Figure 3-3).  This effect was most profound for neurons ipsilateral to CCI.  In DRG 
contralateral to CCI, levels of TRPV1 mRNA hybridization signal were modestly 
attenuated after infusion of NT-3 (Figure 3-3), with the overall percentage of neurons 
expressing detectable levels reduced from 56.13 +/- 0.99% (s.e.m.) to 45.50 +/- 6.98% 
(s.e.m.).  In contrast, a far more dramatic attenuation of TRPV1 expression was 
observed in 7 d CCI animals that received NT-3 infusion for the duration of the injury 
[from 55.90 +/- 2.95% (s.e.m.) to 26.13 +/- 0.61% (s.e.m.)] (Figure 3-3).  The decrease 
in TRPV1 mRNA was observed in all size ranges of neurons, with those expressing 
moderate to high levels of hybridization signal now representing only 5.07 +/- 1.69% 
(s.e.m.) of the neuronal population compared with 24.77 +/- 1.88% (s.e.m.) in animals 
with CCI alone.  Notably, TRPV1 expression was no longer detectable in large-size 
neurons after NT-3 infusion (Figure 3-3). 
Analysis of sections processed to detect neuronal expression of TRPV1 mRNA 
from animals having undergone 14 d CCI with either immediate (days 07) or delayed 
(days 7-14) infusion of NT-3 revealed that the patterns of TRPV1 expression from CCI 
plus immediate NT-3 appeared very similar to those of CCI alone.  Quantification of 
hybridization signal over individual neurons from CCI or CCI plus immediate NT-3 
revealed that detectable TRPV1 mRNA hybridization signal was observed  
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Figure 3- 3:  Message levels for TRPV1 are reduced after NT-3 treatment. 
 
Top: Darkfield photomicrographs of 6 µm thick adult rat L5 DRG sections processed for 
in situ hybridization to detect TRPV1 transcripts contralateral (Intact) or ipsilateral to 7d 
CCI (CCI) and after 7d unilateral CCI plus intrathecal infusion of 600 ng/µl/hr NT-3 
(Intact+NT-3; CCI+NT-3).  Scale bar, 100 µm.  Note: NT-3 infusion results in the 
reduction in relative levels of hybridization signal for TRPV1 over individual neurons, 
with the influence most apparent after CCI.   
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Bottom: Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
TRPV1 mRNA.  The relationship between TRPV1 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states are indicated at 
the top right of each graph are as described above.  Labeling refers to the ratio of silver 
grain density over the neuronal cytoplasm to grain density over areas of the neuropil 
devoid of positive hybridization signal.  Solid lines divide the plots into labeled and 
unlabeled populations; dotted lines separate lightly labeled from moderate to heavily 
labeled populations of TRPV1-expressing neurons.  Note: In DRG contralateral to CCI, 
TRPV1 is expressed predominantly in small to medium neurons.  CCI results in elevated 
TRPV1 expression in small to medium neurons and a novel but low level of expression 
in large neurons.  NT-3 infusion produced a reduction in the levels and percentage of 
neurons expressing detectable TRPV1 mRNA in DRG both ipsilateral and contralateral 
to CCI, with a more pronounced effect ipsilateral to injury. 
 
 
predominantly over small-to-medium neurons, with some large neurons also expressing 
at 14 d after CCI (Figure 3-4).  As with 7 d CCI, neurons expressing moderate to high 
levels of hybridization signal (> 20X background) were observed almost exclusively 
over the small-to-medium-sized neurons (Figure 3-4).  This suggests that removal of 
exogenous NT-3 results in a reinstatement of the CCI phenotype.  In contrast, animals 
receiving delayed NT-3 infusion, relative levels of TRPV1 mRNA expression were 
reduced with the effect most prominent for neurons ipsilateral to CCI [Figure 3-4, CCI + 
NT-3(d)]. 
Tissue sections were also processed for immunohistochemistry to ascertain 
whether modulation of TRPV1 protein expression by CCI and exogenous NT-3 
corresponds to that observed at the mRNA level.  Immunohistochemistry revealed that 
that in the DRG contralateral to CCI (intact), staining for TRPV1 protein was intense in 
a subpopulation of small neurons, whereas a more moderate level of staining was 
observed in other small and medium neurons.  Seven day CCI resulted in a dramatic 
increase in the relative numbers of neurons that were intensely stained for TRPV1, with 
predominantly small and medium neurons, but also the occasional large neuron, fall into 
this category (Figure 3-5).  Infusion of NT-3 for the duration of CCI (7 d) resulted in 
decreased intensity of TRPV1 staining that was most evident in the medium and large 
neurons from DRG ipsilateral to CCI.  In DRG contralateral to CCI, NT-3 infusion did  
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Figure 3- 4: Delayed NT-3 infusion reverses the increase in TRPV1 mRNA detected 
in DRG neurons subjected to CCI. 
 
Top: Darkfield photomicrographs of 6 µm sections of L5 DRG ipsilateral or 
contralateral to 14d unilateral CCI, in response to 7d 600 ng/ µl/hr NT-3 infusion for the 
first 7d of a 14d unilateral CCI [CCI+NT-3(i); Intact+NT-3(i)], or in response to 7d 600 
ng/ µl/hr NT-3 infusion for the last 7d of a 14d unilateral CCI [CCI+NT-3(d); 
Intact+NT-3(d)], as indicated.  Scale bar, 60 µm.  Note: Delayed infusion of NT-3 
[CCI+NT-3(d)] results in a decrease in the relative levels of TRPV1 mRNA detected.   
 
Bottom: Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
TRPV1 mRNA.  The relationship between TRPV1 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states as indicated are 
described above.  Labeling refers to the ratio of silver grain density over the neuronal 
cytoplasm to grain density over areas of the neuropil devoid of positive hybridization 
signal.  Solid lines divide the plots into labeled and unlabeled populations; dotted lines 
separate lightly labeled from moderate to heavily labeled populations of TRPV1 
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expressing neurons.  Note: Delayed infusion of NT-3 [CCI+NT-3(d)] results in a 
decrease in the relative levels of TRPV1 most prominent in medium to large neurons. 
 
 
not have a dramatic impact on TRPV1 immunostaining; however, more intense staining 
was observed over some small neurons (intact + NT-3) (Figure 3-5).  Consistent with the 
immunohistochemistry findings, Western blot analysis revealed that TRPV1 protein 
levels were elevated after 7 d CCI.  NT-3 infusion effectively mitigated this increase in 
DRG ipsilateral to CCI (CCI + NT-3), whereas slightly increased levels were observed 
in DRG contralateral to CCI (intact + NT-3) (Figure 3-5). 
As with 7 d CCI, expression of TRPV1 protein in DRG ipsilateral to 14 d CCI 
was increased in small, medium, and some large neurons, relative to contralateral DRG 
(Figure 3-6).  Delayed infusion of NT-3 resulted in decreased levels of TRPV1, such 
that the pattern and level of expression in neurons subjected to CCI [CCI + NT-3(d)] 
now approximated that observed in the DRG contralateral to CCI (intact) (Figure 3-6).  
The effect of delayed NT-3 infusion was less evident for neurons from DRG 
contralateral to CCI [intact + NT-3(d)], with only slight decreased expression observed 
in some medium neurons.  As observed at the mRNA level, the ability of NT-3 to 
modulate TRPV1 protein expression requires continuous infusion of NT-3, because 
patterns of protein localization and expression levels resembled those of 14 d CCI 
animals when NT-3 infusion was halted for the last 7 d of injury (Figure 3-6). 
 
 
3.4.4 NT-3 reduces the level of activated p38 MAPK after CCI 
 
Tissue sections were processed for immunohistochemistry to ascertain whether 
CCI and exogenous NT-3 effect a coordinate change in activated p38 MAPK protein 
expression, a component of the signaling pathway shown previously to directly regulate 
TRPV1 expression in sensory neurons (Ji et al., 2002b).  In DRG contralateral to CCI 
(intact), staining for phospho-p38 MAPK protein was very intense in a subpopulation of 
small neurons, whereas a more moderate level of staining was observed in other small 
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Figure 3- 5: NT-3 infusion results in decreased expression of TRPV1 protein. 
 
Top: Fluorescence photomicrographs demonstrate levels of TRPV1 and phospho-
p38MAPK-like immunoreactivity in 10 µm sections of DRG ipsilateral (CCI) and 
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contralateral to CCI (Intact) L5 DRG with or without immediate intrathecal infusion of 
NT-3 (CCI+NT-3; Intact+NT-3), as indicated.  Scale bar, 60 µm.  Note: In the DRG 
contralateral to CCI (Intact), levels of TRPV1 protein are highest in small neurons, with 
lower levels of expression observed in several small to medium dorsal root ganglion 
neurons.  Seven days after CCI, levels of expression have increased relative to the intact 
state, with protein now being detected in a few large neurons.  Intrathecal infusion of 
NT-3 at the time of injury results in reduced levels of TRPV1 protein, most notable in 
medium to large CCI neurons.  Levels of phospho-p38MAPK nuclear expression do not 
appear to be altered by CCI.  Cytoplasmic expression of phospho-p38MAPK does 
decrease slightly with CCI.  Infusion of NT-3 results in a dramatic downregulation of 
phospho-p38MAPK staining.  
 
Bottom: Representative Western bolts of TRPV1 (n=4) and phospho-p38MAPK (n=5) 
reflect the staining patterns as described above.  Experimental states are as indicated. 
 
 
 and medium neurons.  Seven day CCI resulted in a slight decrease in the cytoplasmic 
staining.  This does not appear to be reflected in the pattern of nuclear staining that 
remained relatively unchanged (CCI) (Figure 3-5).  Infusion of NT-3 effected a marked 
decrease in the intensity of phospho-p38 MAPK across all size ranges of neurons 
ipsilateral to CCI, with the exception of a subpopulation of small neurons that expressed 
elevated levels of phospho-p38 MAPK (CCI + NT-3) (Figure 3-5).  In DRG 
contralateral to CCI, NT-3 infusion did not appear to alter neuronal nuclear staining 
patterns; however, there was a noticeable increase in perineuronal staining (intact + NT-
3) (Figure 3-5).  Consistent with the immunohistochemistry findings, Western blot 
analysis revealed that a 7 d CCI resulted in a slight decrease in the levels of phospho-
p38 MAPK compared with DRG contralateral to CCI (intact).  Infusion of NT-3 
dramatically reduced the total phospho-p38 MAPK protein present in the DRG 
ipsilateral to CCI (CCI + NT-3), whereas it slightly increased levels of phospho-p38 
MAPK in the DRG contralateral to CCI (intact + NT-3) (Figure 3-5). 
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Figure 3- 6:  Delayed NT-3 infusion reverses the increase in TRPV1 protein 
detected in DRG neurons subjected to CCI. 
 
Fluorescence photomicrographs demonstrate levels of TRPV1-like immunoreactivity in 
10 µm sections of L5 DRG representing DRG ipsilateral (CCI) and contralateral (Intact) 
to a 14d CCI, in response to immediate NT-3 infusion for 7d after CCI, followed by 
removal for the last 7d of the injury [CCI+NT-3(i); Intact+NT-3(i)], or in response to 
delayed NT-3 infusion for 7d starting 7d after CCI [CCI+NT-3(d); Intact+NT-3(d)], as 
indicated.  Scale bar, 60 µm.  Note: Delayed intrathecal infusion of NT-3 results in a 
dramatic decrease in the levels of TRPV1 protein detected [CCI+NT-3(d)], most notably 
in medium to large neurons.  This affect is less pronounced on the DRG contralateral to 
CCI [Intact+NT-3(d)] (bottom center).  Intrathecal infusion of NT-3 for 7d at the time of 
CCI, followed by removal for the last 7d of injury [CCI+NT-3(i)] (top right) results in 
similar levels of TRPV1 protein detected compared with CCI alone, suggesting that 
chronic infusion is required for mitigation of CCI-associated elevated TRPV1 
expression. 
 
 
 
3.5 Discussion 
 
Neuropathic pain is a clinical challenge because of the complex mechanisms 
underlying this pathology.  NT-3 can affect a downregulation in trkA expression, NGF 
high-affinity binding sites, and associated nociceptive phenotype in intact sensory 
neurons (Jongsma Wallin et al., 2001; Karchewski et al., 2002; Gratto and Verge, 2003).  
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Given that enhanced NGF synthesis contributes to various neuropathic pain syndromes, 
I hypothesized that NT-3 could attenuate these pain syndromes and neuronal expression 
of molecules complicit in this state through its antagonistic influence on the trkA 
pathway.  The present study supports this hypothesis, identifying NT-3 as a novel potent 
modulator of thermal hyperalgesia that influences behavioral responses and neuronal 
expression of TRPV1 and activated p38 MAPK. 
NT-3 influences both trkC- and trkA- expressing neurons.  There are two lines of 
evidence suggesting that its influence is selective for these populations.  NT-3 reverses 
injury-associated changes only in the trkC population of sensory neurons (Verge et al., 
1996; Jongsma Wallin et al., 2001; Karchewski et al., 2002).  Furthermore, NT-3 does 
not alter somatostatin levels in either intact or injured sensory neurons that are 
responsive to GDNF and do not colocalize with trkA (Verge at al., 1995; Bennett et al., 
1998; K.A. Gratto and V.M.K. Verge, unpublished observations).  Finally, the influence 
of NT-3 on trkA phenotype is most apparent for that subpopulation of trkA neurons that 
do not express trkC (Jongsma Wallin et al., 2001; Karchewski et al., 2002; Gratto and 
Verge, 2003). 
 
 
3.5.1 NT-3 influences thermal hyperalgesia but not mechanical hypersensitivity 
associated with CCI 
 
The ability of NT-3 to prevent and reverse thermal hyperalgesia, believed 
signalled by C-fibers (Field et al., 1999), is a novel finding with respect to modulation of 
neuropathic pain.  NT-3 is generally thought to influence only large, myelinated 
proprioceptive neurons, despite evidence that it modulates expression of molecules 
associated with nociception (Jongsma Wallin et al., 2001; Karchewski et al., 2002; 
Gratto and Verge, 2003). 
Research examining the influence of NT-3 on neuropathic pain-related behaviors 
is limited.  Inflammatory mechanical hyperalgesia was acutely and transiently reversed 
by local hindpaw injection of NT-3 (Watanabe et al., 2000); however, NT-3 altered 
neither thermal nor mechanical hypersensitivity resulting from spinal nerve ligation 
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(Boucher et al., 2000).  This suggests that the degree of inflammation and/or type of 
injury may dictate whether NT-3 mitigates C-fiber pathologies.  Neuroinflammation 
resulting from CCI plays a major role in the ensuing hyperalgesic pain state (Maves et 
al., 1993) and is associated with elevated NGF and cytokine levels (Maves et al., 1993; 
Sorkin, 2002).  Furthermore, CCI preferentially axotomizes large-diameter neurons 
(Kajander and Bennett, 1992), leaving the remaining intact neurons exposed to a highly 
inflamed environment in which there is a strong infiltration of immune cells (TDW-G, 
unpublished observations). 
The ability of NT-3 to prevent the development of thermal hyperalgesia is not 
likely caused by the elimination of sensory neurons contributing to this state because 
removal of NT-3 leads to a prompt reestablishment of the hyperalgesic state and CCI-
associated TRPV1 phenotype.  The reversion to this state indicates that the influence of 
NT-3 is transient.  NT-3 can also reverse established thermal hyperalgesia.  Both the 
prevention and abolishment of thermal hyperalgesia are likely impacted by the ability of 
NT-3 to suppress p38 MAPK activation and TRPV1 expression.   
In contrast, the mechanical hypersensitivity observed after CCI is not altered by 
NT-3, despite downregulation of injury-associated peptide expression in larger neurons 
(Wilson and Verge, 2001).  Mechanotransduction is mediated by specialized channels 
(Garcia-Anoveros et al., 2001; Price et al., 2001; Suzuki et al., 2003a, 2003b), but the 
manner in which expression or sensitization of these channels is altered by this form of 
injury or NT-3 is unknown; however, a role for NT-3 in the treatment of chronic 
mechanical hypersensitivity resulting from intramuscular acid injection indicates a 
potential role for NT-3 in the treatment of muscular pain (Gandhi et al., 2004). 
 
 
3.5.2 Attenuation of thermal hyperalgesia by NT-3 correlates with a reduction in 
TRPV1 and activated p38 MAPK expression 
 
Localization of TRPV1 expression to primarily small and medium neurons in 
contralateral intact DRG is in agreement with past studies (Caterina et al., 1997; Eglen et 
al., 1999; Ma, 2002).  Although axotomy results in a dramatic reduction in TRPV1 
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expression (Michael and Priestly, 1999), spared neurons express elevated levels of 
TRPV1 (Fukuoka et al., 2001; Hudson et al., 2001), the latter presumably via NGF-
mediated activation of p38 MAPK (Ji et al., 2002b).  Although CCI resulted in slightly 
elevated TRPV1 expression observed in the size range of neurons consistent with C-
fibers, it also induced a low level of expression in a novel population of large neurons.  
It is unknown whether this phenotypic switch factored into the observed thermal 
hyperalgesia.  Alterations in TRPV1 expression effected by NT-3 were most robust for 
neurons ipsilateral to injury.  In accordance with Ji et al. (2002b), the observed 
modulation of TRPV1 expression was most apparent at the protein versus mRNA level.  
The alterations in TRPV1 expression effected by CCI and exogenous NT-3 were 
mirrored by a coordinate modulation of activated p38 MAPK, a known regulator of 
TRPV1 expression (Ji et al., 2002b), implying a direct link to outcome; however, when 
infusion was halted, TRPV1 expression reverted back to that observed with CCI alone, 
as did the thermal hyperalgesia, suggesting a suppressive and not curative role for NT-3 
in modulation of this state. 
 
 
3.5.3 Potential mechanisms underlying NT-3 antagonism of thermal hyperalgesia 
 
Thermal hyperalgesia associated with inflammation is conditioned by NGF and 
requires trkA and TRPV1 (Michael and Priestly, 1999; Shu et al., 1999; Davis et al., 
2000; Galoyan et al., 2003).  NGF promotes the sensitization of TRPV1 via release from 
PtdIns(4, 5)P2-mediated inhibition (Chuang et al., 2001).  Furthermore, trkA signaling 
can be enhanced by transactivation via G-protein-coupled receptors that are activated by 
inflammatory mediators and the pituitary adenylate cyclase-activating peptide, the latter 
being expressed at high levels in an NGF-dependent manner in trkA neurons and 
downregulated by NT-3 (Jongsma Wallin et al., 2001, 2003).  The ability of NT-3 to 
affect a robust downregulation in TRPV1 expression after CCI and a coordinate 
decrease in trkA (TDW-G, unpublished observations) and activate p38 MAPK 
expression would impact on the degree to which an individual neuron responds to 
noxious heat.  The rapid NT-3-mediated abolition or reestablishment of the response 
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after NT-3 removal implies that it is not solely dependent on alterations in protein 
expression but may also involve direct influence on signaling pathways that either alter 
the efficiency of trkA signaling or mediate sensitization of TRPV1.  Whether 
endogenous nerve-derived sources of NT-3 serve to tonically inhibit this pathway is not 
known; however, constitutive levels of NT-3 in normal skin are higher than that of NGF, 
and they drop dramatically in the acute phase of the inflammatory response, suggesting a 
role in tonic inhibition in the uninjured state (Watanabe et al., 2000).  Finally, because 
the NT-3 was delivered intrathecally, one cannot exclude a potential effect on NT-3 on 
central sensitization events that impact on the development of thermal hyperalgesia (for 
review, see Melzak et al., 2001; Romanelli and Esposito, 2004).  Although not the focus 
of this study, previous work has shown that this form of NT-3 delivery mitigates the 
level of BDNF expressed by primary sensory afferents and linked to central sensitization 
events (Groth and Aanonsen, 2002; Garraway et al., 2003; Lever et al., 2003).  The 
degree to which other molecules or cell types involved in this process are similarly 
influenced remains to be elucidated. 
In conclusion, past studies reveal a major role for NGF in driving inflammation-
associated thermal hyperalgesia via its activation of p38 MAPK and subsequent 
regulation of TRPV1 expression and other mediators of inflammatory responses.  NT-3 
is now identified as a potent negative modulator of this state.  The extent to which it 
might ameliorate other aspects of inflammatory neuropathic pain responses remains to 
be elucidated. 
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4 Neurotrophin-3 attenuates expression of acid-sensing ion channel 3 in adult rat 
dorsal root ganglion following chronic constriction injury  
 
 
4.1 Abstract 
 
Chronic constriction injury (CCI) results in a partial nerve injury and marked 
inflammation in the nerve leading to a robust neuronal cell body response in the 
corresponding DRG.  We have previously demonstrated that exogenous NT-3 can 
prevent/reverse a number of these changes including the nerve growth factor (NGF) 
dependent upregulation of transient receptor potential vanilloid receptor-1 (TRPV1) and 
p38 mitogen-activated protein kinase.  ASIC3, a proton-gated sodium channel, localized 
primarily to nociceptive neurons of the DRG, has been shown to be upregulated through 
the trkA/JNK/p38MAPK pathway via NGF under inflammatory conditions.  As NT-3 is 
a potent negative modulator of this pathway, I hypothesized that NT-3 would negatively 
modulate ASIC3 expression in neurons associated with CCI.  In response to either 7 or 
14 day CCI, ASIC3 hybridization signal was increased over all size ranges of neurons.  
NT-3 treatment for 7d at the time of CCI significantly prevented the increase in ASIC3 
mRNA hybridization signal.  Whether NT-3 was infused either immediately or in a 
delayed fashion, the net influence was decreased expression of ASIC3.  Interestingly, 
continuous infusion of NT-3 was not required for this effect, as removal of the pump did 
not result in reversal of the effect, contrary to that previously reported for TRPV1 and 
thermal hyperalgesia (Wilson-Gerwing et al., 2005).  In conclusion, NT-3 infusion 
disables the mechanism by which ASIC3 is upregulated in response to CCI. 
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4.2 Introduction 
 
Neuroinflammation following injury to a peripheral nerve results in a series of 
events that contribute to the ensuing neuropathic pain state.  These events include the 
activation of mast cells (Olsson, 1967), the recruitment of neutrophils and macrophages 
(Perry et al., 1987), and the increased expression of pro-inflammatory cytokines (Cunha 
et al., 1992; Ferreira et al., 1988).  This inflammatory soup, as it has been referred to, 
contributes to the sensitization of peripheral nerve terminals and leads to a drop in 
extracellular pH of the surrounding tissue (for review, see Moalem and Tracey, 2006; 
Myers et al., 2006). 
The chronic constriction injury (CCI) model of neuropathic pain developed by 
Bennett and Xie (1988) results in a complex physiological response characterized by the 
preferential axotomy of large-diameter axons and exposure of the uninjured axons to the 
Wallerian degenerating nerve and denervated skin where many proinflammatory 
molecules, including NGF, are produced (Kajander and Bennett, 1992).  The 
inflammatory condition also results in tissue acidosis brought about by a drop in 
extracellular pH (Steen et al., 1992; Rang et al., 1991; Reeh and Steen, 1996; Helminger 
et al., 1997; Jacobus et al., 1977) which contributes to the ensuing pain states (Steen and 
Reeh, 1993; Steen et al, 1995; Issberner et al, 1996; Reeh and Steen, 1996). 
The molecular basis by which sensory neurons detect these alterations in pH 
have only recently been elucidated. In 1997, Waldmann et al. cloned a channel that 
opened in response to a decrease in extracellular pH that was specific to sensory neurons 
(DRASIC).  This channel was subsequently renamed acid-sensing ion channel 3 
(ASIC3).  ASIC3 is a sodium channel belonging to the epithelial sodium 
channel/degenerins (ENaC/DEG) superfamily  (Waldman and Lazdunski, 1998) whose 
proposed functions include roles in nociception (Krishtal and Pidoplichko, 1981; Benson 
et al., 1999) and mechanosenstation (Garcia-Anoveras et al., 2001; Price et al., 2001; 
Sluka et al., 2003; Mogil et al., 2005).  Of the 6 ASIC isoforms that have been identified 
(Waldmann et al., 1996; Bassilana et al., 1997; Garcia-Anoveros et al., 1997; Lingueglia 
et al., 1997; Waldmann et al., 1997b; Waldmann et al., 1997a; Chen et al., 1998; 
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Grunder et al., 2000), ASIC3 is the most sensitive to protons, opening in response to a 
pH drop of as little at 0.4 (from 7.4 to 7.0) (Sutherland et al, 2001). 
 Consistent with a potential role in the generation and modulation of peripheral 
pain, ASIC3 expression is specific to dorsal root ganglion (DRG) neurons (Chen et al., 
1998; Waldmann and Lazdunski, 1998; Voilley et al., 2001) and is expressed primarily 
by small to medium sized neurons (currently recognized as nociceptors) (Chen et al., 
1998; Waldmann et al., 1997b; Molliver et al., 2005; Voilley et al., 2001).  Most 
importantly, basal expression of ASIC3 is controlled by a low, endogenous level of the 
neurotrophin nerve growth factor (NGF) (Mamet et al., 2002).  Subsequently, under 
conditions of inflammation, where NGF levels are increased, ASIC3 expression is 
upregulated through a trkA/c-jun N-terminal kinase/p38 mitogen activated protein 
kinase pathway (trkA/JNK/p38MAPK) (Mamet et al., 2003). 
 Our lab has previously demonstrated that neurotrophin-3 (NT-3) can effectively 
antagonize a number of the pro-inflammatory effects of NGF (Verge et al., 1989a, b, 
1992, 1995; Jongsma Wallin et al., 2001; Karchewski et al., 2002; Gratto and Verge, 
2003; Wilson-Gerwing et al., 2005).  As well, we have previously demonstrated that 
NT-3 can both prevent and reverse the development of thermal hyperalgesia following 
CCI, likely through its ability to dampen activation of the p38 MAPK pathway.  This 
effect was also associated with reduced expression of the protein complicit in this 
behavioral response, transient receptor potential vanilloid receptor 1 (TRPV1) (Wilson-
Gerwing et al., 2005).  Thus, in this study, we examine whether the ability of NT-3 to 
regulate phospho-p38MAPK following chronic constriction injury (CCI) translates into 
an ability to also modulate ASIC3 expression. 
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4.3 Methods 
 
4.3.1 Animal surgery 
 
All animal procedures were conducted in accordance with the National Institutes 
of Health policy on the use of animals in research and the University of Saskatchewan 
animal care committee guidelines (protocol 19920164).  A total of 47 young adult male 
Wistar rats (Charles River Laboratories, Wilmington, MA) weighing 250-300 g were 
used.  Animals were anesthetized for surgery with sodium pentobarbital (Somnitol, 65 
mg/kg; MTC Pharm, Cambridge, Ontario, Canada).  Pre- and post-operative (for 24 h) 
subcutaneous injections of buprenorphine (Temgesic, 0.1-0.2 mg/kg) were given to 
alleviate any post-operative discomfort.  To examine the effect of NT-3 on the 
expression of ASIC3, 26 rats were used: 13 underwent 7 d unilateral CCI of the sciatic 
nerve (Bennett and Xie, 1988) and 13 received 7 d unilateral CCI with intrathecal 
infusion of NT-3 for the duration of the injury.  To examine the ability of NT-3 to 
reverse the upregulation of ASIC3 after CCI and whether continuous infusion is required 
for this effect, 21 rats were used: 7 underwent 14 d unilateral CCI; 7 received intrathecal 
infusion of NT-3 at the time of CCI with pump removal at 7 d after CCI [Intact + NT-
3(immediately), CCI + NT-3(immediately)]; 7 received intrathecal infusion of NT-3 on 
day 7 after CCI [Intact + NT-3(delayed), CCI + NT-3(delayed)]. 
 NT-3 was delivered intrathecally for 7 d via mini-osmotic pumps (model 2001; 
Alza, Cupertino, CA) inserted at the lumbar sacral junction as per Verge et al. (1989a) at 
a concentration and rate of 600 ng/µl/hr (Karchewski et al., 2002) in a solution of PBS 
containing rat serum albumin (1 mg/ml), streptomycin (100 U/ml), and penicillin (100 
U/ml).  This dose of NT-3 was the minimum dose found to selectively reverse injury-
associated gene expression in injured trkC-expressing neurons (Verge et al., 1996; 
Jongsma Wallin et al., 2001; Karchewski et al., 2002).  At the conclusion of the 
experiments, rats were killed, and tissue was dissected and processed for in situ 
hybridization and/or immunohistochemistry as described below.  Previous studies have 
demonstrated a lack of influence ipsilateral and contralateral to injury when vehicle is 
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infused intrathecally (Verge et al., 1989a; Verge et al., 1995; Jongsma Wallin et al., 
2001; Wilson-Gerwing et al., 2005). 
 
 
4.3.2 In situ hybridization 
 
 Deeply anesthetized animals were perfused via the aorta with 0.1 M PBS, pH 
7.4, followed by 4% paraformaldehyde in 0.1M PBS.  The right and left L4 and L5 DRG 
were rapidly dissected, postfixed for 1 hour in the same fixative, and cryoprotected in 
20% sucrose in 0.1M PBS overnight.  Paired experimental and control tissues were 
mounted in the same cryomold (to ensure processing under identical conditions), 
covered with OCT compound (Tissue Tek; Miles Laboratories, Elkhart, IN, USA) and 
frozen in cooled isopentane.  Transverse sections were cut at 6 µm on a Micron cryostat 
(Zeiss, Canada), thaw mounted onto Probe-On+ slides (Fisher Scientific, Edmonton, AB, 
Canada) and stored with desiccant at 20 oC until hybridization. 
 Prior to hybridization, slides were air dried for 15 minutes, followed by fixation 
in 4% paraformaldehyde for 20 minutes.  Slides were washed 3 X 5 minutes in 1X PBS.  
Sections were then treated with proteinase K (20 µg/ml) containing 10 ml 1M Tris-HCl 
(pH 7.6), 2 ml 0.5 M EDTA, 200 µl proteinase K stock (20 mg/ml) and 188 µl ddH20 for 
6 minutes.  Slides were then rinsed for 5 minutes in 1 X PBS and post-fixed for 5 
minutes in 4% paraformaldehyde.  Slides were then rinsed 2 X 5 minutes in 1 X PBS, 1 
X 5 minutes in DEPC-H2O, and dehydrated in ascending alcohols. 
 An oligonucleotide probe complementary to and selective for ASIC3 mRNA 
[complementary to bases 851-898 (Waldmann et al., 1997b)] was synthesized 
(University of Calgary DNA services, Alberta, Canada).  The probe was checked against 
the GenBank database (NIH) to ensure no greater than 60% homology was found to 
sequences other than the cognate transcript.  The probe was labeled at the 3-end with α-
[35S]dATP (New England Nuclear, Boston, MA, USA) using terminal deoxynucleotidyl-
transferase (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in a buffer containing 
10 mM CoCl2, 1 mM dithiothreitol, 300 mM Tris base and 1.4 M-potassium cacodylate 
(pH 7.2), and purified through Bio-Spin® Disposable Chromatograph Columns (Bio-Rad 
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laboratories, Hercules, CA, USA) containing 200 mg of NENSORB PREP Nucleic 
Acid Purification Resin (NEN®, Boston, MA, USA).  Dithiothreitol was added to a final 
concentration of 10 nM. 
 Hybridization was carried out according to published procedures (Dagerlind et 
al., 1992) on a minimum of 5 slides from each group of experimental and control 
animals.  Briefly, the sections were hybridized at 43 oC for 14-18 hours in a buffer 
containing 50% formamide (Sigma Aldrich, Oakville, ON, Canada), 4X SSC (1X SSC  
0.15 M NaCl, 0.015 sodium citrate), 1X Denharts solution (0.02% bovine serum 
albumin and 0.02% Ficoll), 1% sarcosyl (N-laurylsarcosine), 0.02 M phosphate buffer 
(pH 7.0), 10% dextran sulphate, 500 µg/ml heat-denatured sheared salmon sperm DNA, 
200 mM dithiothreitol and 107 cpm/ml of probe.  After hybridization, the slides were 
washed for 4 X 15 mins in 1X SSC at 55oC, dehydrated in ascending alcohols, processed 
for radioautography as per Karchewski et al., 2002 and exposed for 7 to 10 days before 
developing in D-19 (Kodak, Rochester, NY, USA). 
 The specificity of hybridization signal for the ASIC3 probe was confirmed as 
described in Wilson-Gerwing et al., 2005. 
 
 
4.3.3 Quantification and analysis 
 
 All slides from the 13 groupings of 7 d experimental and control animals and all 
slides from the 7 groupings of the 14 d experimental and control animals were analyzed 
qualitatively and relative changes in hybridization signal from one group to another 
noted for sections mounted on the same slide to avoid bias due to the variance in 
hybridization signal observed from slide to slide.  Representative slides from four (7 d 
group) and 3 (14 d group) were selected and subjected to further quantitative analysis.  
These slides had a similar number of neurons in all DRG sections.  Photomontages of 
each section to be analyzed were prepared and individual neurons with a visible nucleus 
were identified.  Using a 40X light objective and a 2X optivar with an interactive 
computer-assisted image-analysis system (Richardson et al., 1989), cross-sectional areas 
of individual neurons and the percentages of cytoplasmic areas covered by silver grains 
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were measured for each DRG.  The area per grain was constant for all neurons and a 
correction for grain overlap was made to obtain a parameter linearly related to density of 
silver grains (Richardson et al., 1989).  Software for the image analysis system was 
Northern Eclipse, Version 7.0 (Empix Imaging, Mississauga, ON, Canada) and 
supplemented with Microsoft Office Excel 2003 (Microsoft Corporation, Redmond, 
WA) and Prizm 4.0 (Graph Pad Software, San Diego, CA).  Cells were considered 
labeled if they had more than five times background levels of silver grains, as 
determined by averaging grain densities over defined areas of the neuropil devoid of 
positively labeled cell bodies.  This criterion of determining labeled neuronal profiles 
correlates well with the identification of labeled versus unlabeled neurons as determined 
manually using a 63X oil immersion objective.  A stereological approach was not 
employed in this study and therefore the data quantification may represent a biased 
estimate of (i) the percentage of the population expressing individual markers (based on 
incidence in the sections examined whereby all neurons with a nucleus present in that 
section were included in the analysis) and (ii) the actual neuronal size (which was 
determined based on the assumption that the presence of a nucleus in the section 
correlated will with the maximal diameter for that cell). 
 Analysis was performed in each instance on all neurons with a nucleus present in 
the section being quantified:  for 7 d group  on 16 DRG sections or 3087 neuronal 
profiles (Intact: n = 4 animals, CCI: n = 4 animals, Intact + NT-3: n = 4 animals, 
CCI+NT-3: n = 4 animals); for 14 d group  on 18 DRG sections or 3855 neuronal 
profiles (Intact: n = 3 animals, CCI: n = 3 animals, Intact+NT-3(i): n = 3 animals, 
CCI+NT-3(i): n = 3 animals, Intact+NT-3(d): n = 3 animals, CCI+NT-3(d): n = 3 
animals).  Previous research from our lab has demonstrated that CCI does not induce 
bilateral hyperalgesia (Wilson-Gerwing et al., 2005) and we have not discerned any 
qualitative differences between sham-operated or naïve DRG and contralateral intact 
DRG with respect to ASIC3.  Therefore, the contralateral intact DRG was used as an 
intact control. 
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4.3.4 Immunohistochemistry 
 
 Transverse 10 µm sections were cut on the cryostat, thaw-mounted onto Probe-
ON+ slides (Fisher Scientific), and processed for immunohistochemistry.  For ASIC3: 
sections were washed three times for 10 min in 0.1 M PBS, blocked in 2% goat serum 
and 0.3% Triton X-100 in 0.1 M PBS for 1 h at room temperature, incubated overnight 
with guinea pig anti-ASIC3 (1:100; Neuromics Antibodies, Bloomington, MN), diluted 
in 2% goat serum and 0.3% Triton X-100 in 0.1 M PBS at 4 oC, and visualized with goat 
anti-guinea pig F(ab)2 Cy3 conjugate (1:200; Jackson ImmunoResearch Laboratories, 
West Grove, PA) in 2% goat serum in 0.1 M PBS for 1 h at room temperature.  For 
phospho-p38MAPK: sections were washed three times for 10 min in 0.1 M PBS, 
blocked in 10% horse serum and 0.1% Triton X-100 in 0.1 M PBS for 1 h at room 
temperature, incubated overnight with rabbit anti-phospho-p38 MAPK (1:50; Cell 
Signaling Technology, Beverly, MA) diluted in 1.0% BSA and 0.1% Triton X-100 in 
0.1 M PBS at 4 oC, and visualized with donkey anti-rabbit F(ab)2 Cy3 conjugate (1:400; 
Jackson ImmunoResearch Laboratories, West Grove, PA) in 0.1 M PBS for 1 h at room 
temperature.  Slides were washed and coverslipped with 50% glycerol/50% PBS.  
Control sections were processed in the same manner, but without the primary antibody.  
Results were visualized using a Zeiss Axioscope 50 microscope equipped with incident-
light fluorescence optics and a digital camera. 
 
 
4.4 Results 
 
4.4.1 NT-3 prevents CCI-associated increases in ASIC3 mRNA 
 
Analysis of sections processed for ISH to detect neuronal expression of ASIC3 
mRNA revealed that in the DRG contralateral to CCI (Intact), detectable hybridization 
signal was localized over all size ranges of neurons.  Seven days after CCI, relative 
levels or hybridization signal were elevated, predominantly in the small to medium sized 
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neuronal population but also in a small population of large neurons (Figure 4-1).  This 
overall increased incidence of expression resulted in 25% more neurons expressing 
detectable ASIC3 mRNA [from 39.38% +/- 4.200 (s.e.m) to 49.18% +/- 3.766 (s.e.m.)].  
Those neurons expressing moderate to high levels of ASIC3 mRNA were increased 
from 5.575% +/- 3.978 (s.e.m.) to 13.9% +/- 5.156 (s.e.m.) (Figure 4-1).  This increase 
in expression was also reflected in the mean labeling index for these neurons [from 
5.970 +/- 1.150 (s.e.m.) to 9.396 +/- 2.093 (s.e.m.)] (Figure 4-2). 
NT-3s ability to effect reduced ASIC3 mRNA expression was predominantly 
evident on those neurons ipsilateral to CCI (CCI + NT-3) (Figure 4-1).  In DRG 
contralateral to CCI (Intact + NT-3) the mean labeling index was not significantly 
altered [from 5.970 +/- 1.150 (s.e.m.) to 5.491 +/- 1.241 (s.e.m.)] (Figure 4-2) nor was 
the percentage of neurons expressing detectable levels of ASIC3 [from 39.20% +/- 4.126 
to 33.58% +/- 5.381] (Figure 4-1).  In contrast, a dramatic attenuation of ASIC3 
expression was observed in the NT-3 treated DRG ipsilateral to CCI (CCI + NT-3).  
Mean neuronal labeling index was significantly decreased with NT-3 treatment [from 
9.396 +/- 2.093 (s.e.m.) to 5.523 +/- 1.131 (s.e.m.)] (Kruskal-Wallis test with Dunns 
Multiple Comparison test, p<0.01) (Figure 4-2).  The percentages of neurons expressing 
detectable levels of ASIC3 mRNA were also reduced [from 42.79% +/- 4.989 (s.e.m.) to 
33.63% +/- 4.163 (s.e.m.)].  This decrease in the relative level of ASIC3 expression was 
most noticeable in those neurons expressing moderate to high levels of ASIC3 [from 
13.90% +/- 5.156 (s.e.m.) to 5.225 +/- 3.041 (s.e.m.)] (Figure 4-1).  The infusion of NT-
3 decreased levels of ASIC3 expression in all sizes of neurons, with no discernible 
difference between the decrease observed in small to medium versus medium to large 
sized neurons. 
 
 
4.4.2 NT-3 suppresses and attenuates CCI-associated increases in ASIC3 mRNA 
 
Analysis of sections processed to detect neuronal expression of ASIC3 mRNA 
from animals having undergone 14d CCI with either immediate (days 07) or delayed  
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Figure 4- 1:  ASIC3 mRNA levels are reduced in response to NT-3 treatment. 
 
Top: Darkfield photomicrographs of 6 µm thick adult rat L5 DRG sections processed for 
in situ hybridization to detect ASIC3 transcripts contralateral (Intact) or ipsilateral to 7d 
CCI (CCI) and after 7d unilateral CCI plus intrathecal infusion of 600 ng/µl/hr NT-3 
(Intact+NT-3; CCI+NT-3).  Scale bar, 100 µm.  Note: NT-3 infusion results in the 
reduction in relative levels of hybridization signal for ASIC3 over individual neurons 
after CCI.   
 57
 
Bottom: Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
ASIC3 mRNA.  The relationship between ASIC3 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states are indicated at 
the top right of each graph are as described above.  Labeling refers to the ratio of silver 
grain density over the neuronal cytoplasm to grain density over areas of the neuropil 
devoid of positive hybridization signal.  Solid lines divide the plots into labeled and 
unlabeled populations; dotted lines separate lightly labeled from moderate to heavily 
labeled populations of ASIC3-expressing neurons.  Note: In DRG contralateral to CCI, 
ASIC3 is expressed in all size ranges of neurons.  CCI results in elevated ASIC3 
expression primarily in small to medium sized neurons and a small population of large 
neurons.  NT-3 infusion resulted in a reduction in the levels and percentage of neurons 
expressing detectable ASIC3 mRNA ipsilateral to CCI. 
 
 
 
 
 
Figure 4- 2:  Mean neuronal ASIC3 mRNA labeling indices following CCI are 
significantly decreased with NT-3 treatment. 
 
Left:  Graph depicts quantification of relative differences between experimental groups 
(as indicated) in ASIC3 mRNA mean labeling indices for all DRG neurons measured 
following in situ hybridization for 4 separate experiments [representing 4 animals having 
undergone 7 day unilateral CCI [Intact (I) and CCI] and 4 animals having undergone 7 
day unilateral CCI with intrathecal infusion of NT-3 [Intact+NT-3 (I+N) and CCI+NT-3 
(CCI+N)].  Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate 
significant differences between experimental groups (Kruskal-Wallis test with Dunns 
Multiple Comparison test; *** p<0.0001, ** p<0.01).  NT-3 infusion results in a 
significant decrease in mean ASIC3 mRNA expression in L5 neurons ipsilateral to CCI. 
 
Right:  Pooled data depicting the relative differences in mean labeling indices in ASIC3 
mRNA normalized to the intact state in response to unilateral chronic constriction injury 
with or without NT-3 infusion (n=4).  Experimental conditions are as described above.  
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Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate significant 
differences between experimental groups (Kruskal-Wallis test with Dunns Multiple 
Comparison test; *** p<0.0001).  NT-3 infusion results in a significant decrease in mean 
ASIC3 mRNA expression in L5 neurons ipsilateral to CCI. 
 
 
(days 714) infusion of NT-3 revealed that NT-3 effectively reduced levels of ASIC3 
expression regardless of the timing of infusion.  Quantification of hybridization signal  
over individual neurons from 14 d CCI revealed that detectable ASIC3 mRNA 
hybridization signal was observed over all size ranges of neurons (Figure 4-3).  Those 
neurons expressing moderate to high levels of ASIC3 mRNA are significantly increased 
2 weeks following CCI from 9.460% +/- 1.196 (s.e.m.) to 29.83% +/- 1.302 (s.e.m.) 
(Kruskal-Wallis test with Dunns Multiple Comparison test, p<0.05).  The mean 
neuronal labeling index is also increased [from 8.060 +/- 0.08729 (s.e.m.) to 15.55 +/- 
1.110 (s.e.m.)].  Immediate infusion of NT-3 [CCI + NT-3(i)] significantly decreased the 
ASIC3 mean labeling index to a level equivalent to that of neurons contralateral to CCI 
from 15.55 +/- 1.110 (s.e.m.) to 7.844 +/- 0.8070 (s.e.m.) (Kruskal-Wallis test with 
Dunns Multiple Comparison test, p<0.01) (Figure 4-4) despite the fact that the NT-3 
pump was removed for the last 7 days of injury.  The incidence of expression was also 
decreased from 51.57% +/- 0.6333 (s.e.m.) to 41.43% +/- 5.460 (s.e.m.).    This decrease 
was most prevalent in those neurons expressing moderate to high levels of ASIC3 [from 
29.83% +/- 1.302 (s.e.m.) to 12.43% +/- 1.466 (s.e.m.)] (Figure 4-3).  Delayed infusion 
of NT-3 also significantly reduced the ASIC3 mean labeling index [from 15.55 +/- 1.110 
(s.e.m.) to 5.017 +/- 0.08471 (s.e.m.)] (Kruskal-Wallis test with Dunns Multiple 
Comparison test, p<0.0001) (Figure 4-4).  Again, the percentage of neurons expressing 
ASIC3 mRNA was decreased [from 51.57% +/- 0.6333 (s.e.m.) to 33.27% +/- 1.545 
(s.e.m.)], most apparent in those neurons expressing moderate to high levels of ASIC3 
[from 29.83% +/- 1.302 (s.e.m.) to 4.267% +/- 0.4410 (s.e.m.)] (Figure 4-3).  These 
decreases in expression were observed over all size ranges of neurons.  This suggests 
that a single treatment of exogenous NT-3 is effective at both preventing and reversing  
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Figure 4- 3:  Continuous NT-3 infusion is not required to attenuate CCI-associated 
ASIC3 mRNA expression in DRG neurons subjected to CCI. 
 
Top: Darkfield photomicrographs of 6µm sections of L5 DRG ipsilateral and 
contralateral to 14d unilateral CCI [CCI and Intact] in response to 600 ng/µl/hr NT-3 
infusion for the first 7 days of a 14d unilateral CCI [CCI+NT-3(i) and Intact+NT-3(i)], 
or in response to 600 ng/µl/hr NT-3 infusion for the last 7 days of a 14d unilateral CCI 
[CCI+NT-3(d) and Intact+NT-3(d)], as indicated.  Note: Both immediate and delayed 
infusion result in a decrease in the relative levels of ASIC3 mRNA detected, with the 
decrease being more pronounced following delayed NT-3 treatment. Scale bar = 100 µm 
 
Bottom:  Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
ASIC3 mRNA.  The relationship between ASIC3 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states, as indicated, are 
described above.  Labeling refers to the ratio of silver grain density over the neuronal 
cytoplasm to grain density over areas of the neuropil devoid of positive hybridization 
signal.  Solid lines divide the plots into labeled and unlabeled populations; dotted lines 
separate lightly labeled from moderate to heavily labeled populations of ASIC3-
expressing neurons.  Note: 2 week CCI results in elevated ASIC3 expression in a 
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subpopulation of small, medium and large size sensory neurons.  Both immediate and 
delayed infusion of NT-3 result in a decrease in the relative levels of ASIC3 mRNA 
expression ipsilateral to CCI, with the decrease being more pronounced with delayed 
NT-3 treatment. 
 
 
 
 
Figure 4- 4:  Both immediate and delayed NT-3 treatment significantly decrease 
mean ASIC3 labeling indices following CCI. 
 
Left:  Graph depicts quantification of relative differences between experimental groups 
(as indicated) in ASIC3 mRNA mean labeling indices for all DRG neurons measured 
following in situ hybridization for 3 separate experiments [representing 3 animals having 
undergone 14 day unilateral CCI (Intact and CCI), 3 animals having undergone 14 day 
unilateral CCI with intrathecal infusion of NT-3 for the first 7 days of the injury [I+N(i) 
and C+N(i)], and 3 animals having undergone 14 day unilateral CCI with intrathecal 
infusion of NT-3 for the last 7 days of the injury [I+N(d) and C+N(d)].  Bars represent 
the standard error of the mean (s.e.m.).  Asterisks indicate significant differences 
between experimental groups (Kruskal-Wallis test with Dunns Multiple Comparison 
test; *** p<0.0001, ** p<0.01).  NT-3 infusion results in a significant decrease in mean 
ASIC3 mRNA expression in L5 neurons ipsilateral to CCI when given for either the first 
or the last 7 days of a 14 day injury, the former demonstrating that continuous infusion 
of NT-3 is not required for this effect. 
 
Right:  Pooled data depicting the relative differences in mean labeling indices in ASIC3 
mRNA normalized to the intact state in response to unilateral chronic constriction injury 
without NT-3 infusion or with immediate or delayed NT-3 infusion (n=3).  Experimental 
conditions are as described above.  Bars represent the standard error of the mean 
(s.e.m.).  Asterisks indicate significant differences between experimental groups 
(Kruskal-Wallis test with Dunns Multiple Comparison test; *** p<0.0001).  NT-3 
infusion results in a significant decrease in mean ASIC3 mRNA expression in L5 
neurons ipsilateral to CCI when given for either the first or the last 7 days of a 14 day 
injury.  Continuous infusion of NT-3 is not required for this effect. 
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the ASIC3 CCI-associated phenotype and that continuous infusion of NT-3 is not 
required for the former effect. 
 
 
4.4.3 Levels of ASIC3 protein are decreased following NT-3 treatment 
 
Immunohistochemistry revealed that cytoplasmic ASIC3 protein levels were 
elevated both 7 and 14 days after CCI.  This elevated expression was observed across all 
size ranges of neurons.  However, while increases in message expression were more 
readily apparent in the small and medium sized neurons, alterations in protein expression 
were most apparent in the large neurons.  CCI appeared to induce an increase in 
membrane localized expression of ASIC3.  Infusion of NT-3 resulted in reduced levels 
of cytoplasmic and membrane localized ASIC3 protein expression most prominent in the 
DRG ipsilateral to CCI and regardless of the timing of the infusion.  Again, it appears 
that continuous infusion of NT-3 is not required for this effect as levels did not recover 
to those of control injuries as reported for animals where the pump was removed for the 
last 7 days of the injury period (Figure 4-5 and Figure 4-6). 
 
 
4.4.4 Levels of activated p38 MAPK are decreased in response to NT-3 treatment 
following CCI 
 
We next examined whether CCI and/or NT-3 infusion had an impact on the level 
of activation of a transcription factor implicated in the regulation of ASIC3 expression.  
Immunohistochemistry to detect levels of phospho-p38MAPK in DRG sections from 
animals having undergone 14d unilateral CCI with or without immediate or delayed 
infusion of NT-3 revealed that following CCI, levels of phospho-p38MAPK were 
increased in all size ranges of neurons.  Both immediate and delayed infusion of NT-3 
result in a decrease in the relative levels of nuclear localized phospho-p38MAPK-like 
immunoreactivity detected.  This decrease is more pronounced with delayed NT-3 
treatment [CCI + NT-3(d)] (Figure 4-7). 
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Figure 4- 5:  NT-3 infusion results in decreased expression of ASIC3 protein. 
 
Fluorescence photomicrographs demonstrate levels of ASIC3-like immunoreactivity in 
10 µm sections of DRG ipsilateral (CCI) and contralateral to CCI (Intact) L5 DRG with 
or without immediate intrathecal infusion of NT-3 (CCI+NT-3; Intact+NT-3), as 
indicated.  Scale bar, 60 µm.  Note: In the DRG contralateral to CCI (Intact), levels of 
ASIC3 protein are highest in medium sized dorsal root ganglion neurons.  Seven days 
after CCI, levels of expression have increased relative to the intact state, with the highest 
levels of protein being detected in primarily small and medium sized neurons.  
Intrathecal infusion of NT-3 at the time of injury attenuates levels of ASIC3 protein 
expression ipsilateral to injury.  
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Figure 4- 6: Continuous NT-3 infusion is not required to mitigate CCI-induced 
changes in ASIC3-like immunoreactivity in DRG neurons. 
 
Fluorescence photomicrographs depict levels of ASIC3-like immunoreactivity in 10 µm 
sections of L5 DRG representing DRG ipsilateral and contralateral to 14d unilateral CCI 
[CCI and Intact] in response to 600 ng/µl/hr NT-3 infusion for the first 7 days of a 14d 
unilateral CCI [CCI+NT-3(i) and Intact+NT-3(i)], or in response to 600 ng/µl/hr NT-3 
infusion for the last 7 days of a 14d unilateral CCI [CCI+NT-3(d) and Intact+NT-3(d)], 
as indicated. Note: 2 week CCI results in elevated ASIC3 protein expression.  Both 
immediate and delayed infusion decrease the relative levels of ASIC3-like 
immunoreactivity detected ipsilateral to CCI, with the decrease being more pronounced 
with delayed NT-3 treatment.  Scale bar = 40 µm 
 
 
 
Figure 4- 7:  Continuous NT-3 infusion is not required to reverse the increase in 
phospho-p38 MAP Kinase label detected in DRG neurons subjected to CCI. 
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Fluorescence photomicrographs demonstrate levels of phospho-p38 MAP Kinase -like 
immunoreactivity in 10 µm sections of L5 DRG representing DRG ipsilateral and 
contralateral to 14d unilateral CCI [CCI and Intact] in response to 600 ng/µl/hr NT-3 
infusion for the first 7 days of a 14d unilateral CCI [CCI+NT-3(i) and Intact+NT-3(i)], 
or in response to 600 ng/µl/hr NT-3 infusion for the last 7 days of a 14d unilateral CCI 
[CCI+NT-3(d) and Intact+NT-3(d)], as indicated. Note: CCI results in increased 
phospho-p38 MAPK-like nuclear immunoreactivity.  Both immediate and delayed 
infusion result in a decrease in the relative levels of phospho-p38 MAPK-like 
immunoreactivity detected, with the decrease being more pronounced with delayed NT-
3 treatment.  Scale bar = 50 µm 
 
 
4.5 Discussion 
 
Damage to a peripheral nerve and the subsequent invasion of multiple 
inflammatory mediators leads to a condition known as neuroinflammation which has 
been demonstrated to contribute to the sensitization of peripheral nerve terminals leading 
to exaggerated pain responses.  The main contributor to these neuroinflammation 
induced pain states is believed to be alterations in pH sensing channels such as ASIC3.  
Given that enhanced NGF synthesis contributes to various neuropathic pain syndromes 
and has been linked to the upregulation of ASIC3 under conditions of inflammation 
(Mamet et al., 2003), and that NT-3 is able to antagonize many pathways involving 
NGF, I hypothesized that NT-3 could attenuate changes in expression of ASIC3 in 
response to CCI.  The present study supports this hypothesis, identifying NT-3 as a 
novel potent modulator of the pH sensing channel, ASIC3.   
This study describes for the first time that: 1) following CCI, levels of ASIC3 are 
increased in the cytoplasm and possibly membrane presentation seen at both the 
message and protein levels; 2) NT-3 significantly attenuates levels of both mRNA and 
protein ASIC3 independent of the timing of infusion  continuous infusion does not 
appear to be required for this effect as ASIC3 levels remain low and appear slow to re-
establish following pump removal.   
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4.5.1 CCI induces alterations in level and localization of ASIC3 expression 
 
Consistent with previous reports, in the intact state, expression of ASIC3 was 
observed predominantly in small to medium sized DRG neurons, with some large 
neurons also expressing detectable levels of ASIC3 (Waldmann et al., 1997b; Chen et 
al., 1998; Voilley et al., 2001; Molliver et al., 2005) in approximately 35 to 40% of DRG 
neurons (Ugawa et al., 2005; Molliver et al., 2005).  We describe for the first time that 
following CCI, levels of ASIC3 expression were significantly upregulated, primarily in 
the small to medium sized (nociceptive) DRG neurons, as well as a small population of 
large sized neurons.  This supports insights by Mamet et al. (2002, 2003) that the 
increased levels of NGF available under conditions of inflammation drive the increased 
expression/overexpression of ASIC3.   
Following CCI, there appears to be an increased localization of ASIC3 at the cell 
membrane.  This shift in localization is most likely the result of an interaction between 
ASIC3 and the adaptor protein Na+/H+ exchanger regulatory factor-1 (NHERF-1).  It has 
been suggested by Deval et al. (2006) that the interaction between ASIC3 and NHERF-1 
plays a role in the membrane surface expression of ASIC3.  It is thus probable that under 
conditions of inflammation, the mobilization of ASIC3 towards the cell membrane 
would be enhanced in an attempt to respond to the changing pH of the extracellular 
environment. 
 
 
4.5.2 Continuous delivery of NT-3 is not required for suppression of ASIC3 
expression 
 
 The current work also demonstrates that, following CCI, exogenous NT-3 can 
effectively counter the upregulation of ASIC3 expression, reducing levels to 
approximately that of basal expression.  Surprisingly, examination of 14 day CCI with 
infusion of NT-3 for the first 7 days of the injury reveals that upon removal of 
exogenous NT-3, ASIC3 levels remain depressed.  Interestingly, examination of 14 day 
CCI with infusion of NT-3 for the last 7 days of the injury reveals that even if ASIC3 
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levels have increased for the first 7 days of the injury, exogenous NT-3 is capable of 
reversing this response.  These findings are contrary to those reported by Gandhi et al. 
(2004) in which NT-3 was unable to reverse the muscle acid-induced hyperalgesia once 
it had developed.  These conflicting results can likely be explained as a result of the 
differences between the two models.  In the CCI model, there is not only a drop in the 
pH of the extracellular environment, but also a massive production of inflammatory 
molecules that can impact the situation.  The intramuscular acid injection model, 
however, produces a focal, peripheral drop in pH. Furthermore, while in our previous 
study utilizing the same chronic injury model, continuous infusion of NT-3 was required 
in order to attenuate expression of TRPV1 and thermal hyperalgesia (Wilson-Gerwing et 
al., 2005).  This did not appear to be the case for ASIC3 expression which remained at a 
significantly lower level of expression relative to control even 1 week following NT-3 
removal.  This demonstrates, for the first time, that continuous NT-3 is not required to 
reverse the increase in ASIC3 label detected in DRG neurons subjected to CCI, as we 
have previously observed with TRPV1 (Wilson-Gerwing et al., 2005). 
 
 
4.5.3 Attenuation of ASIC3 upregulation by NT-3 does not correlate with the 
regulation of thermal hyperalgesia by NT-3 following CCI 
 
 We have reported previously that exogenous NT-3 could effectively prevent and 
reverse thermal hyperalgesia but had no net effect on mechanical hypersensitivity (von 
Frey stimulation) following CCI and that removal of NT-3 resulted in the rapid 
reestablishment of hyperalgesia (Wilson-Gerwing et al., 2005).  Here, we report that 
exogenous NT-3 applied intrathecally is capable of disabling the mechanism by which 
ASIC3 is upregulated in the DRG in response to CCI.  Thus, we find that 
downregulation of ASIC3 does not appear to influence mechanical hypersensitivity or 
the re-establishment of the thermal hyperalgesic state following NT-3 pump removal. 
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4.5.4 Modulation of ASIC3 by NT-3 is likely due to its impact on the 
trkA/JNK/p38MAPK pathway 
 
 Activation of the trkA/JNK/p38MAPK pathway by inflammationassociated 
increases in NGF has been reported to be responsible for the upregulation of ASIC3 
under inflammatory conditions (Mamet et al., 2003).  Previously, we have reported that 
following CCI, NT-3 is able to downregulate the neurotrophin receptor, tropomyosin-
related kinase A (trkA) (Wilson-Gerwing and Verge, 2006) as well as levels of phospho-
p38MAPK (Wilson-Gerwing et al., 2005). As observed with the regulation of ASIC3 
following CCI, phospho-p38 MAPK expression remains depressed upon removal of 
exogenous NT-3.  Therefore, if the downstream transcriptional action of phospho-
p38MAPK is inhibited, it is likely to have an impact on ASIC3 transcription (Mamet et 
al., 2003).  Interestingly, although levels of phoshpo-p38 MAPK remain depressed, this 
does not inhibit the prompt reestablishment of thermal hyperalgesia following removal 
of exogenous NT-3 (Wilson-Gerwing et al., 2005).  This is likely due to the previously 
reported findings that levels of TRPV1 mRNA are not significantly altered in the 2 week 
model of CCI +/- NT-3, therefore allowing for reactivation of thermal hyperalgesia 
without the immediate need to engage the p38 MAPK pathway. 
 
 
4.5.5 A role for ASIC3 in neuropathic pain? 
 
Exploring the potential roles for ASIC3 as a generator or modulator of pain 
sensations demonstrates that the use of ASIC3 transgenic mice have been widely 
employed with varied results.  These range from ASIC3 knock outs 1) being more 
responsive to light touch, but less responsive to noxious pinch and noxious heat (Price et 
al., 2001); 2) being more sensitive to moderate to high noxious stimuli (Chen et al., 
2002); and 3) exhibiting the absence of mechanical hyperalgesia and central 
sensitization (Sluka et al., 2003).  More recently, it has been reported that ASIC3 
transgenics are more sensitive to both mechanical and chemical/inflammatory pain 
(Mogil et al., 2005) and conversely, that ASIC3 does not mediate responses to 
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mechanical stimuli (Drew et al., 2004).  In concert with those results reported by Drew 
et al. (2004), the findings reported here are indicative of the lack of a critical role for 
ASIC3 in mechanical hypersensitivity following CCI and also the lack of a critical role 
for ASIC3 in the reestablishment of thermal hyperalgesia following CCI.  While one 
might predict from all of the research performed on ASIC3 transgenic mice that there is 
a critical role for ASIC3 in the neuropathic pain state, it should be noted that there may 
be species driven differences in the role of ASIC3 in the generation and maintenance of 
neuropathic pain behaviors as described in Leffler et al. (2006). 
Although we observed changes within the cell body at both the message and 
protein level, we are assuming that ASIC3 did not make a major contribution in the 
rapid reestablishment of the thermal hyperalgesia that was observed.  The possibility that 
there was a redistribution of ASIC3 to the terminal regions of the small fibers that still 
remained following NT-3 treatment cannot be excluded.  However, it is unlikely that 
elevated terminal expression would still be present following NT-3 infusion and be 
actively contributing to the thermal hyperalgesia state still observed.  It is also important 
to note that unlike other inflammatory models where local inflammation is the main 
driver of the local response, the nerve inflammation observed with CCI is far removed 
from the hindpaw where the behavioral testing is taking place, thus involving a more 
complex strategy for the treatment of this type of inflammation. 
While ASIC3 activation is brought about by a drop in extracellular pH 
(Waldmann et al., 1997b), it is not the only channel sensitive to such a shift in pH (i.e. 
TRPV1) (Caterina et al., 1997), providing insight that perhaps ASIC3 must work in 
conjunction with additional channels and/or molecules to effect changes in nociception 
at the level of the DRG.  In conclusion, ASIC3 is undoubtedly involved in some aspect 
of the generation and/or maintenance of neuropathic pain, but it is not a critical channel 
in the CCI model of neuropathic pain. 
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5 Exogenous neurotrophin-3 treatment significantly reduces sodium channel 
expression linked to neuropathic pain states 
 
 
5.1 Abstract 
 
The development of neuropathic pain syndromes as a result of a chronic 
constriction injury (CCI) is critically linked to the sensitization of peripheral 
nociceptors.  Changes in the electrophysiological properties of these neurons are 
controlled by the presence of voltage gated sodium channels.  These channels are major 
contributors to this sensitized state and their expression can be upregulated by the 
presence of nerve growth factor (NGF).  We have previously demonstrated that another 
neurotrophin, neurotrophin-3 (NT-3) can effectively antagonize a number of changes 
brought about by increased NGF, including its high-affinity receptor, tropomyosin 
related kinase A (trkA), and thermal hyperalgesia.  Two tetrodotoxin resistant (TTX-R) 
sodium channels, Nav1.8 and Nav1.9, are upregulated in the presence of 
proinflammatory mediators, including NGF, and play a role in the development of 
neuronal hypersensitivity in a number of models of neuropathic pain.  As NT-3 is a 
potent negative modulator of this pathway, I hypothesized that increases in available 
NT-3 would effectively reduce expression of Nav1.8 and Nav1.9 in DRG neurons 
ipsilateral to CCI.  Neuronal levels of Nav1.8 and Nav1.9 mRNA and protein were 
decreased following 7 day CCI.  Intrathecal infusion of NT-3 for 7 days at the time of 
injury significantly reduced levels of both Nav1.8 and Nav1.9 contralateral and most 
notably ipsilateral to CCI.  This ability of NT-3 to dramatically reduce levels of the 
TTX-R sodium channels Nav1.8 and Nav1.9 is potentially linked to the ability of NT-3 to 
interfere with the sensitization of sensory neurons and the ensuing development of 
thermal hyperalgesia following CCI. 
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5.2 Introduction 
 
 Neuropathic pain has become well characterized over the last decade, including 
the behaviors associated with this chronic pain syndrome.  Among these behaviors is the 
increased sensitivity to noxious stimuli (defined as hyperalgesia) as well as the 
generation of spontaneous pain (related to ectopic discharge of neurons) (reviewed in 
Woolf and Mannion, 1999).  Complicit in the development of hyperalgesia is the 
sensitization of peripheral nerve terminals (nociceptors) whereby the threshold required 
for activation of the nociceptor is decreased.  Ectopic discharges resulting from the 
spontaneous firing of the nociceptive neuron in the absence of a stimulus is also a 
contributing factor to this pain state.  It has been well established that both the activation 
threshold of a neuron and the potential for spontaneous firing is regulated by sodium 
channels (Hodgkin and Huxley, 1952; Catterall, 1995).  This cumulative 
hyperexcitability of sensory neurons following nerve injury has been associated with 
altered expression and the redistribution of voltage gated sodium channels to the tips of 
the injured axons and/or the neuromas (Devor et al., 1989; England et al., 1994, 1996; 
Amir et al., 1999). 
 Sodium channels are characterized on the basis of their ability to respond to the 
puffer fish toxin, tetrodotoxin (TTX).  This results in two diverse groups of sodium 
channels  those that are TTX-sensitive (TTX-S) and those that are TTX-resistant (TTX-
R).  It is the TTX-R sodium channels that have garnered much attention with respect to 
the generation of neuropathic pain syndromes, specifically Nav1.8 and Nav1.9.  In 
general, the TTX-R currents have been detected primarily in small diameter, but also in 
medium and large diameter DRG neurons (Akopian et al., 1996; Black et al., 1996; 
Cummins et al., 1999; Dib-Hajj et al., 1999; Rush et al., 1998; Renganathan et al., 2000; 
Hong and Wiley, 2006) are associated with nociceptive neurons (Djourhi et al., 2003; 
Fang et al., 2002). 
 Expression of the Nav1.8 isoform is linked to the development of nociceptor 
hyperexcitability.  More specifically, the development of thermal hyperalgesia and 
mechanical allodynia in nerve ligation models of neuropathic pain is reduced with 
Nav1.8 antisense treatment (Porreca et al., 1999; Lai et al., 2002; Joshi et al., 2006), 
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while ectopic firing of neurons is correlated with Nav1.8 protein expression (Novakovic 
et al., 1998; Gold et al., 2003).  In contrast to Nav1.8, early evidence of a direct role of 
Nav1.9 in the development of thermal and mechanical hyperalgesia was lacking in rats 
with neuropathic pain states induced by spinal nerve ligation (Porecca et al., 1999) and 
partial ligation of the sciatic nerve (Priest et al., 2005).  However, Nav1.9 may play a 
significant role in the increased excitability and sensitization of nociceptive axons during 
inflammation (Herzog et al., 2001; Baker et al., 2003; Rush and Waxman, 2004; Priest et 
al., 2005) although this is still a matter of debate (Hillsley et al., 2006).   
 Alterations in the levels of expression of both Nav1.8 and Nav1.9 in response to 
chronic constriction injury (CCI) are conflicting.  Following CCI, neuronal Nav1.8 has 
been found to decrease in small diameter neurons (Dib-Hajj et al., 1999), decrease only 
in axotomized cells (Decosterd et al., 2002), or undergo no change at all (Novakovic et 
al., 1998).  Similarly, neuronal levels of Nav1.9 have been found to decrease in small 
diameter neurons (Dib-Hajj et al., 1999) or to decrease only in axotomized cells 
(Decosterd et al., 2002). It is of interest that these two channels respond differently to 
inflammation, with Nav1.8 being upregulated primarily in small neurons (Tanaka et al., 
1998; Black et al., 2004; Gould et al., 2004) while there appears to be no change in the 
expression of Nav1.9 (Black at al., 2004).  The variations in these reported findings may 
be due, in part, to the complexity of the CCI model itself producing preferential axotomy 
of large sized DRG neurons and exposure of the remaining intact axons to an 
inflammatory environment (Bennett and Xie, 1988; Kajander and Bennett, 1992) and 
increased levels of nerve growth factor (NGF) that has been shown to increase injury-
induced expression of these two isoforms (Dib-Hajj et al., 1998; Fjell et al., 1999).  As 
such, it appears that the levels of Nav1.8 as regulated by NGF are dependent on the 
levels of trkA expression, but apparently not Nav1.9 (Fang et al., 2005). 
 I have previously demonstrated that another neurotrophin, neurotrophin-3 (NT-
3), is able to negatively modulate levels of the high-affinity NGF receptor, tropomyosin 
related kinase A (trkA) (Wilson-Gerwing and Verge, 2006), to regulate the development 
and maintenance of thermal hyperalgesia, and in general, to act in a manner that is 
antagonistic to NGF in the CCI model of neuropathic pain (Wilson-Gerwing et al., 
2005).  In accordance with these findings, I have thus investigated whether NT-3 is 
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capable of regulating levels of expression of the TTX-R sodium channel isoforms 
Nav1.8 and Nav1.9 following CCI. 
 
5.3 Methods 
 
5.3.1 Animal surgery 
 
All animal procedures were conducted in accordance with the National Institutes 
of Health policy on the use of animals in research and the University of Saskatchewan 
animal care committee guidelines (protocol 19920164).  A total of 32 young adult male 
Wistar rats (Charles River Laboratories, Wilmington, MA) weighing 250-300 g were 
used.  Animals were anesthetized for surgery with sodium pentobarbital (Somnitol, 65 
mg/kg; MTC Pharm, Cambridge, Ontario, Canada).  Pre- and post-operative (for 24 h) 
subcutaneous injections of buprenorphine (Temgesic, 0.1-0.2 mg/kg) were given to 
alleviate any post-operative discomfort.  To examine the effect of NT-3 on the 
expression of Nav1.8 and Nav1.9, 32 rats were used: 13 underwent 7 d unilateral CCI of 
the sciatic nerve (Bennett and Xie, 1988), 3 received sham CCI surgeries whereby the 
sciatic nerve was exposed but not ligated, 13 received 7 d unilateral CCI with intrathecal 
infusion of NT-3 for the duration of the injury, and 3 received 7 d unilateral CCI with 
sham pump implantation whereby the dorsal roots were exposed, the dura opened as 
with the CCI + NT-3 procedure, but no pump was implanted. 
 NT-3 (generously supplied by Regeneron Pharmaceuticals, Tarrytown, NY) was 
delivered intrathecally for 7 d via mini-osmotic pumps (model 2001; Alza, Cupertino, 
CA) inserted at the lumbar sacral junction as per Verge et al. (1989a) at a concentration 
and rate of 600 ng/µl/hr (Karchewski et al., 2002) in a solution of PBS containing rat 
serum albumin (1 mg/ml), streptomycin (100 U/ml), and penicillin (100 U/ml).  This 
dose of NT-3 was the minimum dose found to selectively reverse injury-associated gene 
expression in injured trkC-expressing neurons (Verge et al., 1996; Jongsma Wallin et al., 
2001; Karchewski et al., 2002).  At the conclusion of the experiments, rats were killed, 
and tissue was dissected and processed for in situ hybridization and/or 
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immunohistochemistry as described below.  Previous studies have demonstrated a lack 
of influence ipsilateral and contralateral to injury when vehicle is infused intrathecally 
(Verge et al., 1989a; Verge et al., 1995; Jongsma Wallin et al., 2001; Wilson-Gerwing et 
al., 2005). 
 
5.3.2 In situ hybridization 
 
 Deeply anesthetized animals were perfused via the aorta with 0.1 M PBS, pH 
7.4, followed by 4% paraformaldehyde in 0.1M PBS.  The right and left L4 and L5 DRG 
were rapidly dissected, postfixed for 1 hour in the same fixative, and cryoprotected in 
20% sucrose in 0.1M PBS overnight.  Paired experimental and control tissues were 
mounted in the same cryomold (to ensure processing under identical conditions), 
covered with OCT compound (Tissue Tek; Miles Laboratories, Elkhart, IN, USA) and 
frozen in cooled isopentane.  Transverse sections were cut at 6 µm on a Micron cryostat 
(Zeiss, Canada), thaw mounted onto Probe-On+ slides (Fisher Scientific, Edmonton, AB, 
Canada) and stored with desiccant at 20 oC until hybridization. 
 Prior to hybridization, slides were air dried for 15 minutes, followed by fixation 
in 4% paraformaldehyde for 20 minutes.  Slides were washed 3 X 5 minutes in 1X PBS.  
Sections were then treated with proteinase K (20 µg/ml) containing 10 ml 1M Tris-HCl 
(pH 7.6), 2 ml 0.5 M EDTA, 200 µl proteinase K stock (20 mg/ml) and 188 µl ddH20 for 
6 minutes.  Slides were then rinsed for 5 minutes in 1 X PBS and post-fixed for 5 
minutes in 4% paraformaldehyde.  Slides were then rinsed 2 X 5 minutes in 1 X PBS, 1 
X 5 minutes in DEPC-H2O, and dehydrated in ascending alcohols. 
 Oligonucleotide probes complementary to and selective for Nav1.8 mRNA 
[complementary to bases 640-687 (Akopian et al., 1996)] and Nav1.9 mRNA 
[complementary to bases 2811-2858 (Dib-Hajj et al., 1998)] were synthesized 
(University of Calgary DNA services, Alberta, Canada).  The probes were checked 
against the GenBank database (NIH) to ensure no greater than 60% homology was found 
to sequences other than the cognate transcript.  The probes were labeled at the 3-end 
with α-[35S]dATP (New England Nuclear, Boston, MA, USA) using terminal 
deoxynucleotidyl-transferase (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in a 
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buffer containing 10 mM CoCl2, 1 mM dithiothreitol, 300 mM Tris base and 1.4 M-
potassium cacodylate (pH 7.2), and purified through Bio-Spin® Disposable 
Chromatograph Columns (Bio-Rad laboratories, Hercules, CA, USA) containing 200 mg 
of NENSORB PREP Nucleic Acid Purification Resin (NEN®, Boston, MA, USA).  
Dithiothreitol was added to a final concentration of 10 nM. 
 Hybridization was carried out according to published procedures (Dagerlind et 
al., 1992) on a minimum of 5 slides/probe from each of the experimental and control 
groupings.  Briefly, the sections were hybridized at 43 oC for 14-18 hours in a buffer 
containing 50% formamide (Sigma Aldrich, Oakville, ON, Canada), 4X SSC (1X SSC  
0.15 M NaCl, 0.015 sodium citrate), 1X Denharts solution (0.02% bovine serum 
albumin and 0.02% Ficoll), 1% sarcosyl (N-laurylsarcosine), 0.02 M phosphate buffer 
(pH 7.0), 10% dextran sulphate, 500 µg/ml heat-denatured sheared salmon sperm DNA, 
200 mM dithiothreitol and 107 cpm/ml of probe.  After hybridization, the slides were 
washed for 4 X 15 mins in 1X SSC at 55oC, dehydrated in ascending alcohols, processed 
for radioautography as per Karchewski et al., 2002 and exposed for 7 to 10 days before 
developing in D-19 (Kodak, Rochester, NY, USA). 
 The specificity of hybridization signal for the Nav 1.8 and Nav 1.9 probes were 
confirmed as described in Wilson-Gerwing et al., 2005. 
 
5.3.3 Quantification and analysis 
 
 All slides from the 13 groupings of 7 d experimental and control animals were 
analyzed qualitatively and relative changes in hybridization signal from one group to 
another noted for sections mounted on the same slide to avoid bias due to the variance in 
hybridization signal observed from slide to slide.  Representative slides were selected for 
further quantitative analysis.  These slides had a similar number of neurons in all DRG 
sections.  Photomontages of each section to be analyzed were prepared and individual 
neurons with a visible nucleus were identified.  Using a 40X light objective and a 2X 
optivar with an interactive computer-assisted image-analysis system (Richardson et al., 
1989), cross-sectional areas of individual neurons and the percentages of cytoplasmic 
areas covered by silver grains were measured for each DRG.  The area per grain was 
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constant for all neurons and a correction for grain overlap was made to obtain a 
parameter linearly related to density of silver grains (Richardson et al., 1989).  Software 
for the image analysis system was Northern Eclipse, Version 7.0 (Empix Imaging, 
Mississauga, ON, Canada) and supplemented with Microsoft Office Excel 2003 
(Microsoft Corporation, Redmond, WA) and Prizm 4.0 (Graph Pad Software, San 
Diego, CA).  Cells were considered labeled if they had more than five times background 
levels of silver grains, as determined by averaging grain densities over defined areas of 
the neuropil devoid of positively labeled cell bodies.  This criterion for determining 
labeled neuronal profiles correlates well with the identification of labeled versus 
unlabeled neurons as determined manually using a 63X oil immersion objective.  A 
stereological approach was not employed in this study and therefore the data 
quantification may represent a biased estimate of (i) the percentage of the population 
expressing individual markers (based on incidence in the sections examined whereby all 
neurons with a nucleus present in that section were included in the analysis) and (ii) the 
actual neuronal size (which was determined based on the assumption that the presence of 
a nucleus in the section correlates with the maximal diameter for that cell). 
 Analysis was performed in each instance on all neurons with a nucleus present in 
the section being quantified:  for Nav1.8 this represents 12 DRG sections or 2236 
neuronal profiles (Intact: n = 3 animals, CCI: n = 3 animals, Intact + NT-3: n = 3 
animals, CCI+NT-3: n = 3 animals); while for Nav1.9 this represents 12 DRG sections or 
2025 neuronal profiles (Intact: n = 3 animals, CCI: n = 3 animals, Intact + NT-3: n = 3 
animals, CCI+NT-3: n = 3 animals).  Previous research from our lab has demonstrated 
that CCI does not induce bilateral hyperalgesia (Wilson-Gerwing et al., 2005) and we 
have not discerned any qualitative differences between sham-operated or naïve DRG and 
contralateral intact DRG for Nav1.8 or Nav1.9.  Therefore, the contralateral intact DRG 
was used as an intact control. 
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5.3.4 Immunohistochemistry 
 
 Deeply anesthetized animals were perfused via the aorta with 0.1M PBS 
followed by 4% paraformaldehyde.  Right and left L4 and L5 DRG were dissected, post-
fixed for 1  1.5 h, and cryoprotected in 20% sucrose overnight at 4 oC.  Paired 
experimental and control tissues were frozen in the same cryomold to ensure processing 
under identical conditions.  Transverse 10 µm sections were cut on the cryostat, thaw-
mounted onto Probe-ON+ slides (Fisher Scientific), and processed for 
immunohistochemistry. 
 For Nav1.8, sections were washed three times for 5 minutes in 0.1 M PBS, then 
permeabilized with 0.3% Triton X-100 in 0.1 M PBS for 45 minutes at room 
temperature.  Sections were blocked overnight at 4 oC in 10% goat serum and 0.3% 
Triton X-100 in 0.1 M PBS, then incubated overnight at 4 oC with rabbit anti-Nav 1.8 
Affinity Purified Polyclonal Antibody (1:200; Chemicon International, Temecula, CA, 
USA) diluted with 10% goat serum and 0.3% Triton X-100 in 0.1 M PBS.  Sections 
were visualized with Alexa Fluor 488 F(ab)2 fragment of goat anti-rabbit IgG (H+L) 
(1:250; Molecular Probes, Eugene, OR, USA) in 2% goat serum in 0.1 M PBS for 2 
hours at room temperature.  Slides were washed and coverslipped with 50% 
glycerol/50% PBS.  For Nav1.9, sections were washed three times for 5 minutes in 0.1 M 
PBS, then permeabilized with 0.3% Triton X-100 in 0.1 M PBS for 45 minutes at room 
temperature.  Sections were blocked overnight at 4 oC in 10% goat serum, 3% BSA, and 
0.3% Triton X-100 in 0.1 M PBS, then incubated overnight at 4 oC with rabbit anti-
Nav1.9 Affinity Purified Polyclonal Antibody (1:100; Chemicon International, 
Temecula, CA, USA) diluted with 10% goat serum, 3% BSA, and 0.3% Triton X-100 in 
0.1 M PBS.  Sections were visualized with Alexa Fluor 546 goat anti-rabbit IgG 
(H+L), F(ab)2 fragment conjugate (1:250; Molecular Probes, Eugene, OR, USA) in 2% 
goat serum for 2 hours at room temperature.  Slides were washed and coverslipped with 
50% glycerol/50% PBS.   Control sections were processed in the same manner, but 
without the primary antibody.  Results were visualized using a Zeiss Axioscope 50 
microscope equipped with incident-light fluorescence optics and a digital camera. 
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5.4 Results 
 
5.4.1 NT-3 significantly reduces levels of Nav1.8 mRNA 
 
Analysis of sections processed for in situ hybridization to detect neuronal 
expression of Nav1.8 mRNA revealed that in the DRG contralateral to CCI (Intact), 
detectable hybridization signal was observed in ~72% of neurons analyzed (Table 5-1).  
This was localized primarily over small to medium sized (<35 µm in diameter) neurons 
with ~88% of the population of small to medium size neurons expressing this message 
and only ~53% of the population of larger sized (>35 µm in diameter) neurons doing so 
at detectable levels (Table 5-1).  Seven days after CCI, there is a reduction in the relative 
levels of hybridization signal (Figure 5-1).  This reduction is also reflected in the 
percentage of neurons expressing detectable levels of Nav1.8 (Table 5-1).  The mean 
labeling index for these neurons is significantly reduced from a normalized value of 1 in 
the intact state to 0.94 following CCI.  This reduction is most apparent in those small to 
medium sized neurons (Kruskal-Wallis test with Dunns Multiple Comparison test, 
p<0.01) (Figure 5-2; Table 5-2). 
NT-3 infusion effected a marked reduction in the levels of Nav1.8 mRNA 
expression observed in neurons both contralateral and ipsilateral to CCI (Intact + NT-3 
and CCI + NT-3) (Figure 5-1).  In NT-3 infused DRG contralateral to CCI (Intact + NT-
3) the mean labeling index was significantly decreased from a normalized value of 1 in 
the intact state to 0.77 in the NT-3 treated group (Kruskal-Wallis test with Dunns 
Multiple Comparison test, p<0.01) (Figure 5-2; Table 5-2) as was the percentage of 
neurons expressing detectable levels of Nav1.8 (Figure 5-1; Table 5-1).  A more 
dramatic attenuation of Nav1.8 expression was observed in the NT-3 treated DRG 
ipsilateral to CCI (CCI + NT-3).  Mean labeling index was significantly decreased with 
NT-3 treatment from 0.94 to 0.41 (Kruskal-Wallis test with Dunns Multiple 
Comparison test, p<0.01) (Figure 5-2; Table 5-2).  The percentages of neurons 
expressing detectable levels of Nav1.8 mRNA were also reduced (Table 5-1).  This 
decrease in the relative level of Nav1.8 expression is most noticeable in those small to 
medium sized neurons (Figure 5-1; Table 5-1).   
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Nav 1.8 Population of total 
neurons examined (%) 
 % of small to medium 
neuronal population 
(neurons < 35µm) 
 % of large neuronal 
population (neurons > 
35µm) 
 > 5X 
bkgd 
> 20X 
bkgd 
> 5X 
bkgd 
> 20X 
bkgd 
> 5X 
bkgd 
> 20X 
bkgd 
       
Intact 72.27 +/- 
6.750% 
40.60 +/-
3.156% 
87.67 +/-
2.685% 
52.80 +/-
8.235% 
36.27 +/-
9.275% 
11.63 +/-
3.115% 
       
Intact + 
NT-3 
55.47 +/-
4.226% 
31.13 +/-
3.593% 
73.67 +/-
3.494% 
46.17 +/-
4.529% 
30.33 +/-
2.945% 
11.67 +/-
4.796% 
       
CCI 52.23 +/-
10.98% 
34.17 +/-
1.994% 
70.3 +/-
3.012% 
43.77 +/-
5.940% 
23.13 +/-
6.020% 
11.53 +/-
1.810% 
       
CCI + 
NT-3 
36.67 +/-
2.955% 
15.30 +/-
4.105% 
43.47 +/-
4.311% 
17.30 +/-
3.851% 
16.10 +/-
8.504% 
8.533 +/-
6.416% 
       
 
 
Table 5- 1:  Effects of CCI +/- NT-3 infusion on numbers of neurons expressing 
Nav1.8 mRNA. 
 
 The above table summarizes the alterations in the incidence (percentage) of 
Nav1.8 mRNA positive neurons in L5 DRG neurons under various experimental 
conditions as indicated in the left column.  Those neurons < 35 µm are characterized as 
small to medium in size and those neurons > 35 µm are characterized as medium to large 
in size.  Detectable levels of hybridization signal are all those > 5X background where as 
moderate to high levels of hybridization signal are those > 20X background.  CCI 
produces a decrease in the percentages of neurons positively labeled for Nav1.8.  
Infusion of NT-3 further decreases the percentage of Nav1.8 mRNA positive neurons 
detected most evident ipsilateral to CCI. 
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Figure 5- 1:  Message levels for the tetrodotoxin resistant sodium channel Nav1.8 
are reduced in response to NT-3 treatment. 
 
Top:  Dark-field photomicrographs of 6 µm thick adult rat L5 DRG sections processed 
for in situ hybridization to detect Nav1.8 transcripts contralateral (Intact) or ipsilateral to 
7d CCI (CCI) and after a 7d unilateral CCI plus intrathecal infusion of 600 ng/µl/hr NT-
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3 (Intact+NT-3; CCI+NT-3).  Scale bar = 100 µm. Note:  Treatment with NT-3 
dramatically reduces levels of Nav1.8 mRNA following CCI. 
 
Bottom:  Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
Nav1.8 mRNA.  The relationship between Nav1.8 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states are indicated at 
the top right of each graph and are as described above.  Labeling refers to the ratio of 
silver grain density over the neuronal cytoplasm to grain density over areas of the 
neuropil devoid of positive hybridization signal.  Solid lines divide the plots into labeled 
and unlabeled populations; dotted lines separate lightly labeled from moderate to heavily 
labeled populations of Nav1.8 expressing neurons.  Note:  In DRG contralateral to CCI, 
Nav1.8 is expressed predominantly in small to medium neurons with some large neurons 
also expressing detectable levels.  CCI results in a slight decrease in Nav1.8 expression.  
NT-3 infusion results in a decrease in the levels of detectable Nav1.8 mRNA in DRG 
both ipsilateral and contralateral to CCI, with a more pronounced effect ipsilateral to 
injury. 
 
 
 
 
 
 
Figure 5- 2:  NT-3 treatment significantly reduces mean Nav1.8 mRNA labeling 
indices. 
 
Left:  Graph depicts quantification of relative differences between experimental groups 
(as indicated) in Nav1.8 mRNA mean labeling indices for all DRG neurons measured 
following in situ hybridization for 3 separate experiments [representing 3 animals having 
undergone 7 day unilateral CCI [Intact (I) and CCI] and 3 animals having undergone 7 
day unilateral CCI with intrathecal infusion of NT-3 [Intact+NT-3 (I+N) and CCI+NT-3 
(CCI+N)].  Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate 
significant differences between experimental groups (Kruskal-Wallis test with Dunns 
Multiple Comparison test; *** p<0.0001).  NT-3 infusion results in a significant 
decrease in mean Nav1.8 mRNA expression in L5 neurons both ipsilateral and 
contralateral to CCI. 
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Right:  Pooled data depicting the relative differences in mean labeling indices in Nav1.8 
mRNA normalized to the intact state in response to unilateral chronic constriction injury 
with or without NT-3 infusion (n=3).  Experimental conditions are as described above.  
Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate significant 
differences between experimental groups (Kruskal-Wallis test with Dunns Multiple 
Comparison test; *** p<0.0001).  NT-3 infusion results in a significant decrease in mean 
Nav1.8 mRNA expression in L5 neurons both ipsilateral and contralateral to CCI. 
 
 
 
Nav 1.8 Total  population of 
neurons examined 
(mean labeling 
index) 
 Small to medium 
neuronal population 
(neurons < 35µm) 
(mean labeling index) 
 Large neuronal 
population 
(neurons > 35µm) 
(mean labeling index) 
    
Intact 1.0000 +/- 0.03496 1.0000 +/- 0.03140 1.0000 +/- 0.1170 
    
Intact + NT-
3 
0.7717 +/- 0.04497 0.8847 +/- 0.05304 0.9569 +/- 0.1271 
    
CCI 0.9428 +/- 0.04333 0.8978 +/- 0.04004 0.9946 +/- 0.1980 
    
CCI + NT-3 0.4096 +/- 0.02767 0.3776 +/- 0.02719 0.8743 +/- 0.1741 
    
 
 
Table 5- 2: Effects of CCI +/- NT-3 infusion on the Nav1.8 mRNA mean labeling 
index. 
 
The above table summarizes the alterations in Nav1.8 mRNA mean labeling index of 
pooled data normalized to intact mean labeling index within each of the 3 experimental 
groupings of animals analyzed in L5 DRG neurons under various experimental 
conditions as indicated in the left column.  Those neurons < 35 µm are characterized as 
small to medium in size and those neurons > 35 µm are characterized as medium to large 
in size.   CCI produces a decrease in the Nav1.8 mean labeling index in the total neurons 
most apparent in those small to medium neurons.  Infusion of NT-3 decreases levels of 
Nav1.8 mRNA both ipsilateral and contralateral to CCI in all size ranges of neurons.   
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5.4.2 Levels of Nav1.8 protein are decreased following NT-3 treatment 
 
Immunohistochemistry revealed that in the intact state, Nav1.8 protein was 
observed most prominently in the smaller DRG neurons, with some medium to large 
sized neurons also expressing low to moderate levels of Nav1.8 protein.  Levels of 
Nav1.8 protein were reduced 7 days following CCI (Figure 5-3).  This reduction was 
most obvious in the medium to large sized neurons that appeared devoid of any Nav1.8 
protein.  Infusion of NT-3 effected a decrease in the levels of Nav1.8 protein in the DRG 
both contralateral and ipsilateral to CCI (Intact + NT-3; CCI + NT-3) (Figure 5-3).   
 
5.4.3 NT-3 significantly reduces levels of Nav1.9 mRNA 
 
Analysis of sections processed for in situ hybridization to detect neuronal 
expression of Nav1.9 mRNA revealed that in the DRG contralateral to CCI (Intact), 
detectable hybridization signal was observed in ~73% of neurons.  This was localized 
primarily over small to medium sized neurons representing ~90% of the population of 
small-medium size neurons with ~37% of the population of large sized neurons also 
expressing detectable levels (Figure 5-4; Table 5-3).  Seven days after CCI, there is a 
reduction in the percentage of neurons expressing detectable levels of Nav1.9 (Figure 5-
4: Table 5-3) and the mean labeling index for these neurons was significantly decreased 
from normalized value of 1 in the intact state to 0.77 following CCI (Kruskal-Wallis test 
with Dunns Multiple Comparison test, p<0.01) (Figure 5-5; Table 5-4). 
NT-3 infusion effected a marked reduction in the levels of Nav1.9 mRNA 
expression observed in neurons both contralateral and ipsilateral to CCI (Intact + NT-3 
and CCI + NT-3) (Figure 5-4).  In DRG contralateral to CCI (Intact + NT-3) the mean 
labeling index was significantly decreased from a normalized value of 1 in the intact 
state to 0.53 in the NT-3 treated group (Kruskal-Wallis test with Dunns Multiple 
Comparison test, p<0.01) (Figure 5-5; Table 5-4) as was the percentage of neurons 
expressing detectable levels of Nav1.9 (Figure 5-4; Table 5-3).  A more dramatic 
attenuation of Nav1.9 expression was observed in the  
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Figure 5- 3:  NT-3 infusion attenuates Nav1.8 protein expression. 
 
Fluorescence photomicrographs depict levels of Nav1.8-like immunoreactivity in 10 µm 
sections of DRG ipsilateral (CCI) and contralateral to CCI (Intact) L5 DRG with or 
without immediate intrathecal infusion of NT-3 (CCI+NT-3; Intact+NT-3), as indicated.  
Scale bar, 60 µm.  Note: In the DRG contralateral to CCI (Intact), levels of Nav1.8 
protein are highest in small to medium sized dorsal root ganglion neurons.  Seven days 
after CCI, levels of expression have decreased slightly relative to the intact state most 
evident in the medium sized neurons.  Intrathecal infusion of NT-3 at the time of injury 
also results in markedly reduced levels of Nav1.8 protein expression ipsilateral to CCI. 
 
 
 
NT-3 treated DRG ipsilateral to CCI (CCI + NT-3).  The mean labeling index was 
significantly decreased with NT-3 treatment from 0.77 to 0.26 (Kruskal-Wallis test with 
Dunns Multiple Comparison test, p<0.01) (Figure 5-5; Table 5-4).  The percentages of 
neurons expressing detectable levels of Nav1.9 mRNA were also reduced (Table 5-3).  
This decrease in the relative level of Nav1.9 expression (Figure 5-5; Table 5-3) as well 
as the significant decrease in the mean labeling index (Kruskal Wallis test with Dunns 
Multiple Comparison test, p<0.01) (Table 5-4) is most apparent in those small to 
medium sized neurons.   
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Figure 5- 4:  Message levels for the tetrodotoxin resistant sodium channel Nav1.9 
are reduced in response to NT-3 treatment. 
 
Top:  Dark-field photomicrographs of 6 µm thick adult rat L5 DRG sections processed 
for in situ hybridization to detect Nav1.9 mRNA transcripts contralateral (Intact) or 
ipsilateral to 7d CCI (CCI) and after a 7d unilateral CCI plus intrathecal infusion of 600 
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ng/µl/hr NT-3 (Intact+NT-3; CCI+NT-3).  Scale bar = 100 µm. Treatment with NT-3 
dramatically reduces levels of Nav1.9 mRNA following CCI. 
 
Bottom:  Representative scatterplots whereby each point represents the labeling index of 
an individual neuron identified in 6 µm thick sections of L5 DRG processed to detect 
Nav1.9 mRNA.  The relationship between Nav1.9 mRNA labeling intensity (y-axis, log 
scale) and perikaryal diameter (x-axis) is depicted.  Experimental states are indicated at 
the top right of each graph and are as described above.  Labeling refers to the ratio of 
silver grain density over the neuronal cytoplasm to grain density over areas of the 
neuropil devoid of positive hybridization signal.  Solid lines divide the plots into labeled 
and unlabeled populations; dotted lines separate lightly labeled from moderate to heavily 
labeled populations of Nav1.9expressing neurons.  Note:  In DRG contralateral to CCI, 
Nav1.9 is expressed predominantly in small to medium neurons with a low level of 
expression detectable in some large neurons.  CCI results in a slight decrease in Nav1.9 
expression.  NT-3 infusion results in a decrease in the levels of detectable Nav1.9 mRNA 
in DRG both ipsilateral and contralateral to CCI, with a more pronounced effect 
ipsilateral to injury. 
 
 
 
Nav 1.9 Population of total 
neurons examined (%) 
% of small to medium 
neuronal population 
(neurons < 35µm) 
 % of large neuronal 
population (neurons > 
35µm) 
 > 5X 
bkgd 
> 20X 
bkgd 
> 5X 
bkgd 
> 20X 
bkgd 
> 5X 
bkgd 
> 20X 
bkgd 
       
Intact 73.07 +/- 
3.259% 
50.50 +/-
0.4933% 
89.97 +/-
1.433% 
73.80 +/-
7.976% 
37.07 +/-
4.651% 
6.467 +/-
3.234% 
       
Intact + 
NT-3 
50.67 +/-
2.017% 
28.90 +/-
3.816% 
76.13 +/-
1.648% 
50.67 +/-
8.161% 
21.87 +/-
1.638% 
4.700 +/-
2.658% 
       
CCI 61.43 +/-
4.653% 
40.43 +/-
3.931% 
74.63 +/-
3.320% 
53.37 +/-
5.393% 
25.70 +/-
4.200% 
6.333 +/-
3.483% 
       
CCI + 
NT-3 
33.27 +/-
6.000% 
11.50+/-
2.458% 
44.07 +/-
5.380% 
16.67 +/-
3.048% 
13.90 +/-
5.284% 
1.133 +/-
1.133% 
       
 
 
Table 5- 3: Effects of CCI +/- NT-3 infusion on numbers of neurons expressing 
Nav1.9 mRNA. 
 
The above table summarizes the alterations in the incidence (percentage) of Nav1.9 
mRNA positive neurons in L5 DRG under various experimental conditions as indicated 
in the left column.  Those neurons < 35 µm are characterized as small to medium in size 
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and those neurons > 35 µm are characterized as medium to large in size.  Detectable 
levels of hybridization signal are all those > 5X background where as moderate to high 
levels of hybridization signal are those > 20X background.  CCI produces a decrease in 
the percentages of neurons positively labeled for Nav1.9.  Infusion of NT-3 further 
decreases the percentage of Nav1.9 mRNA positive neurons detected most evident 
ipsilateral to CCI. 
 
 
 
 
 
 
Figure 5- 5:  Mean Nav1.9 mRNA labeling indices are significantly decreased 
following NT-3 treatment. 
 
Left:  Graph depicts quantification of relative differences between experimental groups 
(as indicated) in Nav1.9 mRNA mean labeling indices for all DRG neurons measured 
following in situ hybridization for 3 separate experiments [representing 3 animals having 
undergone 7 day unilateral CCI [Intact (I) and CCI] and 3 animals having undergone 7 
day unilateral CCI with intrathecal infusion of NT-3 [Intact+NT-3 (I+N) and CCI+NT-3 
(CCI+N)].  Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate 
significant differences between experimental groups (Kruskal-Wallis test with Dunns 
Multiple Comparison test; *** p<0.0001).  NT-3 infusion results in a significant 
decrease in mean Nav1.9 mRNA expression in L5 neurons both ipsilateral and 
contralateral to CCI. 
 
Right:  Pooled data depicting the relative differences in mean labeling indices in Nav1.9 
mRNA normalized to the intact state in response to unilateral chronic constriction injury 
with or without NT-3 infusion (n=3).  Experimental conditions are as described above.  
Bars represent the standard error of the mean (s.e.m.).  Asterisks indicate significant 
differences between experimental groups (Kruskal-Wallis test with Dunns Multiple 
Comparison test; *** p<0.0001).  NT-3 infusion results in a significant decrease in mean 
Nav1.9 mRNA expression in L5 neurons both ipsilateral and contralateral to CCI. 
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Nav 1.9 Total population of 
neurons examined 
(mean labeling 
index) 
 Small to medium 
neuronal population 
(neurons < 35µm) 
(mean labeling index) 
 Large neuronal 
population  
(neurons > 35µm) 
(mean labeling index) 
    
Intact 1.0000 +/- 0.04309 1.0000 +/- 0.03327 1.0000 +/- 0.1192 
    
Intact + NT-
3 
0.5324 +/- 0.03385 0.6460 +/- 0.03636 0.6069 +/- 0.06689 
    
CCI 0.7724 +/- 0.03891 0.7381 +/- 0.03229 0.8273 +/- 0.1116 
    
CCI + NT-3 0.2631 +/- 0.01864 0.2946 +/- 0.02172 0.4271 +/- 0.06281 
    
 
 
Table 5- 4: Effects of CCI +/- NT-3 infusion on the Nav1.9 mRNA mean labeling 
index. 
 
The above table summarizes the alterations in Nav1.9 mRNA mean labeling index of 
pooled data normalized to intact mean labeling index within each of the 3 experimental 
groupings of animals analyzed in L5 DRG neurons under various experimental 
conditions as indicated in left column.  Those neurons < 35 µm are characterized as 
small to medium in size and those neurons > 35 µm are characterized as medium to large 
in size.   CCI produces a decrease in the Nav1.9 mean labeling index in the total neurons 
that is reflected in both those small to medium and medium to large size neurons.  
Infusion of NT-3 decreases levels of Nav1.9 mRNA both ipsilateral and contralateral to 
CCI in all size ranges of neurons.   
 
 
 
5.4.4 Levels of Nav1.9 protein are decreased following NT-3 treatment 
 
Immunohistochemistry revealed that in the intact state, Nav1.9 protein was 
observed predominantly in the small to medium sized DRG neurons.  Levels of Nav1.9 
protein were reduced 7 days following CCI (Figure 5-6) with fewer small neurons 
expressing Nav1.9 and at lower levels.  Infusion of NT-3 effected a decrease in both the 
levels of Nav1.9 protein and the numbers of neurons expressing in the DRG both 
contralateral and ipsilateral to CCI (Intact + NT-3; CCI + NT-3) (Figure 5-6).   
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Figure 5- 6:  NT-3 infusion results in decreased expression of Nav1.9 protein. 
 
Fluorescence photomicrographs demonstrate levels of Nav1.9-like immunoreactivity in 
10 µm sections of DRG ipsilateral (CCI) and contralateral to CCI (Intact) L5 DRG with 
or without immediate intrathecal infusion of NT-3 (CCI+NT-3; Intact+NT-3), as 
indicated.  Scale bar, 60 µm.  Note: In the DRG contralateral to CCI (Intact), levels of 
Nav1.9 protein are highest in small sized dorsal root ganglion neurons.  Seven days after 
CCI, levels of expression have decreased relative to the intact state.  Intrathecal infusion 
of NT-3 at the time of injury results in markedly reduced levels of Nav1.9 protein 
ipsilateral to CCI. 
 
 
5.5 Discussion 
 
5.5.1 NT-3 significantly reduces levels of Nav1.8 and Nav1.9 following CCI 
 
Consistent with previous reports, I have found that in the intact state, both Nav1.8 
and Nav1.9 mRNA and protein are localized primarily over small diameter DRG 
neurons, with some medium and large sized neurons also expressing (Akopian et al., 
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1996; Black et al., 1996; Cummins et al., 1999; Dib-Hajj et al., 1999).  Following 7d 
unilateral CCI, the Nav1.8 mRNA mean labeling index was significantly reduced, 
primarily in those small to medium diameter neurons (consistent with those findings of 
Dib-Hajj et al., 1999) (Table 5-4).  The smaller decrease in the larger cells (presumably 
those that are axotomized with CCI) is consistent with that observed by Decosterd et al. 
(2002).  These results are paralleled in the Nav1.8 protein levels.  
The Nav1.9 mRNA mean labeling is also significantly decreased following CCI.  
This decrease is reflected in both the small to medium and the larger sized neurons 
(Table 5-4).  This decrease in the small sized neurons was observed by Dib-Hajj et al. 
(1999), while the decrease in the larger sized neurons (presumably those axotomized by 
CCI) was observed by Decosterd et al. (2002).  These observations are also observed for 
Nav1.9 protein. 
The current work demonstrates the novel finding that NT-3 can dramatically 
effect a further significant decrease in the mRNA levels and this is also reflected in 
changes observed protein levels of Nav1.8 and Nav1.9 following 7d unilateral CCI in the 
DRG neurons both ipsilateral and contralateral to CCI.  For Nav1.8, this decreased level 
of expression is obvious across all size ranges of sensory neurons in both ipsilateral and 
contralateral DRG.  Alternatively, for Nav1.9, this decrease is most apparent in those 
small to medium sized neurons both ipsilateral and contralateral DRG. 
 
5.5.2 Attenuation of Nav1.8 and Nav1.9 expression correlates with the regulation of 
thermal hyperalgesia by NT-3 following CCI 
 
 Previously, I have reported that administration of exogenous NT-3 at the time of 
CCI successfully prevents the development of thermal hyperalgesia, while having no 
effect on the ensuing mechanical hypersensitivity (Wilson-Gerwing et al., 2005).  In 
concert with these findings, I have now shown that exogenous NT-3 at the time of injury 
is also capable of significantly decreasing levels of the two TTX-R sodium channels 
Nav1.8 and Nav1.9.   
 In support of a role for Nav1.8 in the development of thermal hyperalgesia, it has 
been shown that if Nav1.8 is blocked by antisense oligonucleotides, the development of 
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thermal hyperalgesia is reduced in both the spinal nerve ligation and CCI models 
(Porreca et al., 1999; Lai et al., 2002; Joshi et al., 2006).  However, if antisense 
oligonucleotides to Nav1.9 or genetic ablation of Nav1.9 are employed, there appears to 
be no effect on thermal or mechanical hypersensitivity in the neuropathic rat (Porreca et 
al., 1999; Priest et al., 2005; Amaya et al., 2006).  Interestingly, it appears that Nav1.9 
does play a role in hypersensitivity produced by the application of inflammatory 
mediators to the peripheral terminals of the nociceptors (Amaya et al., 2006).  It has 
been proposed that Nav1.9 plays a crucial role in setting the resting membrane potential 
of a neuron and that an increased density of this channel, such as is seen with the 
accumulation of voltage gated sodium channels at the tips of the injured neurons (Devor 
et al., 1989; England et al., 1994, 1996), may hyperpolarize the neuron (Herzog et al., 
2001). It thus appears that the decreased expression of Nav1.8 by exogenous NT-3 likely 
plays an important role in preventing the development of thermal hyperalgesia, while the 
decreased expression of Nav1.9 may prevent hyperexcitablity and/or repetitive firing of 
the neuron by increasing the resting membrane potential of these neurons. 
 
5.5.3 Potential mechanisms of modulation of sodium channel expression by NT-3 
 
 It has been well characterized that inflammatory mediators (including NGF) are 
capable of increasing the expression voltage gated sodium channels (Dib-Hajj et al., 
1998; Fjell et al., 1999; Gould et al., 2000; Fang et al., 2005; Amaya et al., 2006).  It has 
also been postulated that the NGF regulation of Nav1.8 is limited by the levels of trkA 
available (Fang et al., 2005).  It therefore seems plausible that the ability of NT-3 to 
downregulate expression of trkA (Wilson-Gerwing and Verge, 2006) and to act in an 
antagonistic fashion to the pro-inflammatory effects of NGF (Verge et al., 1989a, 1989b, 
1992, 1995; Jongsma Wallin et al., 2001; Karchewski et al., 2002; Gratto and Verge, 
2003; Wilson-Gerwing et al., 2005) may also underlie its ability to effect  
downregulation of the TTX-R sodium channel Nav1.8 and possibly Nav1.9.  Another 
growth factor, glial derived neurotrophic factor (GDNF), has also been shown to 
upregulate Nav1.8 and Nav1.9 following sciatic nerve transection (Cummins et al., 2000) 
and to reduce ectopic neuronal discharges (spontaneous pain) after nerve injury 
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(Boucher et al., 2000)  a property of neuropathic pain attributed to Nav1.9.  There is 
some evidence that perhaps, NT-3 may be able to act through the GDNF receptor c-Ret 
(Kobayashi and Masuoka, 2000) and thus may exert its effects on Nav1.9 in this manner. 
 Following nerve injury, it has been described that voltage gated sodium channels 
are redistributed to the tips of the injured axons and/or neuromas (Devor et al., 1989; 
England et al., 1994, 1996; Amir et al., 1999).  It then becomes a plausible question 
whether the reduced levels of sodium channels at the DRG are simply the result of this 
translocation.  While this was not directly examined, I would propose that initially there 
is a redistribution of sodium channels, but the extremely low transcript levels following 
NT-3 treatment would support that it is less likely that protein is still abundant at the 
nerve sites at the week post injury time examined as NT-3 was infused for this duration.  
It is also unknown whether or not treatment with exogenous NT-3 dampens/influences 
the inflammatory response to CCI, and may therefore alter the signals that effect this 
translocation. 
 
5.5.4 Clinical relevance of reduced Nav1.8 and Nav1.9 expression 
 
 The use of sodium channel blockers to treat both neuropathic and inflammatory 
pain in a clinical setting is well known to result in analgesia (Clayton et al., 1997; Evans 
et al., 1997; Galer, 1995; McQuay et al., 1995; Trezise and Xie, 1997). These include 
such treatments as topical creams (for example, lidocaine), anticonvulsants, and tricyclic 
antidepressants (reviewed in Rogers et al., 2006).  
It therefore becomes important to ask: Does the decreased expression of Nav1.8 
and Nav1.9 also result in a physiological blockade of these channels?  It has been 
demonstrated that a significant downregulation of these two channels also resulted in the 
significant reduction of the TTX-R sodium current (Dib-Hajj et al., 1999).  Preliminary 
evidence from electrophysiological studies of DRG neurons subjected to both CCI and 
exogenous NT-3 treatment suggests that there is an overall reduction in sodium current 
and a complete lack of a TTX-R current in these neurons (TDW-G and Cheryl Stucky, 
unpublished observations). 
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In conclusion, the investigation into the modulation by exogenous NT-3 of  two 
TTX-R sodium channels, Nav1.8 and Nav1.9, implicated in the generation of neuropathic 
pain has once again shown that NT-3 can effectively antagonize yet another pro-
inflammatory aspect of this pain state and in doing so presumably alter the 
electrophysiological properties of these neurons. 
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6 Neurotrophin-3 differentially modulates levels of activated extracellular signal-
related kinase nuclear localization in trkA versus trkC subpopulations of adult rat 
dorsal root ganglia neurons  
 
 
6.1 Abstract 
  
NT-3 is a negative modulator of trkA expression and associated phenotype in 
intact sensory neurons, while positively regulating trkC and associated phenotype. 
However, how NT-3 effects this response is less clear. NGF mediates its positive 
influence on trkA neurons by activating members of the mitogen-activated protein 
kinase family (i.e. ERKs). This is an important form of signaling associated with NGF s 
role in regulation of neuronal phenotype in nociceptive neurons. The present study 
addresses whether NT-3 in its capacity to differentially modulate gene expression in 
distinct subpopulations of sensory neurons in the intact state, exerts a differential 
influence on levels of activated ERK1/2 in the DRG of adult rats in trk-A versus trkC-
mRNA positive subpopulations of neurons. Analysis focused on defining the level of 
activated phospho-ERK1/2 immunofluorescence signal detected in the nucleus of 
sensory neurons expressing trkA alone, trkC alone, or both trkA and trkC transcripts.  
NT-3 intrathecal infusion decreased the overall percentage of neurons expressing 
detectable trkA only, while increasing the overall percentage of neurons expressing 
detectable trkC only.  The incidence of neurons coexpressing trkA and trkC was not 
altered by infusion of NT-3.  NT-3 also had a differential influence on nuclear phospho-
ERK1/2 levels detected in neurons expressing trkA alone or trkC alone.  Phospho-
ERK1/2 labeling intensity was significantly decreased over nuclei of those neurons 
expressing trkA alone and significantly increased over the nuclei of those neurons 
expressing trkC alone.  Neurons expressing either both trkA and trkC or neurons 
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expressing neither trkA nor trkC showed no significant alteration in levels of phospho-
ERK signaling. In conclusion, it appears that exogenous NT-3 can effect a differential 
regulation of ERK signaling in trkA- versus trkC-only subpopulations of sensory 
neurons that may contribute to the differential influence of NT-3 on downstream gene 
expression in these two subpopulations. 
 
 
6.2 Introduction 
 
 Sensory neurons of the dorsal root ganglion (DRG) are able to recognize and 
respond to a variety of extracellular stimuli (reviewed in Roux and Blennis, 2004).  
Stimuli such as growth factors and other mediators of cellular stress lead to the 
activation of signaling pathways within the neuron - primarily the mitogen-activated 
protein kinase (MAPK) pathway  leading, in part, to the modification of gene 
expression (Keyse, 2000; Camps et al., 2000; Sun et al., 1993; Keyse and Emslie, 1992).  
While multiple MAPK pathways exist within any given cell, it is the extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) MAPK family that is of interest from a 
neurotrophin perspective as they are preferentially activated in response to growth 
factors (reviewed in Pearson et al., 2001).  Set in motion by dimerization of a receptor 
tyrosine kinase binding to a growth factor, the Raf/MEK/ERK signaling cascade 
(English et al., 1999) leads to activation and translocation of phospho-ERK to the 
nucleus where it regulates transcriptional events (Lewis et al., 1998).   
 Members of the MAPK family, such as ERK1/2, p38 MAPK and ERK 5 are 
activated by inflammatory mediators and are proposed to participate in the generation 
and perhaps maintenance of pain syndromes following nerve injury (Ji et al., 2002a; 
Obata et al., 2004; Mizushima et al., 2007; reviewed in Ma and Quirion, 2005). 
 Nerve growth factor (NGF) has been well characterized as influencing the 
phenotype of nociceptive primary sensory neurons (trkA neurons) and regulating both 
inflammatory and homeostatic pain states (Lewin and Mendell, 1993; Woolf et al., 1994; 
Verge et al., 1995; Woolf, 1996; Herzberg et al., 1997; Ramer et al., 1998; Theodosiou 
et al., 1999).  The primary manner in which NGF mediates its positive influence on trkA 
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sensory neurons is by activating members of the MAPK family, such as ERK1/2 
(Averill et al., 2001; Zhuang et al., 2004; Donnerer et al., 2005).  Neurotrophin-3 (NT-
3), another member of the NGF family, has its primary influence on the growth, 
development, and maintenance of large, myelinated proprioceptive sensory neurons that 
are trkC-positive (Ernfors et al., 1994; Farinas et al., 1994).  More recently, it has been 
demonstrated that NT-3 can modulate expression of peptides, molecules and behaviors 
implicated in nociception in an antagonistic fashion to NGF (Jongsma Wallin et al., 
2001; Gratto and Verge, 2003; Wilson-Gerwing et al., 2005; Wilson-Gerwing and 
Verge, 2006). 
 Thus, NT-3 is a negative modulator of trkA expression and associated phenotype 
in sensory neurons, while positively regulating trkC and associated phenotype. However, 
how NT-3 effects this response is less clear. NGF mediates its positive influence on trkA 
neurons by activating members of the MAPK family (i.e. ERKs). This is an important 
form of signaling associated with NGFs role in inflammatory pain. The present study 
addresses whether the ability of NT-3 to differentially modulate gene expression in trkA 
versus trkC subpopulations of adult sensory neurons, in the intact state, is associated 
with differential influence on levels of activated (phospho) ERK1/2 in the DRG of adult 
rats in these subpopulations of neurons.  
 
 
6.3 Methods 
 
6.3.1 Animal surgery 
 
All animal procedures were conducted in accordance with the National Institutes 
of Health policy on the use of animals in research and the University of Saskatchewan 
animal care committee guidelines (protocol 19920164).  A total of 17 young adult male 
Wistar rats (Charles River Laboratories, Wilmington, MA) weighing 250-300 g were 
used.  Animals were anesthetized for surgery with sodium pentobarbital (Somnitol, 65 
mg/kg; MTC Pharm, Cambridge, Ontario, Canada).  Pre- and post-operative (for 24 h) 
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subcutaneous injections of buprenorphine (Temgesic, 0.1-0.2 mg/kg) were given to 
alleviate any post-operative discomfort.  To examine the effect of NT-3 on the 
expression of phospho-ERK1/2, 17 rats were used: 6 underwent intrathecal infusion of 
NT-3 for 7 days, 6 underwent intrathecal infusion of 1X Vehicle for 7 days, and 5 
remained as naïve controls.   
 NT-3 was delivered intrathecally for 7 d via mini-osmotic pumps (model 2001; 
Alza, Cupertino, CA) inserted at the lumbar sacral junction as per Verge et al. (1989a) at 
a concentration and rate of 600 ng/µl/hr (Karchewski et al., 2002) in a solution of PBS 
containing rat serum albumin (1 mg/ml), streptomycin (100 U/ml), and penicillin (100 
U/ml).  This dose of NT-3 was the minimum dose found to selectively reverse injury-
associated gene expression in injured trkC-expressing neurons (Verge et al., 1996; 
Jongsma Wallin et al., 2001; Karchewski et al., 2002).  1X Vehicle consisting of PBS 
containing rat serum albumin (1 mg/ml), streptomycin (100 U/ml), and penicillin (100 
U/ml) was delivered intrathecally for 7 d as described above. At the conclusion of the 
experiments, rats were killed, and tissue was dissected and processed for in situ 
hybridization and/or immunohistochemistry as described below.   
 
6.3.2 In situ hybridization 
 
 Deeply anesthetized animals were perfused via the aorta with 0.1 M PBS, pH 
7.4, followed by 4% paraformaldehyde in 0.1M PBS.  The right and left L4 and L5 DRG 
were rapidly dissected, postfixed for 1 hour in the same fixative, and cryoprotected in 
20% sucrose in 0.1M PBS overnight.  Paired experimental and control tissues were 
mounted in the same cryomold (to ensure processing under identical conditions), 
covered with OCT compound (Tissue Tek; Miles Laboratories, Elkhart, IN, USA) and 
frozen in cooled isopentane.  Transverse serial sections were cut at 6 µm on a Micron 
cryostat (Zeiss, Canada), thaw mounted onto Probe-On+ slides (Fisher Scientific, 
Edmonton, AB, Canada) and prepared for hybridization. 
 Prior to hybridization, slides were air dried for 15 minutes, followed by fixation 
in 4% paraformaldehyde for 20 minutes.  Slides were washed 3 X 5 minutes in 1X PBS.  
Sections were then treated with proteinase K (20 µg/ml) containing 10 ml 1M Tris-HCl 
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(pH 7.6), 2 ml 0.5 M EDTA, 200 µl proteinase K stock (20 mg/ml) and 188 µl ddH20 for 
6 minutes.  Slides were then rinsed for 5 minutes in 1 X PBS and post-fixed for 5 
minutes in 4% paraformaldehyde.  Slides were then rinsed 2 X 5 minutes in 1 X PBS, 1 
X 5 minutes in DEPC-H2O, and dehydrated in ascending alcohols. 
 An oligonucleotide probes complementary to and selective for trkA 
[complementary to bases 1198-1245 (Barker et al., 1993)] and trkC [complementary to 
bases 1189-1236 (Merlio et al., 1992)] messenger RNA (mRNA) were synthesized 
(University of Calgary DNA services, Alberta, Canada).  The probes were checked 
against the GenBank database (NIH) to ensure no greater than 60% homology was found 
to sequences other than the cognate transcript.  The probes were labeled at the 3-end 
with α-[35S]dATP (New England Nuclear, Boston, MA, USA) using terminal 
deoxynucleotidyl-transferase (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in a 
buffer containing 10 mM CoCl2, 1 mM dithiothreitol, 300 mM Tris base and 1.4 M-
potassium cacodylate (pH 7.2), and purified through Bio-Spin® Disposable 
Chromatograph Columns (Bio-Rad laboratories, Hercules, CA, USA) containing 200 mg 
of NENSORB PREP Nucleic Acid Purification Resin (NEN®, Boston, MA, USA).  
Dithiothreitol was added to a final concentration of 10 nM. 
 Hybridization was carried out according to published procedures (Dagerlind et 
al., 1992) on a minimum of 5 slides/probe from each group of experimental and control 
animals.  Briefly, the sections were hybridized at 43 oC for 14-18 hours in a buffer 
containing 50% formamide (Sigma Aldrich, Oakville, ON, Canada), 4X SSC (1X SSC  
0.15 M NaCl, 0.015 sodium citrate), 1X Denharts solution (0.02% bovine serum 
albumin and 0.02% Ficoll), 1% sacrosyl (N-laurylsarcosine), 0.02 M phosphate buffer 
(pH 7.0), 10% dextran sulphate, 500 µg/ml heat-denatured sheared salmon sperm DNA, 
200 mM dithiothreitol and 107 cpm/ml of probe.  After hybridization, the slides were 
washed for 4 X 15 mins in 1X SSC at 55oC, dehydrated in ascending alcohols, processed 
for radioautography as per Karchewski et al., 2002 and exposed for 7 to 10 days before 
developing in D-19 (Kodak, Rochester, NY, USA). 
 The specificity of hybridization signal for the trkA and trkC probes were 
confirmed as described in Wilson-Gerwing et al., 2005. 
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6.3.3 Immunohistochemistry 
 
 Transverse 6 µm sections were cut on the cryostat, thaw-mounted onto Probe-
ON+ slides (Fisher Scientific), and processed for immunohistochemistry.  Sections were 
washed three times for 10 min in 0.1 M PBS, blocked in 2% goat serum and 0.3% Triton 
X-100 in 0.1 M PBS for 1 h at room temperature, incubated overnight with rabbit anti-
phospho-p44/42 MAPK (ERK1/2) (1:3000; Cell Signaling Technology, Beverly, MA), 
diluted in 2% goat serum and 0.3% Triton X-100 in 0.1 M PBS at 4 oC, and visualized 
with a tyramide signal amplification kit (Molecular Probes, Inc., Eugene, OR).  Briefly, 
slides were incubated for 45 min with HRP-conjugated secondary antibody (1:100) 
diluted in 2% goat serum and 0.3% Triton S-100 in 0.1 M PBS at room temperature, 
washed, and incubated for 5 minutes with tyramide stock solution  (1:100) in 
amplification buffer.  Slides were washed and coverslipped with 50% glycerol/50% 
PBS.  Control sections were processed in the same manner, but without the primary 
antibody. Results were visualized using a Zeiss Axioscope 50 microscope equipped with 
incident-light fluorescence optics and a digital camera.  Antibody specificity was 
confirmed by Western blot analysis (McDaid et al., 2005).  
  
6.3.4 Quantification and analysis 
 
Prior to in situ hybridization and immunohistochemistry, serial sections were 
arranged such that those slides processed to detect phospho-ERK1/2 were flanked by 
slides processed to detect trkA mRNA on one side and trkC mRNA on the other side 
(trkA mRNA/ anti-phospho-ERK1/2/ trkC mRNA) such that each DRG neuron 
identified in the phospho-ERK1/2 sections could be trilocalized with those neurons in 
the trkA and trkC sections. 
Rapid qualitative analysis was performed on all slides from the 12 groupings of NT-3, 
1X Vehicle, and naive animals (to avoid fading of the phospho-ERK1/2 
immunofluoresence) and relative changes in the intensity of phospho-ERK1/2 
fluorescence from one group to another noted for sections mounted on the same slide to 
avoid bias due to the variance in signal observed from slide to slide.  Representative 
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slides from 3 different experimental and control groupings were selected based on 
having similar numbers of neurons in each DRG section on the slide and subjected to 
further quantitative analysis. Photomontages of each phospho-ERK1/2 section to be 
analyzed (and the corresponding trkA and trkC sections) were prepared and individual 
neurons with a visible nucleus in phospho-ERK sections were identified in the flanking 
serial sections.  Using a 63X oil fluorescent objective, images of all neurons identified 
on the phospho-ERK1/2 montages were rapidly captured under identical conditions.  
Using the Northern Eclipse software package, Version 7.0 (Empix Imaging, 
Mississauga, ON, Canada), the area of the neuron was measured followed by measuring 
the intensity of phospho-ERK1/2 immunofluoresence in the nucleus.  Data analysis was 
supplemented with Microsoft Office Excel 2003 (Microsoft Corporation, Redmond, 
WA) and Prizm 4.0 (Graph Pad Software, San Diego, CA).   
 Analysis was performed in each instance on all neurons from 9 DRG sections or 
1704 nuclear profiles (Naive: n = 3 animals, Naïve + Vehicle: n = 3 animals, Naïve + 
NT-3: n = 3 animals).  
 Following preliminary analysis of each experimental and control grouping, the 
presence of phospho-ERK1/2 was detected in both the cytoplasm and the nucleus of the 
DRG neurons examined with the most notable influence detected in the nuclei.  As 
phospho-ERK1/2 levels in the nucleus are correlated with the impact this pathway on 
gene expression, only nuclear phospho-ERK1/2 labeling intensity was quantified. 
 
 
6.4 Results 
 
6.4.1 Experimental Controls 
 
In the sections from naïve DRG (n=3), phospho-ERK1/2 signal was detected 
over the nuclei of all size ranges of neurons with a higher level of signal intensity in 
those neurons that are medium to large in diameter (Figure 6-1 and Figure 6-2).   
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Figure 6- 1:  Exogenous NT-3 differentially modulates the intensity of 
immunofluorescence signal depicting degree of nuclear localized activated ERK1/2 
in trkC versus trkA subpopulations of sensory neurons. 
 
Brightfield and fluorescence images representing DRG neurons in adjacent sections 
processed to detect trkA mRNA (left), activated (phospho) ERK 1/2 (center), and trkC 
mRNA (right) in naïve animals receiving either 1X Vehicle [N+Veh (top)] or 600 
ng/µl/hr NT-3 infusions [N+NT-3 (bottom)].  Note:  Following NT-3 treatment (N+NT-
3), levels of nuclear phospho-ERK1/2 immunofluorescence are increased in trkC 
positive neurons (red asterisks) and decreased in trkA positive neurons (black asterisks).  
Scale bar = 100 µm 
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Figure 6- 2:  NT-3 differentially modulates the levels of activated ERK1/2 
immunofluorescence detected in the nucleus of sensory neurons expressing only 
trkA mRNA versus those expressing only trkC mRNA. 
 
Representative scatterplots whereby each point represents the intensity of 
immunofluorescence signal over the nucleus of individual neurons identified as 
expressing trkA, trkC or both trkA and trkC mRNA in flanking adjacent sections 
processed for trkA or trkC in situ hybridization.  The relationship between phospho-
ERK1/2-like labeling intensity (y-axis) and perikaryal diameter (x-axis) is depicted for 
all neurons with a visible nucleus present in the DRG section sampled (left), those 
neurons that are trkA-positive only (black; middle) or, those neurons that are trkC-
positive only (red; middle), and those neurons that are positively labeled for both trkA 
and trkC (right) for each of three conditions:  Naïve animals (top row), Naïve animals 
receiving 1X Vehicle (middle row), and Naïve animals receiving 600 ng/µl/hr NT-3 
(bottom row).  Dotted lines separate graphs into light to moderate levels of 
immunofluorescence signal intensity and high levels of immunofluorescence signal 
intensity.  Note: Following NT-3 treatment (N+NT-3), levels of phospho-ERK1/2 are 
increased in trkC-positive neurons and decreased in trkA-positive neurons.   
 
 
 
Infusion of 1X Vehicle (n=3) did not significantly alter the frequency, distribution 
(Figure 6-2), or the mean labeling intensity (Figure 6-3) of phospho-ERK1/2.  As a 
result, data obtained from each of the three experimental groups were pooled after first  
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Figure 6- 3:  NT-3 differentially affects the overall intensity of activated ERK1/2 
immunofluorescence signal over the nucleus of DRG neurons expressing only trkA 
or only and trkC mRNA. 
 
Bar graphs of relative changes in the average phospho-ERK1/2 immunofluorescence 
signal intensity in the nucleus of individual neurons in DRG sections for each of: A, All 
neurons with a visible nucleus present in the DRG section sampled (total); B, Neurons 
positive for trkA only; C, Neurons positive for trkC only; D, Neurons positive for both 
trkA and trkC. Experimental states as indicated on the graphs are: Naive (N); Naive + 
Vehicle (N + Veh); Naive + NT-3 (N + NT-3). Asterisks indicate significant differences 
between experimental groups (Kruskal-Wallis test with Dunns Multiple Comparison 
test; *** p<0.0001; ** p<0.01).  Note:  Treatment with NT-3 significantly decreases 
mean phospho-ERK1/2 nuclear immunofluorescence signal intensity in neurons 
expressing trkA only and significantly increases mean phospho-ERK1/2 nuclear labeling 
intensity in neurons expressing trkC only.  There are no significant differences between 
Naïve versus Naïve + Vehicle treated animals. 
 
 
being normalized to total nuclear phospho-ERK mean labeling intensity of Naïve + 
Vehicle values for each individual grouping of animals (Figure 6-4 and Figure 6-5).    
 
 
6.4.2 Effect of NT-3 infusion on individual and mean nuclear phospho-ERK1/2 
localization for entire neuronal population 
 
When the impact of NT-3 infusion on nuclear level of phospho-ERK1/2 signal 
was examined for the entire population of individual neurons in the DRG sections, there 
appeared to be an increase in the incidence of medium to large sized DRG neurons 
displaying a high intensity of phospho-ERK1/2 signal as shown in the scatterplot  
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Figure 6- 4:  NT-3 differentially affects the degree and incidence of nuclear 
localized activated ERK1/2 in DRG neurons positive for trkA only and trkC only. 
 
Scatterplots of the total population of all neurons measured (n = 3 animals) whereby 
each point represents the labeling intensity of immunofluorescence signal over nuclei of  
individual neurons identified in 5 µm thick sections of L5 DRG and normalized to the 
mean signal intensity neurons from the naïve animal in its grouping.  The relationship 
between phospho-ERK1/2-like immunofluorescence signal intensity (y-axis) and 
perikaryal diameter (x-axis) is depicted for all neurons with a visible nucleus present in 
the DRG sections sampled (left), those neurons that are trkA-positive only (black; 
middle), those neurons that are trkC-positive only (red; middle), or those neurons that 
are positively labeled for both trkA and trkC (right).   Changes in mean phospho-
ERK1/2 immunofluorescence signal intensity by NT-3 [Naïve + NT-3 (bottom row)] are 
depicted relative to Naïve animals receiving 1X Vehicle [Naïve + Vehicle (top row)].  
Dotted lines separate graphs into light to moderate levels of labeling intensity and high 
levels of labeling intensity.  Note: Following NT-3 treatment (N+NT-3), levels of 
phospho-ERK1/2 are increased in neurons expressing only trkC (red; middle) and 
decreased in neurons expressing only trkA (black; middle). 
 
 
analysis (i.e. those having greater than signal >2; Figure 6-2).  However, when one 
determined the impact of NT-3 infusion on the mean labeling index of phospho-ERK1/2 
signal for the entire neuronal population (n=3) no significant difference was observed 
for each of the individual sets of experimental versus control animals analyzed (Figure 
6-3).  Similarly, when data from the NT-3 infused animals was normalized to the total 
nuclear phospho-ERK mean labeling intensity of Naïve + Vehicle values for each  
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Figure 6- 5:  NT-3 significantly affects the overall intensity of activated ERK1/2 
signal in the pooled population of DRG neurons positive for trkA only or trkC 
only. 
 
Summary bar graphs of data presented in Figure 6-4 showing relative changes in the 
average phospho-ERK1/2 immunofluorescence signal intensity in the nucleus of 
individual neurons in DRG sections for each of: A, All neurons with a nucleus present in 
the DRG sections sampled (total); B, Neurons positive for trkA only; C, Neurons 
positive for trkC only; D, Neurons positive for both trkA and trkC. Changes in mean 
phospho-ERK1/2 immunofluorescence signal intensity by NT-3 [Naïve + NT-3 (bottom 
row)] are depicted relative to Naïve animals receiving 1X Vehicle [Naïve + Vehicle (top 
row)]. Asterisks indicate significant differences between experimental groups (Kruskal-
Wallis test with Dunns Multiple Comparison test; ** p<0.01; * p<0.05).  Note:  
Treatment with NT-3 significantly decreases mean phospho-ERK1/2 
immunofluorescence signal intensity in those neurons expressing only trkA and 
significantly increases mean phopsho-ERK1/2 immunofluorescence signal intensity in 
those neurons expressing only trkC. 
 
 
individual grouping of animals and then pooled (Figure 6-4 and Figure 6-5),  the 
incidence of neurons expressing high labeling intensities (>2) were increased by NT-3 
infusion (from 4.31% to 10.20%) (Figure 6-4).  However, there was no significant 
difference in mean labeling intensity as compared to controls [1.0 +/- 0.0206 (s.e.m.) to 
1.061 +/- 0.02551 (s.e.m.) (Figure 6-5)].  Thus, it became apparent that in order to 
ascertain whether there might be selective alterations in the level of nuclear phospho-
ERK1/2 signal observed in the trkA versus trkC subpopulations of sensory neurons the 
subpopulations would have to be identified and analyzed individually.  Further, as we 
have previously demonstrated that there is extensive overalp in the trkA and trkC 
subpopulations (Karchewski et al., 1999), trilocalization of all three parameters would 
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be necessary in order to draw appropriate conclusions for those neurons expressing only 
trkA or only trkC versus those co-expressing the two receptor mRNAs. 
 
 
6.4.3 Effect of NT-3 treatment on the subpopulation of sensory neurons expressing 
only trkA 
 
Those DRG neurons that were identified as expressing trkA mRNA only where 
primarily, although not exclusively, small to medium in size (Figure 6-2 and Figure 6-4).  
Infusion of NT-3 decreased the incidence of trkA only positive neurons being detected 
(from 24.53% to 17.86%).  Those neurons expressing high labeling intensities of 
phospho-ERK1/2 (>2) were also reduced (from 2.29% to 0%) (Figure 6-4). In addition, 
exogenous NT-3 effected a significant decrease in the mean labeling intensity of 
phospho-ERK1/2 in this population of neurons [from 0.8927 +/- 0.03807 (s.e.m.) to 
0.7416 +/- 0.03684(s.e.m.) (Figure 6-5)].   
 
 
6.4.4 Effect of NT-3 treatment on the subpopulation of sensory neurons expressing 
only trkC only 
 
Those DRG neurons that were identified as expressing trkC mRNA only were 
primarily medium to large in size, with some small to medium sized neurons also  
observed (Figure 6-2 and Figure 6-4).  Infusion of NT-3 slightly increased the incidence 
of detectable trkC only positive neurons  (from 23.78% to 29.76%) while markedly 
increasing the percentage of those neurons expressing high labeling intensities of 
phospho-ERK1/2 (>2) from 5.51% to 18.29% (Figure 6-4).  NT-3 infusion also had a 
significant impact on the mean labeling intensity of phospho-ERK1/2 in this population 
of neurons increasing it from 1.057 +/- 0.0438 (s.e.m.) to 1.307 +/- 0.04723 (s.e.m.) 
(Figure 6-5). 
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6.4.5 Effect of NT-3 treatment on the subpopulation of sensory neurons expressing 
both trkA and trkC 
 
The population of DRG neurons identified as expressing both trkA and trkC 
mRNA was distributed over all size ranges of neurons (Figure 6-2 and Figure 6-4).  
Infusion of NT-3 did not markedly alter the incidence of neurons expressing both trkA 
and trkC (18.91% versus16.33%), nor the incidence of neurons expressing high labeling 
intensities of phospho-ERK1/2 (4.95% versus 5.21%). Further, it did not significantly 
influence the mean labeling signal intensity of phospho-ERK1/2 in this population of 
neurons [0.988 +/- 0.0499 (s.e.m.) versus 1.031 +/- 0.0562 (s.e.m.) (Figure 6-5)]. 
 
 
6.5 Discussion 
 
 In this study we have shown for the first time a differential regulation by NT-3 of 
nuclear localized phospho-ERK1/2 in intact lumbar sensory neurons expressing only 
trkA versus those expressing only trkC in vivo.  These findings are consistent with our 
previous studies demonstrating that NT-3 modulates trkA-associated neuronal 
phenotype in an opposite manner to that of NGF in intact sensory neurons (Jongsma 
Wallin et al., 2001; Karchewski et al., 2002; Gratto and Verge, 2003).   Subsequently we 
have also shown that NT-3 can effectively prevent and reverse the development of 
thermal hyperalgesia, associated phenotype and signaling molecules complicit in this 
response in the chronic constriction injury (CCI) model of neuropathic pain, a behavioral 
response/phenotype attributable largely to the trkA subpopulation (Wilson-Gerwing et 
al., 2005).   All these lines of evidence support a role for NT-3 acting antagonistically to 
NGF on the trkA subpopulation of sensory neurons. 
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6.5.1 phospho-ERK1/2 is present in the nucleus of naïve DRG neurons. 
 
 In the naïve DRG, it was determined that there was a detectable level of 
phospho-ERK1/2 in the nuclei of the neurons examined.  This is in contrast to other 
published reports whereby phospho-ERK staining was weak or absent in the majority of 
DRG cells (Averill et al., 2001; Dai et al., 2002; Takahashi et al., 2006).  It has been 
described that phospho-ERK1/2 is present throughout unstimulated cells, but a 
significant amount is only translocated to the nucleus in response to stimulation which 
may underlie the technical difficulties in visualizing it under homeostatic conditions 
(Chen et al., 1992; Gonzalez et al. 1993; Lenormand et al., 1993).  The findings of this 
study demonstrate that phospho-ERK1/2 is present in both the cytoplasm and the 
nucleus of unstimulated cells.  One possible explanation for these contradictory findings 
is the sensitivity of the phospho-ERK1/2 antibody and protocol employed.  The use of a 
tyramide amplification system likely allowed for the enhanced detection of extremely 
low levels of phospho-ERK1/2 within the nucleus.  Further, similar results were 
attainable with the protocol in the absence of the tyramide amplification step when 
classic avidin biotin approaches were employed although at a reduced signal to noise 
ratio (TDW-G, personal observation).  Intuitively, one would expect there to be a low 
level of continuous activation as constant retrograde signaling by target-derived NGF or 
NT-3 to these fibers must occur if homeostatic phenotype is to be maintained. 
 This is also the first analysis of the presence and distribution of phospho-ERK1/2 
in the nucleus of those cells contained within both the trkA and the trkC subpopulations 
of DRG neurons.  The finding that those neurons containing only trkA are primarily 
small to medium in diameter, but also contain some large sized neurons and that those 
neurons containing only trkC are primarily medium to large in size but also contain 
some small neurons support previous findings on the heterogeneity of trk-containing 
neurons (Karchewski et al., 1999; Jongsma Wallin et al., 2001; Karchewski et al., 2002).  
This is further supported by the population of DRG neurons shown here containing both 
trkA and trkC and consisting of all size ranges.  Interestingly, the mean level of nuclear 
localized phospho-ERK1/2 was higher in the trkC only expressing neurons versus the 
trkA only.  This is consistent with the potential higher level of activation that one would 
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expect to see in the former population which consists largely of proprioceptive fibers 
which should receive continual input/stimulation as the animal locomotes around his 
environment.  
 
 
 
6.5.2 NT-3 differentially modulates phospho-ERK1/2 levels in those neurons 
positive for either trkA or trkC. 
 
 In the naïve DRG, NT-3 effectively decreased both the incidence of neurons 
expressing trkA alone as well as the labeling intensity of phospho-ERK1/2 within this 
population.  Conversely, but not unexpectedly, NT-3 infusion effectively increased both 
the percentage of neurons expressing detectable trkC alone as well as the labeling 
intensity of phospho-ERK1/2 within this population.  There appeared to be no net effect 
of NT-3 infusion on those neurons expressing both trkA and trkC presumably due to the 
differential influence on each receptor.  These findings are consistent with a role for 
exogenous NT-3 in negatively modulating gene expression in the trkA population of 
neurons while positively regulating that in the trkC population that we have previously 
observed in regards to phenotype modulation (Verge et al., 1989a, 1989b; 1992; 1995; 
1996 Jongsma Wallin; 2001; Karchewski et al., 2002; Gratto and Verge, 2003; Wilson-
Gerwing et al., 2005, 2006).  
 
 
6.5.3 Possible roles for phospho-ERK1/2 modulation by NT-3 in nociception. 
 
 Numerous lines of research have demonstrated an important role for phospho-
ERK in the promotion of neuropathic pain syndromes in rats (Mizushima et al., 2007; 
reviewed in Ma and Quirion, 2005; Ji et al., 2002a; Dai et al., 2002; Obata et al., 2004; 
Aley et al., 2001; Averill et al., 2001, Obata et al., 2003; Dina et al., 2003; Song et al., 
2005; reviewed in Obata and Noguchi, 2004).  It has been shown that NGF also 
promotes neuropathic pain syndromes (Lewin and Mendell, 1993; Woolf et al., 1994; 
 109
Herzberg et al., 1997; Ramer et al., 1998; Theodosiou et al., 1999), associated neuronal 
phenotype (Verge et al., 1995; Woolf, 1996) and an increase in the expression of 
phospho-ERK (Hundle et al., 1995; Averill et al., 2001).  This increase in phospho-ERK, 
in turn correlates with increases in the expression of the pain-related neuropeptide SP 
(Kawasaki et al., 2004), and the neurotrophin brain derived neurotrophic factor (BDNF) 
(Yajima et al., 2002; Kawasaki et al., 2004).  Finally, NT-3 has been demonstrated to 
antagonize thermal hyperalgesia (Wilson-Gerwing et al., 2005), the expression of certain 
pain-related neuropeptides (Jongsma Wallin et al., 2001; Gratto and Verge, 2003; 
Wilson-Gerwing and Verge, 2006) and BDNF (Karchewski et al., 2002; TDW-G, 
unpublished observations). 
 Much of the examination into the role of phospho-ERK in nociceptive 
processing, has focused on the upregulation BDNF by NGF in models of peripheral 
inflammation from the perspective that activation of the  phospho-ERK signaling 
cascade results in the transcription of BDNF (Woolf and Costigan, 1999; Ji and Woolf, 
2001).  From this standpoint, it is reasonable to assume that NT-3 is capable of 
inhibiting phospho-ERKs role in nociception as 1) NT-3 has been demonstrated to act 
antagonistically to NGF in numerous incidences; 2) NT-3 is now shown to differentially 
regulate levels of phospho-ERK in the nuclei of trkA or trkC expressing DRG neurons; 
and 3) NT-3 has been observed to mitigate increased expression of BDNF protein and 
mRNA normally observed following CCI (TDW-G, unpublished observations). 
How NT-3 is mediating this effect on the trkA associated signaling pathways is still 
unknown.  It remains to be determined whether NT-3 through its ability to bind to an 
isoform of trkA (Barker et al., 1993; Clary and Reichardt, 1994; Barbacid, 1994) that we 
have shown is expressed by all neurons in this subpopulation of trkA-positive sensory 
neurons (Karchewski et al., 1999) is having a direct effect on levels of phospho-ERK.  
The recent description of  hotspots for NT-3 binding on the trkA receptor when 
expressed in HEK293 cells support a complex role for NT-3 in serving as both an 
agonist or antagonist to NGF-mediated responses (Ivanisevic et al., 2007).  This also 
raises the possibility that some of yet unexamined roles for NT-3 in the nociceptive 
subpopulation may actually be additive to the NGF-mediated response.  One can also 
not exclude that the ability of NT-3 to dampen the MAPK signaling pathway may be 
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linked to interactions with the p75 common neurotrophin receptor that is also expressed 
by the trkA population (Verge et al., 1992).  This has recently been shown to be the case 
for BDNF where it is believed that BDNF binding to p75 may interfere with the ability 
of NGF to bind with high-affinity to trkA (Obata et al., 2006).  While these are 
intriguing possibilities it is unlikely that in the present model where we infuse NT-3 
intrathecally thereby giving it access to receptors on the dorsal roots that there is a major 
interference by NT-3 with NGF binding to p75 and trkA as the major source of NGF is 
derived from the peripheral target of these fibers and not centrally.  Thus it is likely that 
the net influence of NT-3 on the MAPK pathway observed is due to the convergent 
alterations by NT-3 on the NGF/trkA signaling pathway.   
 In conclusion, the findings of this study once again support a biologically 
relevant role for NT-3 in the regulation of nociceptive pathways. 
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7 Discussion 
 
 
7.1 CCI as a neuropathic pain model 
 
 Understanding neuropathic pain associated with pathologies of the sciatic nerve 
remains somewhat clouded even in spite of the large bodies of research that have taken 
place over the years.  The difficulty in obtaining a clear understanding of this condition 
results from the inherent complexities of the associated pain syndromes whereby 
multiple symptoms may be elicited by a single mechanism or, conversely, various single 
mechanisms may all produce the same symptom (Woolf and Decosterd, 1999). 
 For a number of years, the complete sciatic nerve transection model was 
employed to examine cellular and molecular changes that occurred at various levels of 
the peripheral and central nervous systems without the ability to easily correlate these 
changes and the behavior of the animal due to the target no longer being innervated.  
With the development of the CCI model of neuropathic pain (Bennett and Xie, 1988), 
whereby there is only a partial injury coupled with an inflammatory response, it became 
possible to determine whether or not phenotypic changes in the dorsal root ganglia 
(DRG) as a result of injury (or treatment) correlated with behavioral changes.  For these 
reasons, the CCI model was chosen to examine the behavioral and biochemical changes 
as a result of peripheral nerve injury and the ability of exogenous neurotrophin-3 (NT-3) 
to alter these changes. 
 The body of knowledge that has been obtained from this thesis work provides 
novel insights into the ability of NT-3 to modulate certain aspects of the homeostatic 
state of sensory neurons and neuropathic pain syndromes.  I also confirm portions of the 
existing knowledge regarding the phenotype of intact neurons and select biochemical 
changes in the DRG as a result of CCI. 
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7.2 Review of chronic constriction injury model (CCI), inflammation, and 
neuropathic pain behaviors 
 
 The chronic constriction injury (CCI) model of neuropathic pain involves a 
partial lesion of the sciatic nerve induced by tying loosely constrictive chromic gut 
sutures around the sciatic nerve (Bennett and Xie, 1988).  This results in the slow, 
edematous axotomy of predominantly large diameter myelinated axons (90% of Aβ and 
Aδ fibers and 30% of C fibers) by three days post-ligation (Kajander and Bennett, 1992) 
while the uninjured, smaller axons remain intact, but exposed to the Wallerian 
degenerating nerve in which many pro-inflammatory molecules are produced  a state 
akin to that observed in man (Bennett and Xie, 1988).  These inflammatory and immune 
cells release a variety of neuroactive agents including cytokines (IL-6, for example) and 
growth factors (NGF, for example) (Woolf and Costigan, 1999). 
 Neuropathic pain that develops following CCI is characterized by the presence of 
abnormal sensory behaviors.  These include thermal hyperalgesia, mechanical 
allodynia/hypersensitivity, and spontaneous pain.  Hyperalgesia following nerve injury 
is identified as an increased sensitivity to a normally noxious stimulus (a decreased 
threshold) and/or suprathreshold stimulation producing an abnormally exaggerated 
response (reviewed in Millan, 1999; Woolf and Mannion, 1999).  Following nerve 
injury, painful sensations can also be elicited by a normally non-noxious stimulus  
commonly referred to as allodynia (Woolf and Mannion, 1999).  Finally, spontaneous 
pain is the result of aberrant pain sensations in the apparent absence of any stimuli 
(Mannion et al., 1999; Woolf and Decosterd, 1999; Woolf and Mannion, 1999; Han et 
al., 2000; Liu et al., 2000) 
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7.3 Summary of major findings 
 
7.3.1 Behavioral analysis 
 
 The ability of NT-3 to prevent and reverse thermal hyperalgesia following CCI is 
a novel finding with respect to modulation of neuropathic pain.  Included in this finding 
is that continuous infusion of NT-3 is required for this effect, as removal of exogenous 
NT-3 results in the rapid reestablishment of the thermal hyperalgesic state.  In contrast, 
the mechanical hypersensitivity observed after CCI is not altered by NT-3, despite 
downregulation of injury-associated peptide expression in larger neurons. 
 
 
7.3.2 TRPV1 analysis 
 
 Localization of TRPV1 expression to primarily small and medium neurons in 
contralateral intact DRG is in agreement with past studies (Caterina et al., 1997; Eglen et 
al., 1999; Ma, 2002).  Although CCI resulted in slightly elevated TRPV1 expression 
observed in the size range of neurons consistent with C-fibers, it also induced a low 
level of expression in a novel population of large neurons.  Alterations in TRPV1 
expression effected by NT-3 were most robust for neurons ipsilateral to injury.  In 
accordance with Ji et al. (2002b), the observed modulation of TRPV1 expression was 
most apparent at the protein versus mRNA level. 
 
 
7.3.3 ASIC3 analysis 
  
Consistent with previous reports, in the intact state, expression of ASIC3 was 
observed predominantly in small to medium sized DRG neurons, with some large 
neurons also expressing detectable levels of ASIC3 (Waldmann et al., 1997b; Chen et 
al., 1998; Voilley et al., 2001; Molliver et al., 2005) in approximately 35 to 40% of DRG 
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neurons (Ugawa et al., 2005; Molliver et al., 2005).  We describe for the first time that 
following CCI, levels of ASIC3 expression were significantly upregulated, primarily in 
the small to medium sized (nociceptive) DRG neurons, and also in a small population of 
large sized neurons.  The current work also demonstrates that, following CCI, exogenous 
NT-3 can effectively counter the upregulation of ASIC3 expression, reducing levels to 
approximately that of basal expression.  Surprisingly, examination of 14 day CCI with 
infusion of NT-3 for the first 7 days of the injury reveals that upon removal of 
exogenous NT-3, ASIC3 levels remain depressed, suggesting that continuous infusion of 
NT-3 is not required for this effect. 
 
 
7.3.4 Nav1.8 and Nav1.9 analysis 
 
 Consistent with previous reports, I have found that in the intact state, both Nav1.8 
and Nav1.9 mRNA and protein are localized primarily over small diameter DRG 
neurons, with some medium and large sized neurons also expressing these channels 
(Akopian et al., 1996; Black et al., 1996; Cummins et al., 1999; Dib-Hajj et al., 1999).  
Following 7d unilateral CCI, the Nav1.8 mRNA was significantly reduced, primarily in 
those small to medium diameter neurons (similar to those findings of Dib-Hajj et al., 
1999).  Neuronal expression of Nav1.9 mRNA is also significantly decreased following 
CCI.  The current work demonstrates the novel finding that NT-3 can significantly 
decrease both the mRNA and protein levels of Nav1.8 and Nav1.9 following 7d unilateral 
CCI in the DRG neurons both ipsilateral and contralateral to CCI. 
 
 
 
 
7.3.5 Phospho-p38 MAPK analysis 
   
While the levels of phospho-p38 MAPK expression were found to be unaltered 
by 7 d CCI, exogenous NT-3 effected a dramatic downregulation of phospho-p38 
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MAPK.  Further experiments demonstrate that exogenous NT-3 can effectively prevent 
and reverse the CCI-associated increases in phospho-p38 MAPK expression.  Upon 
removal of exogenous NT-3, levels of phospho-p38 MAK remain low, again suggesting 
that continuous infusion is not required for this effect. 
 
 
7.3.6 Phospho-ERK analysis 
 
In the naïve DRG, it was determined that phospho-ERK1/2 can be detected in the 
nuclei of the neurons examined.  This is in contrast to other published reports whereby 
phospho-ERK staining was weak or absent in the majority of DRG cells (Averill et al., 
2001; Dai et al., 2002; Takahashi et al., 2006).  In the naïve DRG, NT-3 effectively 
decreased both the incidence of neurons expressing trkA alone as well as the phospho-
ERK1/2 immunofluorescence signal over the nuclei of neurons within this population.  
Conversely, but not unexpectedly, NT-3 effectively increased both the percentage of 
neurons expressing trkC alone as well as the phospho-ERK1/2 immunofluorescence 
signal over the nuclei of neurons within this population.  There appeared to be no net 
effect of those neurons expressing both trkA and trkC.    
   
 
7.4 Thermal hyperalgesia with respect to TRPV1, ASIC3, and sodium channels 
 
 The demonstration that intrathecal NT-3 infused at the time of CCI is able to 
prevent the development of thermal hyperalgesia, while intrathecal NT-3 infused 7 d 
post-CCI is able to reverse established thermal hyperalgesia is a novel finding with 
respect to the modulation of neuropathic pain.  NT-3 is generally thought of as being a 
neurotrophin that influences large, myelinated sensory neurons despite evidence that it is 
capable of modulating peptides and molecules that are associated with nociceptive 
function.  Research exploring the ability of NT-3 to influence pain-related behaviors in 
an injury model is limited, but expanding.  In one such study, inflammatory mechanical 
hyperalgesia  induced by intraplantar injection of complete Freunds adjuvant (CFA)  
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was transiently reversed by local hindpaw injection of NT-3 (Watanabe et al., 2000).  
This study, in accordance with my findings on thermal hyperalgesia and associated 
phenotype, suggests that NT-3 (in the CCI model) might exert its effect by altering the 
inflammatory response of uninjured nociceptors. 
 Many of the studies exploring the role of NT-3 in modulation of pain states are 
from naïve animals and examine whether NT-3 might alter baseline nociceptive 
thresholds.  Conflicting results have been obtained.  Shu et al. (1999) report that 
intradermal injection of NT-3 (200ng) into an uninjured hindpaw had no influence over 
thermal sensitivity.  This is supported by my previous finding that NT-3 infused into 
normal animals did not alter thermal sensitivity (Wilson-Gerwing et al., 2005).  In 
contrast, Theodosiou et al. (1999) found that significant thermal sensitivity was induced 
by a subcutaneous injection of NT-3 (500ng) into an uninjured rat hindpaw.  The higher 
dose of injected NT-3  or the place of injection  may result in local responses not 
observed at the lower dose (for example, mast cell activation) although this possibility 
was not ascertained in the study.  It remains unknown whether intrathecal infusion of 
NT-3 can effect changes in the environment surrounding the peripheral nerve terminal.  
This may be feasible as anterograde transport of NT-3 has been demonstrated in the 
optic nerve (von Bartheld and Butowt, 2000). 
 The vanilloid receptor, TRPV1, has been described as being expressed primarily 
on small, nociceptive neurons in the intact state (Caterina et al., 1997; Eglen et al., 1999; 
Ma, 2002).  My results are in agreement with this.  Following CCI, my results 
demonstrate that there is a dramatic increase in the numbers of neurons that express 
TRPV1 including small, medium and large sized DRG neurons.  Hudson et al. (2001) 
and Fukuoka et al. (2002) have previously reported similar findings.  Not surprisingly, 
Winston et al. (2001) demonstrated that, in culture, DRG neurons treated with NGF 
increased TRPV1 expression and that these effects were dependent on the trkA receptor.  
One of the novel findings that have emerged from this body of thesis work is that 
exogenous NT-3, given at the time of injury, results in a reduction in TRPV1 expression.  
While this may be a direct effect of NT-3 on the TRPV1 receptor expression, it is also 
plausible that the further downregulation of trkA by NT-3 after injury may also play a 
role. It has been shown that TRPV1 knock-out mice are deficient in their responses to 
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heat, vanilloid compounds and protons (all of which activate the TRPV1 receptor) 
(Caterina et al., 2000).  More recently, it has also been shown that by blocking the 
TRPV1 receptor, sensitivity to thermal stimulation is significantly attenuated (Garcia-
Martinez et al., 2002).  Jin and Gereau (2006) have also demonstrated a role for TRPV1 
in inflammation-induced thermal hyperalgesia.  Collectively, these demonstrate that 
TRPV1 is necessary for the development of sensitization to thermal stimuli following 
nerve injury.  These findings, taken together with the ability of NT-3 to prevent an 
increase in TRPV1 expression following CCI, suggest that the relationship between 
reduced TRPV1 expression and reduced thermal hyperalgesia as a result of NT-3 
treatment is likely a causal one. 
 The proton sensitive ion channel, ASIC3, plays no apparent role in thermal 
hyperalgesia.  My finding that ASIC3 levels remain depressed following discontinuation 
of NT-3 treatment provide novel insight into the lack of a necessary role for ASIC3 in 
the reestablishment of thermal hyperalgesia following CCI.   
Previous reports have described that, in the intact state, both Nav1.8 and Nav1.9 
mRNA and protein as being localized primarily over small diameter DRG neurons, with 
some medium and large sized neurons also expressing (Akopian et al., 1996; Black et 
al., 1996; Cummins et al., 1999; Dib-Hajj et al., 1999).  My findings are in accordance 
with these studies.  Following CCI, the levels of both Nav.8 and Nav1.9 mRNA and 
protein were significantly decreased similar to the findings of Dib-Hajj et al. (1999).  
The current work demonstrates the novel finding that NT-3 can significantly decrease 
both the mRNA and protein levels of Nav1.8 and Nav1.9 following 7d unilateral CCI in 
the DRG neurons both ipsilateral and contralateral to CCI.  It has not yet been 
determined whether the downregulation of Nav1.8 and Nav1.9 mRNA/ protein 
corresponds to a negative modulation of the electrophysiological properties of these 
channels.  In support of a role for Nav1.8 in the development of thermal hyperalgesia, it 
has been shown that if Nav1.8 is blocked by antisense oligonucleotides, the development 
of thermal hyperalgesia is reduced in both the spinal nerve ligation and CCI models 
(Porreca et al., 1999; Lai et al., 2002; Joshi et al., 2006).  Alternatively, Nassar et al. 
(2005) found that Nav1.8 played no role in the development of neuropathic pain.  
However, if antisense oligonucleotides to Nav1.9 or genetic ablation of Nav1.9 are 
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employed, there appears to be no effect on thermal or mechanical hypersensitivity in the 
neuropathic rat (Porreca et al., 1999; Priest et al., 2005; Amaya et al., 2006).  In contrast, 
Amaya et al. (2006) found that under conditions of CFA inflammation, Nav1.9 (-/-) mice 
display remarkably reduced thermal, but not mechanical, hypersensitivity.  While from 
the conflicting reports, it is not possible to draw any sound conclusions regarding the 
role(s), or lack of role(s), of these two sodium channels in the generation of thermal 
hyperalgesia, this thesis work establishes a correlation between the decreased expression 
of these channels and the prevention of thermal hyperalgesia following CCI.  The use of 
sodium channel blockers to treat both neuropathic and inflammatory pain in a clinical 
setting is well known to result in analgesia (Clayton et al., 1997; Evans et al., 1997; 
Galer, 1995; McQuay et al., 1995; Trezise and Xie, 1997). This in itself provides further 
evidence that it is likely that at least one of the isoforms studied plays a crucial role in 
the development of neuropathic pain.   
 Although, at first glance, it appears that the regulation of TRPV1 following CCI 
can account for the development of thermal hyperalgesia, it is important to remember 
that more than one mechanism may be responsible for the generation of a single 
symptom (Woolf and Decosterd, 1999).  After chronic constriction of the sciatic nerve, 
there are a number of additional changes that take place outside of the DRG, all of which 
may also be responsible for the development of neuropathic pain behaviors, including 
alterations in axonal firing which are attributable to the decreased activation threshold of 
TTX-R sodium channels.  For these reasons, a potential role for Nav1.8 and/or Nav1.9 in 
thermal hyperalgesia cannot be dismissed.  As CCI results in both peripheral nerve 
injury and inflammation, there is a large inflammatory response that takes place - the 
components of which have been demonstrated to influence neuropathic pain behaviors 
(Bennett et al., 1998; Sommer and Schafers, 1998; Khalil et al., 1999; Syriatowicz et al., 
1999; Cui et al., 2000; Perkins and Tracey, 2000; Zhao et al., 2000).  In addition, it has 
been hypothesized that the formation of sympathetic baskets around large size DRG 
neurons may play a role in the development and maintenance of neuropathic pain 
(Ramer et al., 1999; Woolf and Mannion, 1999; Zhou et al., 1999). 
 
 
 119
7.5 Mechanical hypersensitivity with respect to TRPV1, ASIC3, and sodium 
channels 
 
In my experiments, it was determined that following CCI, intrathecal NT-3 did 
neither prevent, nor reverse, the development of mechanical hypersensitivity.  This 
directly contradicts the findings of Gandhi et al. (2004) in which they report that NT-3 
can effectively reverse mechanical hyperalgesia produced by intramuscular acid 
injection in mice.  Currently, much of the literature that examines the effect of 
exogenous NT-3 on mechanical sensitivity is based on the injured state.  It has been 
reported, however, that both antibodies to NT-3 (delivered directly to injured DRG) and 
antisera to NT-3 (injected intraperitoneally) attenuates nerve lesion-induced increases in 
von Frey hair-evoked foot withdrawals during later stages of nerve injury (Deng et al., 
2000; Zhou et al., 2000).  This suggests that although intrathecal infusion of NT-3 in 
concert with CCI does not alter the ensuing mechanical hypersensitivity, it may still 
influence it when delivered in alternate manners or for different durations.  In support of 
this, Zhou et al. (2000) also found that intrathecal infusion of NT-3 did not significantly 
alter mechanical allodynia.  In another experiment during which NT-3 was infused 
intrathecally for 14 days, White (1998) determined that this treatment significantly 
decreased mechanical thresholds.   Given the controversy surrounding the effect of NT-3 
on mechanical thresholds, it appears that the dosage, duration and route of 
administration may critically alter the outcomes of these experiments.   
While the primary role for TRPV1 appears to be that of thermal hyperalgesia 
modulation, there is some emerging evidence that it may also play a role in mechanical 
hypersensitivity.  Kanai et al. (2005) report that upregulation of spinal TRPV1 in the rat 
CCI model shows involvement in the development and/or maintenance of mechanical 
allodynia.  Liedtke (2007) demonstrates that transduction of mechanical stimuli involves 
TRPV1, and Christoph et al. (2007) used a TRPV1 antagonist applied intravenously 
following rat spinal nerve ligation to reduce mechanical hypersensitivity.  My findings 
do not support a critical role for TRPV1 in mechanical hypersensitivity.   
Consistent with previous reports, in the intact state, expression of ASIC3 was 
observed predominantly in small to medium sized DRG neurons, with some large 
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neurons also expressing detectable levels of ASIC3 (Waldmann et al., 1997b; Chen et 
al., 1998; Voilley et al., 2001; Molliver et al., 2005).  We describe for the first time that 
following CCI, levels of ASIC3 expression were significantly upregulated, primarily in 
the small to medium sized (nociceptive) DRG neurons, as well as a small population of 
large sized neurons.  This supports insights by Mamet et al., (2002, 2003) that the 
increased levels of NGF available under conditions of inflammation drive the increased 
expression/overexpression of ASIC3.  The current work also demonstrates the novel 
finding that, following CCI, exogenous NT-3 can effectively counter the upregulation of 
ASIC3 expression, reducing levels to approximately that of basal expression.  
Surprisingly, examination of 14 day CCI with infusion of NT-3 for the first 7 days of the 
injury reveals that upon removal of exogenous NT-3, ASIC3 levels remain depressed.   
There have been numerous studies undertaken to establish a critical role for ASIC3 in 
the development of mechanical hypersensitivity.  Sluka et al. (2003, 2007) have 
described a critical role for ASIC3 on muscle afferents in the development of 
mechanical hyperalgesia resulting from intramuscular acid injection in.   It was 
determined by Mogil et al. (2005) that while ASICs are involved in the increased 
sensitivity to mechanical stimuli, they are not likely directly involved in the heightened 
response to nociceptive stimuli, and Drew et al. (2004) reports that ASIC3 is not 
important in mechanotransduction in the DRG.  Additional evidence of a role for ASIC3 
in mechanical allodynia comes from Ohtori et al. (2006), who found that the level of 
mechanical allodynia was significantly decreased following lidocaine application to 
spinal nerve roots affected by disc herniation and a concurrent decrease in ASIC3 
immunoreactivity in DRG neurons.  A critical evaluation of the findings of Ohtori et al. 
(2006) leads me to the conclusion that the downregulation of ASIC3 observed was 
coincident, similar to my findings.  In addition, the ability of lidocaine to decrease 
mechanical allodynia would lead me to surmise an important role of sodium channels in 
this pathology. 
 There is little evidence to either support of refute a role for Nav1.8 and/or Nav1.9 
in mechanical hypersensitivity.  It has been proposed that Nav1.8 does play a role in the 
development and maintenance of persistent mechanical hypernociception following 
intraplantar treatment with prostaglandin E2 (PGE2) (Villarreal et al., 2005).  In 
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contrast, the deletion or inactivation of Nav1.9 reportedly had little or no effect on 
mechanical hypersensitivity in the neuropathic rat (Porreca et al., 1999; Priest et al., 
2005).  Again, my findings support the lack of a role for these two sodium channels in 
mechanical hypersensitivity. 
Taken together, it appears that of the channels examined throughout this thesis, 
ASIC3 presents itself as the most likely candidate to be involved in the generation 
and/or maintenance of mechanical hypersensitivity.  This role would most likely be 
based on the activation of ASIC3 resulting from a drop in extracellular pH (Waldmann 
et al., 1997b).  However, ASIC3 is not the only channel examined that is sensitive to 
such a shift in pH (i.e. TRPV1) (Caterina et al., 1997).  Both the patterns of expression 
of TRPV1 and ASIC3 and their functional properties suggest that they are the primary 
channels involved in sensing changes in pH (Leffler et al., 2006).   Together, this 
provides insight that perhaps ASIC3 must work in conjunction with additional channels 
and/or molecules to effect changes in nociception at the level of the DRG.  In 
conclusion, ASIC3 is undoubtedly involved in some aspect of the generation and/or 
maintenance of neuropathic pain, but it is not a critical channel in behavioral responses 
associated with the CCI model. 
 
 
7.6 Spontaneous pain 
 
 While the behavioral assessment of spontaneous pain was not included in the 
scope of this thesis, it is of interest to the study of neuropathic pain.  As the term 
suggests, spontaneous pain observed after nerve injury is the result of non-elicited 
activity of the sensory neuron.  This activity occurs as a consequence of an increase in 
oscillations in membrane potential and a decreased neuronal firing threshold, both under 
the influence of sodium channels (Amir et al., 1999).  There is much debate regarding 
which fibers are actually involved in spontaneous firing, with some labs claiming it is 
the uninjured C fibers that contribute to this pain state (Wu et al., 2001; Wu et al., 2002; 
Djouhri et al., 2006).  Others find that this ectopic discharge does not occur in C fibers 
(where expression of the sodium channel Nav1.8 is reduced) (Cummins et al., 1997; Dib-
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Hajj et al., 1996; Dib-Hajj et al., 1998; Novakovic et al., 1998; Sleeper et al., 2000; Lai 
et al., 2003), but rather in the medium and large size fibers where the alterations in 
Nav1.8 are minimal (Dib-Hajj et al., 1996; Novakovic et al., 1998; Lai et al., 2003).  
Conversely, spontaneous firing has been demonstrate in injured DRG neurons by 
Gallego et al. (1987) and Gurtu and Smith (1988) and has been attributed to the 
translocation of sodium channel to the tips of the injured axons and/or neuromas  
(Devor et al., 1989; England et al., 1994, 1996).  In separate experiments, Nav1.8 has 
been deemed essential to (Roza et al., 2003) and Nav1.9 has been described as 
contributing to (Priest et al., 2005) the development of spontaneous pain following nerve 
injury.  As the study of neuropathic pain behaviors in animals seldom includes the 
assessment of neuropathic pain, it remains elusive as to which voltage-gated sodium 
channel(s) are intrinsically involved in its generation.  What is clear is that both Nav1.8 
and Nav1.9 are downregulated by treatment with exogenous NT-3.  It is easy to 
hypothesize then, that exogenous NT-3 may dampen the generation of ectopic 
discharges leading to spontaneous pain, however, comprehensive studies would need to 
be undertaken to support this hypothesis. 
 
 
7.7 The neurotrophin receptors, trk signaling, and MAPK in neuropathic pain 
 
 One of the biggest hurdles when presenting these findings to those not intimately 
associated with neurotrophins and their receptors is the fact that NT-3 can be a ligand for 
each of these receptors.  The receptor tyrosine kinase (trk) family of neurotrophin 
receptors is composed of three members  trkA, trkB and trkC  that selectively bind 
neurotrophins with similar high affinity (reviewed in Huang and Reichardt, 2003). NGF 
binds to trkA (Kaplan et al., 1991; Klein et al., 1991), BDNF and NT-4/5 both bind to 
trkB (Klein et al., 1990; Soppet et al., 1991; Squinto et al., 1991) and NT-3 binds 
primarily to trkC, but can also interact with trkB and an isoform of trkA that contains a 6 
amino acid insert in the extracellular domain (reviewed in Huang and Reichardt, 2003).  
There also exists the p75 neurotrophin receptor that is capable of binding all members of 
the NGF family of neurotrophins with approximately equal specificity, but a lower 
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affinity than the trk receptors (reviewed in Bothwell, 1996 and McMahon et al., 1997) 
(Figure 7-1). 
 As NT-3 is considered to be a promiscuous neurotrophin based on its ability to 
interact with number of receptors, there are two characteristics of NT-3 that are of 
particular importance when contemplating its role in antagonizing NGF to modulate 
neuropathic pain.  First, the isoform of trkA that does not have the 6 amino acid insert is 
only activated by NGF, while the trkA isoform with the insert allows for increased 
activation by NT-3, but does not affect the ability of NGF to activate it (Clary and 
Reichardt, 1994).  Second, high-affinity binding of NGF to trkA to occur, p75 must also 
be present (Hempstead et al., 1991; Benedetti et al., 1993; Davies et al., 1993; Clary and 
Reichardt, 1994; Bibel et al., 1999).  Finally, since the specificity for trkA to bind its 
primary ligand (i.e. NGF) is increased by p75, this makes NT-3 less effective at 
activating trkA when p75 is present (Clary and Reichardt, 1994; Lee et al., 1994; Bibel 
et al., 1999; Benedetti et al., 1993; Mischel et al., 2001; Brennan et al., 1999) although 
the latter has not been specifically tested in sensory neurons. 
 Upon the binding of ligand to the trk receptors, there are three primary signaling 
pathways that may be activated.  These are: 1) the Ras-MAPK signaling pathway; 2) the 
PLC-γ1 signaling pathway; and 3) the PI3 Kinase signaling pathway (reviewed in Huang 
and Reichardt, 2003) (Figure 7-2). Of particular interest to this thesis is the Ras-MAPK 
pathway, as it was two of the MAPK pathways that were examined with respect to NT-
3s ability to modulate neuropathic pain syndromes.  However, a preliminary 
understanding of the other two pathways becomes important for understanding potential 
alternative modes of modulation by this neurotrophin. 
 Briefly, phosphorylation of the trk receptor at key tyrosine residues results in the 
binding to the signaling protein Shc which in turn activates the Ras-MAPK signaling 
pathway whereby the MAPKKK Raf leads to activation of the MAPKK MEK which 
activates the MAPK ERK (English et al., 1999; reviewed in Huang and Reichardt, 
2003).  Phosphorylated ERK then phosphorylates target proteins and is also translocated 
to the nucleus where it phosphorylates and activates transcription factors involved in the 
transcription of immediate early genes (reviewed in Segal, 2003).  Alternatively, the p38 
MAPK pathway may be activated by numerous extracellular stimuli in response to  
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Figure 7- 1: The nerve growth factor (NGF) family of neurotrophins and their 
receptors. 
 
The receptor tyrosine kinase (trk) family binds their cognate neurotrophin ligand with 
similar high-affinity (as identified by thick lines).  NGF preferentially binds to trkA, 
BDNF and NT-4/5 both preferentially bind to trkB and NT-3 binds preferentially to 
trkC, but can also interact with trkB and an isoform of trkA that contains a 6 amino acid 
insert in the extracellular domain with a lower affinity (thin red lines).  The p75 
neurotrophin receptor that is capable of binding all members of the NGF family of 
neurotrophins with approximately equal specificity, but a lower affinity than the trk 
receptors. 
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trkA trkB trkC
NT-3
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Figure 7- 2:  An overview of the basic signaling pathways engaged upon binding of 
neurotrophin to receptor. 
 
Upon binding of ligand to membrane-associated trk receptors, dimerization of the 
receptor results in cross activation of the catalytic domains and phosphorylation of the 
receptors at key tyrosine residues (P) flanking the catalytic domain.  These 
phosphotyrosines bind to intermediate signaling molecules (Shc, PLC) and can activate 
three primary signaling pathways.  These are: 1) the Ras-MAPK signaling pathway 
[phospho-ERK1/2 (orange), phospho-p38 (red)]; 2) the PLC-γ1 signaling pathway 
(purple); and 3) the PI3 Kinase signaling pathway (blue). 
 
 
 
cellular stresses and inflammation, (reviewed in Huang and Reichardt, 2003; Segal, 
2003).  As the p38 MAPK pathway can be activated by a number of stimuli, there is a 
diverse range of MAPKKK (including TAK1, ASK1, DLK, MEKK4) that lead to the 
activation of the MAPKK (MKK6, MKK3) that ultimately result in the phosphorylation 
of p38 MAPK (reviewed in Keren et al., 2006).  The PLC-γ1 pathway results in the 
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generation of inositol tri-phosphate (IP3) and diacylglycerol (DAG) upon hydrolization 
of PtdsIns(4,5)P2 and the promotion of Ca2+ release from internal stores (reviewed in 
Huang and Reichardt, 2003; Segal, 2003).  The final pathway of interest is the PI3-
Kinase pathway results in the activation of Akt whose actions include the promotion of 
cell survival and translation of mRNAs (Kimaball et al., 2002; reviewed in Huang and 
Reichardt, 2003). 
 
 
7.8 Potential implications of regulation of phospho-ERK and phospho-p38 MAPK 
in pain treatment with respect to TRPV1, ASIC3, and sodium channels 
 
7.8.1 Thermal and mechanical 
 
 There is evidence from experiments directly linking both phospho-ERK and 
phospho-p38 MAPK to the development of thermal and/or mechanical hypersensitivity 
following injury and/or inflammation.  By inhibiting MEK (the MAPKK needed for 
ERK activation), behavioral assessments have shown the attenuation of thermal 
hyperalgesia after capsaicin injection (Dai et al., 2002).   Similarly, CCI-induced thermal 
and mechanical hypersensitivity induced by CCI can be attenuated by either MEK 
inhibition or attenuation of ERK expression with antisense oligonucleotides (Song et al., 
2005).  In a similar study using the spinal nerve ligation model of neuropathic pain, 
mechanical allodynia was reversed by inhibitors of both ERK and p38 MAPK, while 
thermal hyperalgesia was only attenuated by the p38 MAPK inhibitor (Obata et al., 
2004).  The differential regulation of mechanical versus thermal sensitivity by ERK and 
p38 MAPK suggests that the various models of neuropathic pain and inflammation 
likely employ different mechanisms in their generation of neuropathic pain behaviors. 
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7.8.2 TRPV1 
 
 A vast amount of research has been undertaken to characterize the signaling 
cascades involved in regulation of TRPV1.  It was originally described by Ji et al. 
(2002b) that NGF-induced activation of p38 MAPK during inflammation was required 
for increases in TRPV1 to occur.  It was subsequently demonstrated that ERK could 
positively regulate levels of TRPV1 (Bron et al., 2003) in at least one case in 
conjunction with the PI3 signaling pathway (Zhuang et al., 2004).  It was also described 
that the PI3 pathway is involved in the generation of inflammatory pain through TRPV1 
independent of ERK (Zhuang et al., 2004; Zhang et al., 2005; Stein et al., 2006).  While 
I have previously proposed that the various models of neuropathic pain and 
inflammation likely employ different mechanisms in their generation of neuropathic 
pain behaviors, it is also becoming clear that these signaling pathways do not necessarily 
act in isolation from one another and that more than one pathway may be responsible for 
the generation of a single pain syndrome and/or molecular change resulting in a single 
pain behavior. 
 
 
7.8.3 ASIC3 
 
Far less research has been undertaken to describe the precise signaling pathways 
that lead to the regulation of ASIC3.  It has been shown that ASIC3 expression and 
activity and are decreased by activation of the ERK1/2 cascade (Zentner et al., 1998; 
Booth and Stockland, 2003; Frank et al., 2003), but upregulated via the p38 MAPK 
pathway (Mamet et al., 2003).  It is intriguing that these pathways are involved in the 
differential modulation of this channel. 
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7.8.4 Sodium channels 
 
Similar to ASIC3, the tetrodotoxin-resistant sodium channels have been 
demonstrated to be positively regulated by p38 (Jin and Gereau, 2006) but 
downregulated by activated ERK (Yanagita et al., 2002).   
 The findings of this thesis are based on the assumption that NT-3 is acting 
through one or more of the trk receptors (and possibly p75, although this is not 
addressed) to exert its effects on the CCI-induced changes examined.  There is, however, 
the very real possibility that NT-3 may also be acting through another type of receptor  
namely c-RET, the glial-derived neurotrophic factor (GDNF) receptor.  Evidence for this 
hypothesis is based on the findings of Amaya et al. (2004) and Malin et al. (2006).  
Amaya et al. (2004) found that inflammation rapidly increased NGF and thus TRPV1 
while GDNF increased more gradually, but also increased TRPV1 expression. 
Furthermore, Malin et al. (2006) have described an ability of GDNF to potentiate 
TRPV1 function at doses up to 100 times lower than NGF and also to increase thermal 
sensitivity.  It is therefore possible that the effects of NT-3 on TRPV1 expression and 
thermal hyperalgesia  at least in the 14 d CCI model  may be the result of NT-3 
counteractions of both NGF and GDNF. 
 
 
7.9 Potential clinical relevance of NT-3 as a therapeutic treatment for neuropathic 
pain 
 
 Examination of the usefulness of NT-3 in treating neuropathies has occurred 
primarily in two models of artificial neuropathy.  One model, using streptozotocin 
(STZ)-induced diabetes, is a model of diabetic neuropathy characterized by 
demyelination (Pradat et al., 2001), altered calcium homeostasis (Huang et al., 2002), 
slowing of motor and sensory conduction velocities (Mizisin et al., 1999; Pradat et al., 
2001; Zochodne et al., 2001), abnormal axonal transport of activated stress activated 
protein kinases c-jun N-terminal kinase (JNK) and p38 MAPK (Middlemas et al., 2003) 
and neuronal atrophy (Schmidt et al., 2001; Zochodne et al., 2001).  It has been shown 
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that the cell body response of the neurons is not akin to a nerve injury response, but 
rather a degenerative one (Zochodne et al., 2001).  A second model, employing 
acrylamide experimental neuropathy, results in diffuse sensorimotor neuropathy (Pradat 
et al., 2001).  Promising studies in STZ-induced diabetic rats have shown that NT-3 
treatment (1 month) was able to normalize established sensory and motor neuron 
conduction velocities (Mizisin et al., 1999; Huang et al., 2005).  In a separate study, NT-
3 administration was able to prevent the slowing of neuron conduction velocities in these 
rats (Pradat et al., 2001). Altered calcium homeostasis observed with STZ-induced 
diabetes can also be corrected with NT-3 therapy (Huang et al., 2002).  Findings by 
Middlemas et al. (2003) also demonstrate that treatment with NT-3 can effectively 
reduce the abnormal axonal transport of p38 MAPK in diabetic rats.  Finally, it has been 
demonstrated that NT-3  either alone or in combination with NGF  can significantly 
increase myelinated innervation compared to control diabetic mice (Christianson et al., 
2007). Additionally, muscle innervation was demonstrated to increase in acrylamide 
experimental neuropathy treated with NT-3 (Pradat et al., 2001).   
 As a possible role for activated microglia in promoting the inflammatory 
response is emerging, there are two studies that support a role for NT-3 in preventing 
this response.  In a model of lipopolysaccharide-induced inflammation, the production of 
the proinflammatory mediators nitric oxide, tumor necrosis factor-α and interleukin-1β 
have been shown to be inhibited by NT-3 (Tzeng and Huang, 2003; Tzeng et al., 2005).  
In addition, it was also shown that the ability of NT-3 to attenuate production of 
inducible nitric oxide synthetase correlates with a similar effect on MAP Kinase and PI3 
kinase signaling pathways (Tzeng et al., 2005). 
Taken together, NT-3 may prove to be therapeutically useful for treating the 
symptoms of large fiber neuropathy - including atrophy  as this is the endogenous 
trophic factor for large sized neurons.  Caution must be exercised, however, when any 
trophic factor is proposed as a therapy for neuronal alterations, as detrimental side 
effects may result, simply due to the inhibition of a non-target signaling pathway.  This 
was in fact the case in the phase II clinical trials using NGF to treat diabetic 
polyneuropathy and HIV-related neuropathy.  It was proven that painful side effects 
limited the useful dosage of NGF (Apfel, 2002). 
 130
7.10 Concluding comments and summary 
 
 Neuropathic pain remains an elusive clinical problem due to its complex etiology 
and the variety of behavioral syndromes that accompany it.  By definition, neuropathic 
pain occurs as a result of damage to or dysfunction of the nervous system.  These can 
include, but are not limited to, a lesion or disease of the nervous system.  The behavioral 
syndromes associated with this type of pain are just as varied.  They include the 
development of hyperalgesia (a decrease in the threshold of a normally noxious stimuli), 
allodynia (a non-noxious stimulus becomes noxious), and spontaneous pain (pain in the 
apparent absence stimuli).  To further complicate any attempts at the treatment of 
neuropathic pain, these pain syndromes seldom occur in isolation and are brought about 
by a variety of mechanisms.  
Over the past decade or so, numerous advances have been made in the area of 
pain research.  These have included the identification, isolation and cloning of certain 
ion channels that now appear to play an intrinsic role in the development and 
maintenance of neuropathic pain.  They are: the transient receptor potential vanilloid 
receptor-1 (TRPV1) (Caterina et al., 1997); the acid sensing ion channel 3 (ASIC3) 
(Waldmann et al., 1997b); and the tetrodotoxin-resistant sodium channels Nav1.8 
(Akopian et al., 1996) and Nav1.9 (Dib-Hajj et al., 1998). Numerous avenues of research 
employing the use of transgenic knock-outs, specific channel blockers, and the inhibition 
of signaling pathways have been undertaken in an attempt to fully understand the 
individual contributions of these channels to neuropathic pain.  Interestingly, each of 
these channels appears to be positively regulated by increasing levels of nerve growth 
factor (NGF) (Dib-Hajj et al., 1998; Fjell et al., 1999; Ji et al., 2002b; Mamet et al., 
2003).   
Based upon my hypothesis that NT-3 acts antagonistically to NGF to modulate 
certain aspects of the CCI-associated neuropathic pain phenotype, the findings that NT-3 
effected a downregulation of TRPV1, ASIC3, Nav1.8, Nav1.9, and phospho-p38 MAPK 
following chronic constriction injury (CCI) are in support of this hypothesis.  With an 
understanding of these findings firmly in hand, the differential regulation of phospho-
ERK in the trkA versus trkC populations of naive neurons by NT-3 provides a 
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reasonable mechanism of how NT-3 serves to primarily downregulate CCI-induced 
changes in phenotype in the nociceptive (trkA) population of dorsal root ganglion 
(DRG) neurons.  From these experiments, it seems likely that NT-3 may effectively act 
through the isoform of trkA that can bind NT-3.  What is not clear, however, is whether 
or not NT-3 affects the affinity with which NGF is able to bind with its cognate trkA 
receptor or alternatively is activating aspects of the p75 pathway that lead to this result 
and have yet to be elucidated.  Further studies into this area are therefore required. 
Given the apparent global ability of NT-3 to antagonize injury/NGF - 
associated changes in the DRG following CCI, it leads one to question what other 
possible effects it may be having.  It has previously been demonstrated that there is an 
infiltration of numerous inflammatory mediators following CCI (Olsson, 1967; Perry et 
al., 1987; Ferreira et al., 1988; Cunha et al., 1992).  Perhaps, then, NT-3 may also be 
effective in reducing the impact of this inflammatory soup thereby mitigating the drop 
in pH that accompanies tissue inflammation (for review, see Moalem and Tracey, 2006; 
Myers et al., 2006).  Another possibility is that exposure to exogenous NT-3 is inhibiting 
any number of the six signaling pathways through which trkA acts including a MAPK 
pathway involving ERK1/2, a PI-3 kinase pathway involving serine/threonine kinase 
Akt, and a PLCγ pathway (reviewed in Friedman and Greene, 1999; Kaplan and Miller, 
2000), thus inhibiting gene expressing in this population of nociceptive neurons. 
 Effective treatments for neuropathic pain will remain elusive until such time as 
the numerous channels, peptides, trophic factors, receptors, and signaling pathways 
governing the development and maintenance of hyperalgesia, allodynia, and 
spontaneous pain are identified and characterized.  In addition, it is becoming clear that 
it is not the involvement of individual molecules that require investigation, but rather the 
interaction of these molecules collectively on the response.  It is only once the complex 
biochemical interactions of all the players in the neuropathic pain game are understood 
that hopefully curative, rather than simply palliative, treatments can be developed. 
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